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ABSTRACT

SCP-1, a potent derivative of acetaminophen, exhibits significantly diminished hepatotoxicity
and nephrotoxicity relative to acetaminophen and nitrate ester derivatives of acetaminophen. It
was therefore of interest to explore the development of nitric oxide donor analogs of SCP-1 to
identify compounds that could have enhanced analgesic and/or antipyretic activity while taking
advantage of the very low liver and kidney toxicity inherent to SCP-1. In this project, a series of
nitrate ester analogues of the SCP-1 were prepared as potential nitric oxide donors. The synthesis
of SCP analogs was achieved by triflic acid catalyzed O-acylation of SCP-1 with chloroalkanoyl
chlorides followed by nitration with silver nitrate. The chloroesters and corresponding nitrate
esters were obtained in high yields (>90%). Preliminary hepatotoxicity studies revealed the nitrate
esters to be well tolerated by human hepatocytes and had little effect on the three cytochrome P450
enzymes tested (CYP3A4, CYP2E1 and CYP2D6). In addition, the nitrate esters exhibited
antipyretic activity similar to acetaminophen.
With the emerging interest in 3,3-diarylazetidines as novel motifs in drug discovery programs,
an easy, efficient, scalable synthetic method that could accommodate the introduction of both
electron-rich and electron-deficient aryl groups for preparation of diversely substituted 3,3diarylazetidines would be valuable to medicinal chemists. In this second project, a versatile
synthesis of 3,3-diaryl azetidines from N-Boc-3-aryl-3-azetidinols using Friedel-Crafts arylation
conditions with AlCl3 is described. A series of substituted diaryl azetidines were readily prepared
and isolated as the oxalate salts in high yield and high purity. The 3,3-diaryl azetidine oxalates
were then easily converted into N-alkyl and N-acyl analogues in high overall yields (>85%).

xviii

In the last project, A general synthesis of pyruvate esters was developed. Using this method, a
series of alkyl pyruvate esters were synthesized in moderate to high yields (56-93%). This was
achieved in four steps starting from the readily available triethyl-2-phosphonopropionate which
was converted to the alkene ethyl 2,3-dimethyl-2-butenoate using Horner-Wadsworth-Emmons
reaction. The ethyl ester was hydrolyzed to the corresponding carboxylic acid after which a series
of esters were prepared using Steglich esterification. The esters were then converted to their
corresponding pyruvate esters via ozonolysis.

Keywords: Acetaminophen, NO donor, SCP-1, hepatoxicity, azetidines, Friedel-Crafts arylation,
butyllithium, N-alkylation, pyruvate esters, -keto acids, ozonolysis

xix

CHAPTER 1
Synthesis, hepatotoxic evaluation and antipyretic activity of nitrate ester analogs
of the acetaminophen derivative SCP-1
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ABSTRACT
SCP-1 is a potent saccharin derivative of acetaminophen which is used for acute and chronic
pain. SCP-1 demonstrated an analgesic profile similar that to that of acetaminophen. However,
SCP-1 exhibited significantly diminished hepatotoxicity and nephrotoxicity relative to
acetaminophen and nitrate ester derivatives of acetaminophen. It was therefore of interest to
explore the development of nitric oxide donor analogs of SCP-1 to identify compounds that could
have enhanced analgesic and/or antipyretic activity while taking advantage of the very low liver
and kidney toxicity inherent to SCP-1. In this project, a series of nitrate ester analogues of the
SCP-1 were prepared as potential nitric oxide donors. The synthesis of SCP analogs was achieved
by triflic acid catalyzed O-acylation of SCP-1 with chloroalkanoyl chlorides followed by nitration
with silver nitrate. The chloroesters and corresponding nitrate esters were obtained in high yields
(>90%). Preliminary hepatotoxicity studies revealed the nitrate esters to be well tolerated by
human hepatocytes and had little effect on the three cytochrome P450 enzymes tested (CYP3A4,
CYP2E1 and CYP2D6). In addition, the nitrate esters exhibited antipyretic activity similar to
acetaminophen.
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INTRODUCTION
1.1 Nitric oxide donors
Nitric oxide donors (NO donors) are compounds that under physiological conditions release
nitric oxide (NO). The most popular NO donor is Glyceryl trinitrate (GTN) or nitroglycerin.
Although the use of GTN for medicinal purposes dates back to more than 150 years, little had
been revealed about its physiological mechanism of action before the 1980s [1]. GTN was first
discovered in 1847 by Ascanio Sobrero in Turin, following work with Theophile‐Jules Pelouze.
Alfred Nobel joined Pelouze in 1851 and recognized the potential of GTN. The invention realized
by Alfred Nobel in 1863 paved the way for controlled detonation of GTN. Therefore, when
Nobel’s physician recommended GTN as treatment of his angina pectoris, Nobel wrote “Isn’t it
the irony of fate that I have been prescribed nitroglycerin to be taken internally! They called it
Trinitrin, so as not to scare the chemist and the public” [2]. There would not be any irony for
Nobel if he knew that it was nitric oxide (NO), released from GTN in vivo, that helped to relieve
his angina. During the mid‐19th century, scientists in Britain took an interest in the newly
discovered amyl nitrite, and recognized it as a powerful vasodilator. Lauder Brunton, the father of
modern pharmacology, used the compound to relieve angina in 1867, noting the pharmacological
resistance to repeated doses. In 1977, Ferid Murad discovered the release of NO from GTN and
its action on vascular smooth muscle [3]. In 1980, Robert Furchgott and John Zawadski
recognized the importance of the endothelium in acetylcholine‐induced vasorelaxation and in
1987, Louis Ignarro and Salvador Moncada identified NO as the endothelial‐derived relaxing
factor (EDRF) [4] [5]. The surprising and exciting discovery of the multiple roles that NO plays
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in physiological and pathophysiological functions in humans earned Furchgott, Ignarro, and
Murad the Nobel Prize in 1998.

1.2 Organic nitrates
NO is a colorless gas and may react with a variety of atoms and radicals. For example, it may
react readily with O2 to give nitrogen dioxide (NO2) [6]; the reaction of NO with superoxide anion
generates peroxynitrite (ONOO-), an oxidative species that is responsible for certain types of NOmediated toxicity in vivo [7]. Due to the instability and inconvenient handling of aqueous solutions
of authentic NO, there is an increasing interest in using compounds capable of generating NO in
situ, i.e., NO donors. Organic nitrates, such as GTN (1), may be the most well-known and the
oldest class of NO donors. Some of the other organic nitrates include pentaerythrityl tetranitrate
(PETN, 2), isosorbide dinitrate (ISDN, 3), isosorbide 5-mononitrate (ISMO, 4), and nicorandil (5)
[2].

Fig. 1. Some well-known organic nitrates
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Organic nitrates can be readily prepared from the esterification of corresponding alcohols or
the substitution between reactive alkyl halides and AgNO3 (Scheme 1) [8]. They are sparingly
soluble in water and are generally stable in neutral or weakly acidic aqueous solutions. Under
strong alkaline conditions, they are susceptible to hydrolysis to give alcohol and nitrate (SN2
substitution), -elimination to give an alkene, and -H elimination to give aldehyde and nitrate
(Scheme 2) [9] [10].

Scheme 1. Synthesis of organic nitrates

Scheme 2. Alkaline hydrolysis of nitrate esters
The NO release from organic nitrates requires enzymatic or non-enzymatic bioactivation.
Although the biochemical process of NO release from GTN has not been fully defined, it is likely
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that multiple intracellular and extracellular pathways contribute to NO formation from these
compounds in vivo [11].

Fig. 2. Biotransformation of organic nitrate esters
It has been suggested that cellular thiols are involved in nonenzymatic formation of NO from
GTN [12] [13]. However, since the degradation of GTN by thiols is very slow at room
temperature, it appears that the release of NO from reasonable concentrations of GTN and thiols
almost certainly involves an enzymatic process [14].

1.3 Biological applications of NO donors
Organic nitrates have long been used to relieve angina pectoris; a disease state caused by
constriction of heart arteries. In fact, GTN has a relaxant effect on all types of vessels. Coronary
arteries have been found to be more sensitive to GTN than peripheral arteries. GTN has also been
used as treatment of acute myocardial infarction [15], congestive heart failure [16], as well as
blood pressure control. In addition to relaxation of vascular smooth vessels, GTN is successful in
the treatment of children with anal fissures when administered as an ointment [17] and as an
alternative to sildenalfil (Viagra) for the treatment of erectile dysfunction [18]. Rectal
administration of 1 has been claimed as treatment for prophylaxis of inflammatory bowel disorders
[19]. It has been suggested that 3 can be used as a long-term transdermal therapy in preeclamptic
6

women to avoid maternal hypertension and fetal distress [20]. It was recently reported that organic
nitrates eventually inhibited the proliferation of smooth muscle cells (SMC), which was associated
with the pathogenesis and progression of atherosclerosis [21] [22] [23].
The role in tumor growth arrest by NO was initially suggested by the observation that murine
activated macrophages synthesized nitrite and nitrate leading to cytotoxicity of tumor cells and
bacteria [24] [25] [26]. This anti-tumor activity of NO first opened the door to identifying a
function of NO as a potential oncologic agent. In general, it has been suggested that at high
concentrations NO may have an anti-neoplastic function whereas at low levels it can be proangiogenic and pro-tumor formation [27]. NO at high concentrations causes programmed cell
death and at low levels protects the cell from apoptosis, which has been suggested to be the result
of a dual role of the transformation-related protein 53 (p53) [28]. In this phenomenon, low
concentrations of NO may induce p53 alterations or mutations, which cause tumor cell resistance;
however, at high concentrations, the DNA damage induced by NO increases wild-type p53 leading
to programmed cell death [29] [30].

1.4 NO-drug hybrids
The specific characteristics of NO in vasodilatation and a potential role as an anti-neoplastic
agent on its own and has led to the development of new hybrid drugs with synergistic activities
and minimal side effects that may be caused by either drug alone. For instance, a recent study by
Chan et al. showed that the regular use of the non-steroidal anti-inflammatory drug (NASAID),
aspirin, reduced the risk of colorectal cancers in tumors that over-expressed COX-2 [31].
However, in tumors that showed weak or absent expression of COX-2 the chemo preventive
effects were minimal; while the potential side effects of aspirin, including peptic ulcer disease,
7

were retained in both cohorts. Since established drugs that inhibit carcinogenesis are COX-2
inhibitors, a logical hybrid is one that combines nitric oxide and the non-steroidal antiinflammatory drugs (NO-NSAIDs). The NO-aspirin analog 6 (Fig. 3) developed by Thatcher et
al., demonstrated no toxicity when given to human subjects while maintaining COX-1 and
antiplatelet activity [32].
NO-NSAIDs are composed of typical non-steroidal anti-inflammatory drugs such as aspirin,
salicylic acid, indomethacin, ibuprofen or sulindac to which an NO-releasing moiety has been
attached via a covalent bond that is cleaved by non-specific esterase activity. It is the bond between
the linker and the NSAID that is cleaved by enzymatic activity. Upon cleavage, the NSAID exerts
its COX-inhibitory functions and the generated NO acts in synergy to potentiate the actions of
both compounds [32].

In 2000, Swayeh et al. reported that nitric oxide (NO) releasing derivatives of NSAID exhibit
greater anti-inflammatory, antinociceptive and anti-thrombotic activity than the parent NSAID
[33]. With this in mind, they synthesized NO releasing derivative of acetaminophen. This nitrate
ester of acetaminophen (NO-APAP, 7) has been reported to exhibit enhanced anti-nociceptive and
anti-inflammatory activity relative to APAP over similar dose ranges. More recently, NO-APAP
has been shown to have a reduced hepatotoxicity in human hepatocytes than APAP. Nitric oxide
release from NO-APAP is a metabolic and not a spontaneous process. Furthermore, this process
causes the production of discrete amounts of NO that do not interfere with blood pressure
regulation but could account for the improved pharmacological profile of NO-APAP.
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Fig. 3. Structures of some well-known NO-NSAIDS

1.5 Acetaminophen toxicity
The most commonly employed method of managing pain involves the systemic administration of
analgesics. Traditionally, analgesics fall into two broad categories: (1) simple, non-narcotic
analgesics, such as aspirin, which appear to work by inhibition of prostaglandin synthetase [34],
and (2) narcotic analgesics, which appear to work through interaction with the
endorphin/enkephalin receptor system of the central nervous system [35]. Narcotic analgesics, can
be further divided into two groups, the opioids and non-opioids. The opioid analgesics include
among others the phenanthrene alkaloids of opium, comprising morphine, codeine, and thebaine.
9

The drugs that comprise the group known as the non-opioid analgesics include: (1) N-methyl-Daspartate (NMDA) receptor antagonists, such as dextromethorphan and ketamine [36]; (2) alpha2
adrenoreceptor agonists, such as clonidine, metomidine, detomidine, dexmetomidine,
dexmedetomidine and xylazine, that reduce the release of norepinephrine; (3) other agents, such
as tramadol, often mistakenly referred to as an opioid, that produce analgesia by their inhibitory
actions on monoamine re-uptake rather than by agonist effect; (4) non-steroidal anti-inflammatory
drugs such as aspirin, ibuprofen and other drugs that inhibit cyclooxygenase enzymes [37] and (5)
mixed agonist-antagonist analgesics such as buprenorphine, dezocine, nalbuphine. Opioid and
non-opioid analgesics may cause a variety of side effects including sedation, constipation,
hypotension, nausea, vomiting, elevation of cerebrospinal fluid pressure, respiratory depression,
physical dependence and tolerance [38]. Therefore, there is a serious need to develop
combinations of drugs that supplement the activity of the opioid and non-opioid analgesics, which
allows the use of smaller doses of the opioid and non-opioid analgesics [39].
Analgesics such as acetaminophen and other NSAID type drugs have been used for some time
for the treatment of pain and/or as antipyretics. However, its high toxicity is the foremost cause
of acute liver failure in the western world [40] [41] [42]. In therapeutic use, it is metabolized by
hepatic cytochrome P450 enzyme CYP2E1 to N-acetyl-p-benzoquinone imine (NAPQI), which
is then immediately conjugated with glutathione (GSH) to form a non-toxic mercapturic acid
conjugate which is excreted in urine [43] [44]. In the case of an overdose, glutathione stores are
overwhelmed and free NAPQI is able to combine with hepatic macromolecules to produce
hepatocellular damage (Fig. 4).

10

Fig. 4. Mechanism of acetaminophen toxicity

1.6 A series of N-acylated-4-hydroxyphenylamine derivatives (SCP series)
In 1996, Bazan et al. synthesized a series of N-acylated-4-hydroxyphenylamine derivatives,
linked via an alkyl bridge to the nitrogen atom of a saccharin molecule. This series of compounds
was named the “SCP series” (Fig. 5) [45]. The SCP series are non-narcotic analgesics that are free
from antipyretic activity and have little hepatotoxic effect. The compounds in this series do not
produce the metabolite (NAPQI) that is responsible for acetaminophen toxicity and they do not
reduce fever. As a result, they are more useful than acetaminophen and other non-narcotic
analgesics in the treatment of chronic pain and in situations in which controlling fever is
contraindicated, such as after surgery, where fever control can mask infection. Moreover, unlike
conventional non-narcotic analgesics, such as aspirin or ibuprofen, the SCP series does not
suppress blood coagulation.
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Fig. 5. SCP series, n = 1 to 5

One of them, SCP-1 (n=1) showed analgesic activity equivalent to acetaminophen but, in
contrast to the latter, possesses much lower toxicity. Furthermore, SCP-1 (12) had the great
advantage of not showing antipyretic activity, since antipyresis can mask the presence of latent
infections during the post-operative period. It was found to rapidly hydrolyze in vivo to give SCP123 (13) which is equipotent on a molar basis with 12.

Fig. 6. Structures of SCP-1 and SCP-123

1.7 Synthesis of SCP-1 and SCP-123
In 1996, Bazan et al. developed the synthesis of 12 which was prepared by the means of two
synthetic routes [45]. In route 1 (Scheme 3), 2-chloro-N-(4-hydroxyphenyl)acetamide (14) was
reacted with the sodium salt of saccharin (15) in dimethylformamide (DMF). The mixture was
heated at reflux for 3 hours. At the end of this time, the NaCl formed was filtered off and the
12

filtrate was evaporated under reduced pressure. The resulting oil was crystallized in 200 mL of nhexane/acetone (1:1) and the product thereby obtained was recrystallized in ethanol which yields
12 as a white crystalline solid in 86% yield.

Scheme 3. Synthesis of 12 (Route 1)

Alternatively, in route 2 (Scheme 4), the acid 16 was reacted with 4-aminophenol (17) in the
presence of a coupling agent such as dicyclohexylcarbodiimide (DCC). The reaction was carried
out in anhydrous methylene chloride (DCM). The reaction was stirred at room temperature for 2
hours. The resulting solid was filtered off and recrystallized in ethanol/water (1:1) to give 12 in
70 % yield.

Scheme 4. Synthesis of 12 (Route 2)

In 2009, Miao et al. developed the first multigram synthesis of SCP-123 and its sodium salt
[46]. Two synthetic routes have been established for its synthesis with two routes differing
primarily in the sequence in which the saccharin moiety is added to the acetyl unit. In Route A
(Scheme 5), the saccharin moiety (15) is added in the last step to the 2-chloroacetamide
13

intermediate 18 that is generated from 4-aminophenol (17, 150g) and 2-chloroacetyl chloride (19,
155 g) in a solution of acetic acid and sodium acetate. The reaction is kept cold and stirred at ≤ 5
℃. The intermediate 18 precipitates out as a white solid which is then filtered with distilled water
to give 18 in a 70% yield.

Scheme 5. Synthesis of SCP-1 (Route A)

Chloroacetamide (18, 326 g) is then added to the sodium salt of saccharin (15, 433 g) in
the presence of a catalytic amount of sodium iodide (NaI). The reaction is heated at reflux in DMF
for 2 hours. Ice-water is added to the reaction mixture until no more precipitate forms. The sticky
white precipitate is then recrystallized in 50% ethanol-water to yield SCP-1 (12) in 72% yield.
Alternatively, in Route B (Scheme 6), the intermediate acetic acid 16 is formed initially from
sodium saccharin (15) and bromoacetic acid (20). The acid 16 is then coupled with 17 to give 12
also via a two-step process. Route A was deemed to be of greater merit due the low cost of the
commercially available starting materials and also because both the intermediate 18 and 12 could
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be obtained in a state of high purity (>95%) by precipitation or recrystallization. Alternatively,
Route B is potentially limited by the hygroscopic intermediate acid 16, which is difficult to handle,
as well the multiple recrystallizations of 12 that are necessary to remove DCC present as a
byproduct from the coupling reaction.

Scheme 6. Synthesis of SCP-1 (Route B)

The hydrolysis of 12 was readily achieved with NaOH solution followed by treatment with 2
N HCl (Scheme 7). This afforded the corresponding acid 21 (SCP-123) in 93% yield. The
hydrolysis step was found to be sensitive to the concentration of the saccharin derivative 12 in the
basic solution. If the reaction mixture was not sufficiently dilute, the formation of side product 22,
that resulted from oxidative phenolic coupling, was obtained.
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Scheme 7. Synthesis of SCP-123

An optimized concentration of 12 in 0.5 N NaOH was determined to be 0.25 M. At this
concentration, the hydrolysis of 12 proceeded cleanly, and the oxidative-coupling product 22 was
not observed.

Fig. 7. Byproduct 22

1.8 Design strategy for NO-SCP-1 hybrids
The goal of this project was to synthesize a series of NO-donor analogs of SCP-1 which could
have similar analgesic properties to SCP-1 but also show reduced hepatotoxicity. Since,
previously synthesized NO-drugs typically had a linker molecule that attached the NO moiety to
the parent NSAID, similar design was incorporated in the synthesis of NO-SCP-1. Comparable to
NO-acetaminophen, it was decided that that linker molecule would be an alkyl chain attached to
the phenolic OH via an acyl group. Fig. 8 shows the general formula for the NO-SCP-1 analogs.
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Fig. 8. NO-SCP-1 analogs; n = 1-4
A retrosynthetic route for the synthesis of the NO-SCP-1 analogs is outlined in Scheme 8. The
synthesis would start from the readily available SCP-1. The linker alkyl chain would be attached
to the phenolic OH via O-acylation using various chloroalkanoyl chlorides. The chloro group
would then be substituted with a nitrate (-ONO2) group using a simple substitution reaction.

Scheme 8. Retrosynthetic route for synthesis of NO-SCP-1 analogs

17

1.9 Hydrophobicity in drug design
Hydrophobicity is most commonly understood as the tendency of non-polar molecules to form
aggregates in order to reduce their surface of contact with polar molecules such as water [47]. A
drug’s solubility in water plays a significant role in its design and discovery since the cells in our
bodies contain about 65% water. In living matter, water acts as an inert solvent, a dispersing
medium for colloidal solutions and as a nucleophilic reagent in numerous biological reactions.
Furthermore, hydrogen bonding and hydrophobic interactions in water influence the
conformations of biological macromolecules, which in turn affects their biological behavior. It
also makes drug toxicity testing and bioavailability evaluation as well as clinical application
easier. This means that there is usually a need to design a reasonable degree of water solubility
into the structure of a new drug early in the development of that drug [48].
Oral ingestion is the most commonly employed route of drug delivery due to its ease of
administration. However, the major challenge with the design of oral dosage forms lies with their
poor bioavailability. The most frequent causes of this poor bioavailability are attributed to poor
solubility and low permeability. Drugs administered orally have to dissolve in the aqueous gastric
fluid before they can be absorbed and transported to their site of action. Drugs that are sparingly
soluble in water will be deposited before they reach their site of action. This can clog up blood
vessels and damage organs. Water solubility also affects the transport of drugs through membranes
such as the blood-brain barrier. The water solubility of an organic compounds depends of the
number and nature of polar groups in the structure. In general, higher the number of polar groups,
the more water soluble the compound. However, if a drug is too water soluble, it will not be readily
transported across lipid membranes [49].
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1.9.1 Design of water-soluble analogs of SCP-1
One of the major drawbacks of SCP-1 is its low water solubility. Therefore, there was a need
to develop analogs of SCP-1 with increased water solubility. One of the methods to increase water
solubility was to attach a polar group to the phenolic moiety such as a glucose molecule. Addition
of a carbohydrate molecule to the structure of SCP-1 will not only increase its water solubility but
also potentially reduce toxicity [50]. Small molecule drugs, no matter how heavily glycosylated,
will always have the potential to pass into the kidneys, through glomerular filtration, and be
rapidly cleared.
Alternatively, the water-solubility of SCP-1 could be increased by hydrolyzing the saccharin
ring. This can be achieved by synthesizing an array of open ring esters or amides. Amides would
be preferred since they are more stable and water-soluble compared to esters.

Fig. 9. Design strategy for water-soluble analogs of SCP-1
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RESULTS AND DISCUSSION
1.10 Nitrate ester analogs of SCP-1 (NO-SCP-1)

1.10.1 Synthesis of chloroalkanoyl ester analogs of SCP-1
As illustrated in Scheme 9, the synthesis of the chloroalkanoyl ester analogs of SCP-1 was
achieved by the O-acylation of the phenolic OH of 12. Complete O-acylation of 22a, 22b, 22c and
22d was achieved using 2% TfOH/acetonitrile solution [51].

It was observed that lower

concentrations of TfOH led to incomplete conversion while higher concentrations of TfOH
afforded intractable mixtures.
The O-acylation must be carried out in an inert atmosphere and the acid chloride should be
added dropwise or in small aliquots. Adding the acid chloride all at once resulted in the formation
of the C-acylated product. This was observed when 3 equivalents of 4-chlorobutyryl chloride was
added to SCP-1. Addition of acid chloride all at once, led to the formation of a mixture of the
desired O-acylated product 23c and the C-acylated product 22.

H-bonding shifts
OH peak

Fig. 10. Structure of C-acylated product 22
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OH peak at
12.19

Fig. 11. 1H NMR of 22

The structure of 22 was confirmed using 1H NMR (Fig. 11). The NMR showed a peak at 12.19
ppm which corresponded to the phenolic OH of 22. The peak for the phenolic OH of SCP-1
appears at ⁓10.00 ppm. This shift in the OH peak is attributed to the hydrogen bonding between
the carbonyl oxygen of the acyl group at the ortho position and the hydrogen of the phenolic OH.
This hydrogen bonding shifts the signal for the OH peak downfield.
The optimized reactions conditions produced nearly quantitative yields of the corresponding
O-acylation products (22a-d) with no observable C-acylation of the electron-rich aromatic ring
via Friedel-Crafts acylation.
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Scheme 9. Synthesis of Chloroalkanoyl esters of SCP-1

The amount of chloroalkanoyl chloride varied with the length of the carbon chain; the shorter
alkyl chain required additional molar equivalents of the chloroalkanoyl chlorides as well as longer
reaction times for complete conversion into the esters 23a and 23b. Both 23a and 23b required 16
hours for complete O-acylation with 3 equivalents of the corresponding chloroalkanoyl chloride.
However, esters 23c and 23d were prepared using only 1.5 and 1.1 equivalents of the
chloroalkanoyl chlorides respectively, with shorter reaction times (1 hour). The isolated yields of
the chloroesters are reported in Table 1. The structure of the esters 23b and 23c were
unequivocally confirmed by X-ray crystallography (Fig. 12) [52].
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Fig. 12. X-ray crystal structure of esters 23b and 23c
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Table 1. Optimized yields of chloroalkanoyl esters of SCP-1

a

Equivalents of

Time (h)

Yield (%)a

3

16

99

2

3

16

98

23c

3

1.5

1

99

23c

4

1.1

1

99

Compound

n

23a

1

23b

acid chloride

Isolated yields

1.10.2 Synthesis of Nitrate esters of SCP-1 (NO-SCP-1)
The synthesis of the nitrate esters was attempted by using AgNO3 in acetonitrile (Scheme 10).
Reactions were set up by varying the number of equivalents of AgNO3 and the reaction time.
Initially, 1.5 equivalents of AgNO3 was added to 23c and the reaction was heated at reflux for 2
hours. The reaction was monitored by Thin Layer Chromatography (TLC) and after 2 hours, there
was no visible product formation. The reaction time was increased to 6 hours with 2 equivalents
of AgNO3. There was still no product formation by TLC. Reactions were the carried out 3, 4, 6,
8, 10 and 12 equivalents of AgNO3 with different reaction times (Table 2).

Scheme 10. Attempted synthesis of 24b

24

It was concluded that the molecular polarities of the chloroesters and nitrate esters were similar
and therefore had the same Rf values on the TLC plate and also exhibited nearly identical 1H NMR
spectra (Fig. 13).

13

C NMR was found to be extremely valuable for following the reaction

progression. A distinct signal for the (C-ONO2) carbon at δ 73.3 ppm was used to follow the
formation of nitrate esters while the (C-Cl) signal at δ 44.9 ppm inherent to the chloroesters
decreased as 23b was converted to 24b (Fig. 14).

(i)

(ii)
Fig. 13. 1H NMR for (i) 23b and (ii) 24b
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C-Cl
44.9 ppm

(i)

C-ONO2
73.3 ppm

(ii)
Fig. 14. 13C NMR for (i) 23b and (ii) 24b
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Complete conversion of chloroesters to nitrate esters was observed using 12 equivalents of
AgNO3 with a reaction time of 72 hours. Using fewer equivalents of AgNO3 resulted in mixtures
of chloroesters and nitrate esters. This was confirmed by obtaining the X-ray crystal structure of
the product obtained in entry 5 (Table 2). It was observed that the product was a disordered mix
of the chloroester and the nitrate ester which means atomic sites in a single crystal contained a
hybrid atom that contained either the chloro or the nitrate atom. Refinement of the population
parameters yielded 78% chloro and 22% nitrate (Fig. 15).

Fig 15. X-ray crystal structure of chloro and nitrate hybrid product
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Table 2. Optimization yields for nitrate ester 24b

a
b

Entry

Equivalents of AgNO3

Reaction time (h)

Percent yield (%)

1

1.5

2

86a

2

2

6

90a

3

3

24

78a

4

4

48

80a

5

6

48

86a

6

8

72

90a

7

10

72

88a

8

12

72

80b

Mixtures of chloroesters and nitrate esters
Isolated yield of nitrate ester 24b

Reactions were then set up using anhydrous CH3CN to see if would further optimize the
reaction conditions. It was observed that using anhydrous CH3CN, only 2 equivalents of AgNO3
was required for a full conversion to the nitrate ester 24b and the product was obtained in 96%
yield. Furthermore, the reaction time was also reduced to 24 hours (Scheme 11). These optimized
conditions were then used to synthesize nitrate esters 24b to 24d in good yields (>90%). Attempts
to prepare the nitrate ester 24a were unsuccessful and led to an intractable mixture. However, the
longer chain derivatives 24b–d were quite stable and no decomposition was observed over a
period of several months. The structure of the nitrate ester 24b was established by X-ray
diffraction (Fig. 16).
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Scheme 11. Synthesis of nitrate esters 24a-d using optimized condition

Fig 16. X-ray crystal structure of 24b
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1.10.3 Biological evaluation of nitrate esters 24b and 24c
The nitrate esters 24b and 24c were then evaluated for hepatotoxicity. Hepatic GSH
(Glutathione) levels were measured in human liver cells over a period of 3, 6 and 12 h for nitrate
esters 24b (MD-38) and 24c (MD-39). At 500 μM, both 24b (MD-38) and 24c (MD-39) led to
some GSH depletion as compared to SCP-1 and APAP. However, the level remains constant over
a period of 12 h and does not deplete any further (Fig. 17). At 1000 μM of 24b (MD-38) and 24c
(MD-39), GSH levels for both compounds were found to be comparable to SCP-1 and higher than
that of APAP after a period of 12 h. Therefore, both 24b (MD-38) and 24c (MD-39) were well
tolerated by the human hepatocytes and were generally less toxic than APAP.

Fig. 17. Comparison of the glutathione depletion caused by nitrate esters 24b (MD-38) and 24c
(MD-39) over 3 h, 6 h and 12 h with APAP and SCP-1
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Nitrate esters 24b (MD-38) and 24c (MD-39) were also evaluated for necrotic cell death by
measuring LDH (lactate dehydrogenase) release over a period of 12 h (Fig. 18). At a concentration
of 500 μM, 24c (MD-39) had higher LDH release than both APAP and SCP-1 over the 12-hour
period. However, the nitrate ester 24b (MD-38, 500 M) had significantly less LDH release than
APAP and with similar activity to SCP-1. At the higher concentration of 1000 M, 24b (MD-38)
had significantly less LDH release than either APAP or SCP-1. This indicates that that 24b (MD38) is better tolerated than APAP and exhibits a similar necrotic profile to that of SCP-1.

Fig. 18. Comparison of the LDH released by nitrate esters 24b (MD-38) and 24c (MD-39) over
3 h, 6 h and 12 h with APAP and SCP-1
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As shown in Fig. 19, the cytochrome P450 (CYP450) enzyme profiles were also evaluated for
the nitrate esters in three human isozymes (CYP3A4, CYP2E1 and CYP2D6) typically involved
in hepatic drug metabolism. Enzyme inhibition by 24b and 24c was compared to known inhibitors
ketoconazole (keto), tranylcypromine (TCP) and quinidine as well as to APAP and SCP-1. At a
concentration of 1 μM, the compounds 24b and 24c were found not to be enzyme inhibitors and
did not damage the three CYP450 system enzymes tested (CYP3A4, CYP2E1 and CYP2D6). The
enzyme activity levels were generally higher for 24b and 24c than for APAP in CYP3A4 and
CYP2E1 enzymes systems and were similar to SCP-1.

Fig. 19. CYP450 enzyme profiles for 24b (MD-38) and 24c (MD-39).
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Satisfied that the nitrate esters exhibited a toxicity profile superior to APAP and comparable
to SCP-1, it was interesting to evaluate the potential NO-donor capability of terms of possible
enhanced anti-inflammatory activity. It was envisaged that the nitrate esters should exhibit
enhanced anti-inflammatory activity relative to SCP-1 similar that observed for NO-APAP
relative to APAP. To this end, the antipyretic activity was evaluated. SCP-1 does not exhibit
antipyretic activity, so any reduction fever could be presumed to be due to NO-release from the
nitrate esters., Yeast-induced fever reduction in rats was determine for 24b and 24c and
compared to APAP. Rectal temperature was measured 2 hours after the LPS injection and every
2 hours after compound administration. Fig. 20 illustrates that the antipyretic activity of the
nitrate ester 24c (MD-39) was significantly different and comparable to APAP at reducing fever
at the dose tested (1 M). The antipyretic profile of 24b was not significantly different than
vehicle and was slightly less effective than APAP.

Fig. 20. Antipyretic profile for 24b (MD-38) and 24c (MD-39).
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1.11 Water-soluble analogs of SCP-1 and SCP-123

1.11.1 Attempted synthesis of nitrate ester analogs of SCP-123

Strategy 1: Following solubility issues, the focus of the project was then shifted toward the
synthesis of nitrate ester analogs of SCP-123. Since it has been previously established that SCP-1
is a prodrug and it is converted to SCP-123 in vivo, it was envisioned that the nitrate ester analogs
of SCP-123 would be more effective and will be more water-soluble. This strategy involved the
hydrolysis of already synthesized nitrate esters of SCP-1. One equivalent of 0.5 N solution of
sodium hydroxide was added to 24c and the reaction was left to stir overnight at room temperature.
However, the 13C NMR showed a shift in the C-ONO2 peak from 73.3 ppm to 56.4 ppm which
suggests hydrolysis of the nitrate ester to the alcohol 25 (Scheme 12). The reaction was then
repeated with 0.5 N solution of LiOH and KOH, however, the result was the same. It was therefore
concluded, that even a dilute solution of LiOH, NaOH and KOH resulted in the hydrolysis of the
nitrate ester to an alcohol.

Scheme 12. Attempted synthesis of nitrate ester analogs of SCP-123 (Strategy 1)
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Strategy 2: The next attempt at synthesizing water-soluble analogs involved the hydrolysis of
the saccharin ring in SCP-1 while simultaneously forming the ester. To achieve this, sodium 2bromoethoxide, which was first prepared from sodium hydride and 2-bromo-1-ethanol, was added
to SCP-1. This produced the bromoester intermediate 26 in moderate yield (66%) (Scheme 13).
The intermediate 26 was then reacted with AgNO3. The reaction was followed by TLC and it was
observed that the intermediate had converted to SCP-1 instead of the nitrate ester. It was concluded
that the heat required for this reaction facilitates ring closure and forms produces SCP-1.

Scheme 13. Attempted synthesis of nitrate ester analogs of SCP-123 (Strategy 2)
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1.11.2 O-glycosylation of SCP-1
Since the attempts at synthesizing nitrate ester analogs of SCP-123 were not successful, a
different approach was sought to synthesize derivatives that were water-soluble. Incorporating a
glucose molecule would not only increase the water solubility but also lower the toxicity. It was
decided that the phenolic OH could by glycosylated using glucose pentaacetate as the donor.
Instead of glycosylating SCP-1, chloroacetamide (18) was O-glycosylated first after which sodium
salt of saccharin (15) was added to it. In 1942, Bembry and Powell synthesized phenolic
glycosides using fully acylated sugar in the presence of phosphorus oxychloride (POCl3) [53].
Using the same approach, chloroacetamide 18 was dissolved in anhydrous benzene and reacted
with -D-glucose pentaacetate (27) in the presence of 99% POCl3/water as the catalyst which
produced the  anomer of the glycosylated chloroacetamide in 12 % yield (Scheme 14).

Scheme 14. Synthesis of -glycoside tetraacetate of 18 using POCl3 as catalyst

In order to achieve higher yields and cleaner reaction conditions, the Schmidt
glycosylation method was utilized [54]. This method involves the use of a Lewis acid like
BF3•OEt2 as the catalyst. Using this approach, 18 was dissolved in anhydrous dichloromethane
(DCM) at 0 ℃ followed by the addition of BF3•OEt2 and  (Scheme 15). The low temperature
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facilitates the formation of the ortho ester which when heated up gave the O-glycoside as a mixture
of  and  anomers in 43% and 57% yield respectively. The mixture of anomers was separated
by column chromatography.

Scheme 15. Synthesis of O-glycoside tetraacetate of 18 using BF3•OEt2 as catalyst
The  and  anomers were characterized using 1H NMR spectroscopy. One distinguishable
characteristic is the spin spin coupling (JH-H) of the anomeric proton. The alpha anomeric proton
(equatorial) has a coupling constant of about 3 Hz, while the beta anomeric proton (axial) has a
coupling constant of about 7.9 Hz (Fig. 21).

Beta

Alpha

7.9 Hz

3 Hz

Fig 21. Spin spin coupling of anomeric protons
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The structure of 29 was also confirmed using X-ray crystallography (Fig. 22).

Fig. 22. X-ray crystal structure of 29

 was then treated with the 15 in the presence of a catalytic amount of sodium iodide (NaI). The
reaction was heated for 2 hours after which it was poured over ice. The -glycoside of SCP-1 (30)
precipitated in quantitative yield as an off-white solid (Scheme 16). The product was characterized
by 1H NMR, 13C NMR and mass spectrometry.

Scheme 16. Synthesis of -O-glycoside tetraacetate of SCP-1
38

The final step involves the deacetylation of the glucose molecule. This was achieved by
treating the -O-glycoside tetraacetate of SCP-1 (30) with potassium cyanide in anhydrous
methanol (Scheme 17). The reaction was monitored by TLC which showed the deacetylation of
every acetyl group one by one as multiple product spots developed. Only one spot remained after
18 hours which indicated complete deacetylation. The product (31) was obtained as a yellow solid
in 67% yield.

Scheme 17. Synthesis of -O-glycoside of SCP-1

1.11.3 Synthesis of amides of SCP-1

A series of amide analogues of SCP-1 were synthesized. This was achieved by reacting SCP1 with various alkyl amino alcohols and amino acids. The nucleophilic amines attacked the
carbonyl group on the saccharin moiety and then formed the respective amides. First, a series of
alkyl amino alcohols 32-37 (Fig. 23) were reacted with SCP-1 in ethanol. The reactions were
heated at reflux overnight. The products 38-43 (Fig. 24) were extracted in ethyl acetate and
obtained as shiny white solids in low to moderate yields (23-48%) (Scheme 18). These compounds
were found to be very hygroscopic and water-soluble. This resulted in low yields as a large amount
of the product dissolved in the aqueous layer during the liquid/liquid extraction. The compounds
were obtained in high purity and no further purification was required.
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Fig. 23. Alkyl amino alcohols used

Scheme 18. Synthesis of amides of SCP-1 using amino alcohols 32-37

Table 3. Optimized yields of amides 38-43
Compound no.

Amine used

Isolated Yield (%)

38

32

23

39

33

24

40

34

24

41

35

30

42

36

47

43

37

48

40

Fig. 24. Structures of amides of SCP-1 38-43

The same procedure was also used to synthesize 44 by reacting SCP-1 with ammonia (NH3).
The reaction was carried out at room temperature without any solvent and gave the product in
78% yield as a colorless oil (Scheme 19).

Scheme 19. Synthesis of amide 44
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The scope of the reaction was further explored by using amino acids glycine hydrochloride
(45) and -alanine methyl ester hydrochloride (46). These reactions required the addition of a base
which converted the hydrochloride salt into the free base. Two equivalents of sodium bicarbonate
(NaHCO3) was used for this purpose. Reactions were carried out in methanol and DMF
respectively to give products 47 and 48 as white solids in moderate yields (49-50%) (Scheme 20).

Table 4. Synthesis of amides of SCP-1 using amino acids 45 and 46
Amino acid

Amino acid structure

Solvent

Isolated yield (%)

45

MeOH

49

46

DMF

50

Scheme 20. Synthesis of amides of SCP-1 using amino acids 45 and 46
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1.11.4 Hydrophobicity studies
Hydrophobicity studies were conducted on compounds 39-43, 47 and 48. The
hydrophobicity of any compound can be measured by calculating the logP value where P is the
partition coefficient between octanol and water. Lower the logP value, the less hydrophobic the
compound. In general, water-soluble compounds have a logP value of less than 1.
Equal amounts of octanol and water needed to be stirred overnight. The water-saturated
octanol layer and octanol-saturated water layer were then stored in separate bottles. The
Octanol-saturated water was used to prepare 5M, 10 M, 20 M, 40 M and 60 M solutions
of each compound. UV-vis spectroscopy was used to measure the absorbance between 200-450
nm (Fig. 25) for each concentration and a calibration curve was produced (Fig. 26).

3.50E+00
3.00E+00

Absorbance

2.50E+00
2.00E+00
1.50E+00
1.00E+00
5.00E-01
0.00E+00
200

250

300

350

400

Wavelength (nm)
5 uM

10 uM

20 uM

40 uM

Fig. 25. Absorbance chart for 39

43

60 uM

450

0.6
y = 0.0079x + 0.0098
R² = 0.9994

0.5
0.4

Series1

0.3

Linear (Series1)
0.2
0.1
0
0

20

40

60

80

Fig. 26. Calibration curve for 39 at 250 nm

Table 5. Wavelengths used to produce calibration curve for each compound
Compound

Wavelength used for calibration curve

39
40

250
(nm)
248

41

250

42

240

43

250

47

230

48

225

Next, seven samples of 50 M solutions were prepared. Six of these samples were shaken
with water-saturated Octanol for 4 hours. Once it was shaken, some of the sample dissolved in the
octanol layer. One sample was left unshaken. UV-vis spectroscopy was used to measure the
absorbance for octanol-saturated water for all seven samples. Using the calibration curve, the
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concentration of the compound in the octanol-saturated water was calculated (Fig. 27) after which
the average of the six shaken samples were taken. The concentration of the compound in the
octanol layer can be calculated by subtracting the concentration of the sample in the water layer
of the shaken sample from the concentration in water of the unshaken sample.

The partition coefficient (P) of each compound was then calculated using the formula:

P=

𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑂𝑐𝑡𝑎𝑛𝑜𝑙

x 100

𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑤𝑎𝑡𝑒𝑟

Therefore, P =

𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑢𝑛𝑠ℎ𝑎𝑘𝑒𝑛−𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠ℎ𝑎𝑘𝑒𝑛
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠ℎ𝑎𝑘𝑒𝑛

x 100
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Fig. 27. Concentration of all shaken and unshaken samples for each compound
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The logP values of compounds 39-43, 47 and 48 are depicted in the chart below (Fig. 28).
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-0.4

47
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-0.6

-0.48
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-0.67

-0.8

Fig. 28. LogP values of the amides compared to SCP-1 and APAP

Table 6. Comparison between logP and clogP values [55]

Compound

LogP

clogP

39

-0.11

-0.13

40

-0.48

-0.77

41

-0.021

0.08

42

-0.67

-0.77

43

0.099

0.08

47

-0.48

-0.45

48

0.25

0.1
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As shown in Fig. 28, the logP values of SCP-1 and APAP are 0.71 and 0.27 respectively. With
a logP value of greater than 0.5, SCP-1 has very low water solubility and therefore has poor
bioavailability and also affects the transport of the drug between cell membranes. APAP has a
lower logP value and therefore is more water-soluble than SCP-1. The amides 39-43, 47 and 48
have very low logP values with 39-42 and 47 having negative logP values (-0.11, -0.48, -0.021
and -0.67) and 43 having logP value close to zero. The logP values of the amides are very close
and comparable to the computational logP (clogP) values (Table 6). These values prove that these
amides are highly water-soluble and can prove to be ideal drug candidates. This will undoubtedly
increase their oral bioavailability and possibly reduce toxicity.
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CONCLUSION
In summary, a series of novel nitrate ester congeners of the acetaminophen derivative SCP-1
were synthesized. The nitrate esters 24b (MD-38) and 24c (MD-39) exhibited a hepatotoxicity
profile similar to SCP-1. In addition, the nitrate esters exhibited little effect on the three
cytochrome P450 isozymes tested (CYP3A4, CYP2E1 and CYP2D6). The nitrate ester 24c (MD39) exhibited antipyretic activity similar to APAP. Overall, these preliminary studies
demonstrated that attachment of a NO-donor moiety to the SCP-1 ring system can lead to
compounds with enhanced antipyretic activity compared to SCP-1 without increased toxicity.
Following solubility issues, a series of water-soluble analogs of SCP-1 were synthesized.
These was achieved by synthesizing O-glycosylated analogs and amide derivatives of SCP-1 A
series of amides were prepared by hydrolysis of the saccharin moiety. Amides 39-43, 47 and 48
underwent hydrophobicity studies. All amides were found to be highly water-soluble having low
logP values comparable to the clogP values. Further testing of these compounds is underway and
results will be reported in due course.
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EXPERIMENTAL
General information
All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, or VWR and were used as
received without further purification. Chromatography refers to flash silica gel column
chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent Technology was used as the
stationary phase). 1H NMR and 13C NMR spectra were recorded at room temperature in DMSOd6 on a Bruker 300 MHz instrument. 1H chemical shifts were referenced to the DMSO solvent
signal (2.48 ppm). 13C chemical shifts were referenced to the DMSO solvent signal (40.00 ppm).
Atlantic Microlab Inc., Norcross, GA performed all CHN microanalyses.

General procedure A: Preparation of chloroesters of SCP-1 (23a-d)
SCP-1 (1.00 g, 3.00 mmol) was dissolved in 2% solution of triflic acid in acetonitrile (15 mL) (A
1% solution was used for the preparation of acetyl ester 23a) followed by the indicated amount of
acid chloride. The mixture was stirred at room temperature and the reaction was followed by TLC
(70% EtOAC-Hex). When no more starting material was seen by TLC, the mixture was poured
over ice-cold water (50 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layer was
washed with 1N HCl (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL). The organic layer
was then dried over anhydrous sodium sulfate. The sodium sulfate was filtered and the solvent
was removed in vacuo to yield a white solid.
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4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl-2chloroacetate (23a)

General procedure A. Product was prepared using chloroacetyl chloride (0.720 mL, 9.00 mmol,
3 equiv., 16 h) and was isolated as a white solid (1.21 g, 99% yield). mp 199.1-200.0 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 10.45 (s, 1H), 8.36 (d, J = 7.7, 1H), 8.17 (d, J = 7.7Hz, 1H),

8.12-8.01 (m, 2H), 7.61 (d, J = 8.8, 2H), 7.15 (d, J = 8.8, 2H), 4.68 (s, 2H), 4.59 (s, 2H).
C NMR (DMSO-d6, 75 MHz) : 166.8, 163.7, 159.1, 146.3, 137.4, 136.8, 136.4, 135.7, 126.8,

13

125.6, 122.2, 122.1, 120.7, 41.7.

4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl-3chloropropionate (23b)
General procedure A. Product was prepared using 3-chloropropionyl chloride (0.86 mL, 9.0
mmol, 3 equiv., 16 h) and was isolated as a white solid (1.24 g, 98% yield). mp 195.3-197.0 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34 (d, J = 7.7 Hz. 1H)), 8.15 (d, J = 7.4 Hz,

1H), 8.05 (dt, J = 23.1, 7.4 Hz, 2H), 7.58 (d, J = 8.9, 2H), 7.08 (d, J = 8.9, 2H), 4.57 (s, 2H), 3.88
(t, J = 6.2 Hz, 2H), 3.08 (t, J = 6.2 Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 169.6, 163.7, 159.1, 146.3, 137.4, 136.6, 136.4, 135.8, 126.8,

13

125.6, 122.4, 122.2, 120.6, 41.1, 37.5.
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4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl-4chlorobutanoate (23c)
General procedure A. Product was prepared using 4-chlorobutyryl chloride (0.5 mL, 4.5 mmol,
1.5 equiv., 1 h) and was isolated as a white solid (1.30g, 99% yield). mp 189.2-190.6 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 10.40 (s, 1H), 8.34 (d, J = 9 Hz, 1H), 8.15 (d, J = 7.3 Hz, 1H),

8.11-8.00 (m, 2H), 4.57 (s, 2H), 3.72 (t, J = 6.4 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.06 (p, J = 7.0
Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 171.5, 163.7, 159.1, 146.5, 137.4, 136.3, 135.7, 126.8, 125.6,

13

122.5, 122.1, 120.6, 44.8, 41.1, 31.3, 27.8.

4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl-5chloropentanoate (23d)
General procedure A. Product was prepared using 5-chlorovaleroyl chloride (0.43 mL, 3.3
mmol, 1.1 equiv., 1 h) and was isolated as a white solid (1.34g. 99% yield). mp (154.4-155.9 ℃).
1

H NMR (DMSO-d6, 300 MHz) : 10.40 (s, 1H), 8.35 (d, J = 7.5 Hz, 1H), 8.15 (d, J = 7.0 Hz,

1H), 8.00-8.17 (m, 2H), 7.57 (d, J = 8.9 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 4.57 (s, 2H), 3.67 (t, J
= 6.1 Hz, 2H), 2.60 (t, J = 7.1 Hz, 2H), 1.82-1,70 (m, 4H).
C NMR (DMSO-d6, 75 MHz) : 172.1, 163.7, 159.1, 146.5, 137.4, 136.4, 136.4, 133.8, 126.8,

13

125.6, 122.5, 122.2, 120.6, 45.4, 41.0, 33.0, 31.7, 22.1.
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General procedure B: Preparation of nitrate esters of SCP-1 (24b-d)
The chloroester (3.00 mmol) was dissolved in dry acetonitrile (20 mL) and silver nitrate (1.02g,
6.00 mmol) was then added to the solution. The mixture was heated at reflux for 24 h. The
precipitate was filtered through a pad of Celite. The filtrate was then poured into water (50 mL)
and extracted with ethyl acetate (3 x 20 mL). The organic layer was washed with brine (3 x 20
mL) and dried over anhydrous sodium sulfate. The sodium sulfate was filtered and the solvent
was removed in vacuo. The residue was recrystallized from ethyl acetate/hexanes to yield a yellow
solid.

4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl 3(nitrooxy)propionate (MD-38, 24b)
General procedure B. Product was isolated as a yellow solid (1.29g, 96% yield). mp 174.3 ℃
(decomp).
1

H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 7.4 Hz,

1H), 8.11-7.99 (m, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 8.8 Hz, 2H), 4.57 (s, 2H), 3.89 (t, J
= 6.2 Hz, 2H), 3.08 (t, J = 6.2 Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 169.3, 163.7, 159.1, 146.3, 137.4, 136.6, 136.4, 135.8, 126.8,

13

125.6, 122.4, 122.2, 120.6, 69.3, 32.0.
Anal. calcd. for C18H15N3O9S: C, 48.11; H, 3.36; N, 9.35. Found: C, 48.02; H, 3.45; N, 9.10.
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4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl 4(nitrooxy)butanoate (MD-39, 24c)
General procedure B. Product was isolated as a yellow solid (1.25g, 90% yield). mp 159.1 ℃
(decomp.).
1

H NMR (DMSO-d6, 300 MHz) : 10.42 (s, 1H), 8.36 (d, J = 7.7 Hz, 1H), 8.16 (d, J = 7.3 Hz,

1H), 8.06 (dt, J = 15.4, 7.4 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 4.61 (t, J =
5.8 Hz, 2H), 4.59 (s, 2H), 2.70 (t, J = 7.0, 2H), 2.03 (p, J = 6.9 Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 171.6, 163.7, 159.1, 146.5, 137.4, 136.5, 126.8, 125.6, 122.5,

13

122.2, 120.5, 73.2, 30.2, 22.1.
Anal. calcd. for C19H17N3O9S: C, 49.24; H, 3.70; N, 9.07. Found: C, 49.18; H, 3.75; N, 9.00.

4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)acetamido)phenyl 5(nitrooxy)pentanoate (24d)
General procedure B. Product was isolated as a yellow solid (1.33g, 93% yield). mp 144.6 ℃
(decomp.).
1

H NMR (DMSO-d6, 300 MHz) : 10.41 (s, 1H), 8.34, (d, J = 7.7, 1H), 8.15 (d, J = 8.0, 1H), 8.11-

7.99 (m, 2H), 7.57 (d, J = 8.9 Hz, 2H), 7.08 (d, J = 8.9 Hz, 2H), 4.58 (s, 1H), 4.55 (t, J = 6.1 Hz,
2H), 2.62 (t, J = 6.8 Hz, 2H), 1.81-1.63 (m, 4H).
C NMR (DMSO-d6, 75 MHz),  172.0, 163.7, 159.1, 146.5, 137.4, 136.4, 135.6, 126.8, 125.6,

13

122.5, 122.1,121.4,120.6, 73.8, 33.1, 25.8, 21.0.
Anal. calcd. for C20H19N3O9S: C, 50.31; H, 4.01; N, 8.80. Found: C, 50.06; H, 4.12; N, 8.67.
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Preparation of 2-(acetoxymethyl)-6-(4-(2-chloroacetamido)phenoxy)tetrahydro2H-pyran-3,4,5-triyl triacetate (O-glycoside of chloroacetaminophen, 29)
2-Chloroacetaminophen (0.501g, 2.70 mmol) was dissolved in anhydrous dichloromethane (20
mL). followed by the addition of -D-Glucose pentaacetate (0.952g, 2.44 mmol). The mixture
was cooled in an ice bath to 0 ℃. BF3•OEt2 (0.452 mL, 3.66 mmol) was then added to the solution
dropwise and the reaction was stirred at 0 ℃ for 30 minutes. The reaction was then heated at
reflux for 18 hours. The reaction was quenched with 1N NaOH solution and the layers were
separated. The aqueous layer was extraction with dichloromethane (3 x 10 mL). The organic layers
were combined and washed with brine (20 mL). The organic layer was dried over anhydrous
Na2SO4 and filtered. The solvent was removed under vacuum and the residue was purified using
column chromatography (50% EtOAc/Hexanes). The  anomer was isolated as a colorless oil
(0.717g, 57% yield).
1

H NMR (DMSO-d6, 300 MHz) : 10.23 (s, 1H), 7.50 (d, J = 9.0 Hz, 2H), 6.95 (d, J = 10.3 Hz,

2H), 6.15 (d, J = 3 Hz, 1H), 5.45 (t, J = 9.9 Hz, 1H), 5.32 (t, J = 9.9 Hz, 1H), 5.10-4.97 (m, 2H),
4.21 (s, 2H), 4.02-3.97 (m, 2H), 2.16 (s, 12H).

Preparation of 2-(acetoxymethyl)-6-(4-(2-(1,1-dioxido-3-oxobenzo[d]isothiazol2(3H)-yl)acetamido)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (-Dglycoside of SCP-1, 30)
29 (1.50 g, 3.00 mmol) and 15 (0.743g, 3.62 mmol) were dissolved in anhydrous DMF (20 mL).
Sodium iodide (0.0500g, 0.300 mmol) was then added to it. The reaction was stirred at 110 ℃
for 2 h. Any solids were filtered off and the filtrate was poured over ice-water. More ice was
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added until no more precipitate formed. The precipitate was filtered off and dried under vacuum
to give 30 as a yellow solid (2.00 g, 100% yield). mp 196-198 ℃
1

H NMR (DMSO-d6, 300 MHz) : 10.28 (s, 1H), 8.34 (d, J = 7.7 Hz, 2H), 8.20 – 7.98 (m, 3H),

7.50 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 5.47 (d, J = 7.8 Hz, 1H), 5.38 (t, J = 9.6 Hz,
1H), 5.08 – 4.93 (m, 2H), 4.54 (s, 2H), 4.21 (s, 2H), 4.05 (d, J = 10.8 Hz, 1H), 2.02 – 1.94 (m,
12H).

Preparation of 2-(1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)-N-(4-((3,4,5trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamide
(31)
30 (2.00g, 3.00 mmol) was dissolved in anhydrous MeOH (20 mL) and potassium cyanide (0.100
g, 1.51 mmol) was added to it. The reaction was stirred at room temperature for 18 h. The mixture
was passed through a silica gel plug. The solvent was removed under vacuum to give 32 as a
yellow solid (1.00 g, 67% yield). mp 152 ℃ (decomp.)
1

H NMR (DMSO-d6, 300 MHz) : 10.27 (s, 1H), 8.33 (d, J = 7.7 Hz, 2H), 8.11-7.95 (m, 3H), 7.53

(d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 5.83 (d, J = 7.8 Hz, 1H), 4.21 (s, 2H), 3.96-3.42 (m,
10 H).

General procedure C: Preparation of amides of SCP-1 (38-43, 47-48)
SCP-1 (1.00g, 3.00 mmol) was dissolved in absolute ethanol (30 mL). The amino alcohol 32-37
(9.00 mmol) was added to the reaction mixture. The solution was stirred at reflux for 24 h. The
reaction mixture was cooled down to room temperature and then diluted with deionized water (50
mL). The aqueous solution was extracted with ethyl acetate (3 x 20 mL). The organic layers were
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combined and washed with 2N HCl (20 mL) and brine (20 mL). The organic layer was dried over
anhydrous Na2SO4, filtered and the solvent was removed under vacuum to give amides 38-43 and
47-48.

N-(5-hydroxypentyl)-2-(N-(2-((4-hydroxyphenyl)amino)-2oxoethyl)sulfamoyl)benzamide (38)

General procedure C. The product was prepared using 32 (1.00 mL, 9.00 mmol) and was isolated
as a light pink solid (0.300 g, 23 % yield).

1

H NMR (DMSO-d6, 300 MHz) : 9.75 (s, 1H), 9.18 (s, 1H), 8.75 (t, J = 5.6 Hz, 1H), 7.87 (d, J

= 7.5 Hz, 1H), 7.71 – 7.5 (m, 2H), 7.52 (d, J = 7.3 Hz, 1H), 7.42 (t, J = 5.9 Hz, 1H), 7.19 (d, J =
8.9 Hz, 2H), 6.63 (d, J = 8.9 Hz, 2H), 3.65 (d, J = 5.9 Hz, 2H), 3.39 (t, J = 6.4 Hz, 2H), 3.23 (q, J
= 6.8 Hz, 2H), 1.45 (dtd, J = 33.9, 14.6, 5.9 Hz, 9H).

C NMR (DMSO-d6, 75 MHz) : 168.7, 165.8, 154.0, 138.0, 137.3, 136.3, 133.2, 130.3, 129.7,

13

129.0, 121.4, 115.5, 61.1, 46.4, 32.7, 29.0, 23.4.

2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)-N-(3hydroxypropyl)benzamide (39)
General procedure C. The product was prepared using 33 (0.700 mL, 9.00 mmol) and was
isolated as a white solid (0.300 g, 24 % yield).
1

H NMR (DMSO-d6, 300 MHz) : 9.75 (s, 1H), 8.72 (t, J = 5.6 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H),

7.70 – 7.57 (m, 2H), 7.52 (d, J = 8.8 Hz, 1H), 7.43 (t, J = 5.9 Hz, 1H), 7.19 (d, J = 8.9 Hz, 2H),
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6.63 (d, J = 6.8 Hz, 2H), 3.65 (d, J = 5.9 Hz, 2H), 3.48 (t, J = 6.3 Hz, 2H), 3.30 (q, J = 6.6 Hz,
2H), 1.68 (p, J = 6.5 Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 168.7, 165.8, 154.0, 137.3, 136.3, 133.2, 130.3, 129.7, 129.0,

13

121.4, 115.5, 59.0, 46.4, 37.2, 32.4.
Anal. Calcd. for C18H21N3O6S•H2O: C, 50.81; H, 5.45; N, 9.88. Found: C, 50.80; H, 5.47; N, 9.78

N-(1,3-dihydroxypropan-2-yl)-2-(N-(2-((4-hydroxyphenyl)amino)-2oxoethyl)sulfamoyl)benzamide (40)
General procedure C. The product was prepared using 34 (0.820 mL, 9.00 mmol) and isolated
as a white solid (0.305g, 24 % yield).
1

H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 9.19 (s, 1H), 8.56 – 8.41 (m, 1H), 7.84 (d, J = 8.7

Hz, 1H), 7.74 (t, J = 6.0 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.59 – 7.52 (m, 2H), 7.10 (d, J = 8.8 Hz,
2H), 6.61 (d, J = 8.8 Hz, 2H), 4.86 (t, J = 5.3 Hz, 2H), 3.93 (dt, J = 7.9, 5.7 Hz, 1H), 3.76 – 3.70
(m, 2H), 3.53 (t, J = 5.4 Hz, 4H).
C NMR (DMSO-d6, 75 MHz) : 168.1, 166.2, 154.1, 137.1, 136.7, 133.1, 130.2, 130.0, 129.80,

13

129.0, 121.7, 115.48, 60.6, 54.3, 46.1.
Anal. Calcd. for C18H21N3O7S•H2O: C, 48.97; H, 5.25; N, 9.52. Found: C, 48.97; H, 5.25; N, 9.50
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N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)-N-(1-hydroxypropan-2yl)benzamide (41)
General procedure C. The product was prepared using 35 (0.700 mL, 9.00 mmol) and isolated
as a white solid (0.366 g, 30 % yield).
1

H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 8.76 (t, J = 6.3 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H),

7.68 – 7.51 (m, 5H), 7.12 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 3.81 (q, J = 5.9 Hz, 1H),
3.69 (d, J = 5.9 Hz, 2H), 3.53 (s, 2H), 3.40 (s, 3H), 3.24 –3.15 (m, 1H).
C NMR (DMSO-d6, 75 MHz) : 168.1, 165.7, 153.6, 136.1, 132.8, 129.8, 129.3, 128.6, 121.2,

13

115.1, 65.1, 47.0, 45.8, 21.1.
Anal. Cald. for C18H21N3O6S•H2O: C, 50.81; H, 5.45; N, 9.88. Found: C, 50.81; H, 5.49; N, 9.86.

N-(2,3-dihydroxypropyl)-2-(N-(2-((4-hydroxyphenyl)amino)-2oxoethyl)sulfamoyl)benzamide (42)
General procedure C. The product was prepared using 36 (0.700 mL, 9.00 mmol) and isolated
as a white solid (0.600 g, 47% yield).
1

H NMR (DMSO-d6, 300 MHz) : 9.76 (s, 1H), 9.18 (s, 1H), 8.72 (t, J = 6.3 Hz, 1H), 7.85 (dd, J

= 7.6, 1.1 Hz, 1H), 7.66 (td, J = 7.6, 1.4 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.56 – 7.52 (m, 1H), 7.13
(d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 4.94 (d, J = 4.8 Hz, 1H), 4.57 (t, J = 5.2 Hz, 1H),
3.72 – 3.68 (m, 2H), 3.38 (t, J = 5.6 Hz, 2H), 3.29 (s, 2H), 3.19 – 3.03 (m, 1H).
C NMR (DMSO-d6, 75 MHz) : 168.6, 166.0, 154.0, 137.2, 136.4, 133.1, 130.2, 129.8, 129.0,

13

121.6, 115.5, 70.6, 64.2, 46.2, 43.3.
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Anal. Calcd. for C18H21N3O7S: C, 51.06; H, 5.00; N, 9.92. Found: C, 50.88; H, 5.25: N, 9.76.

2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)-N-(2hydroxypropyl)benzamide (43)

General procedure C. The product was prepared using 37 (0.700 mL, 9.00 mmol) and isolated
as a white solid (0.600 g, 48% yield).
1

H NMR (DMSO-d6, 300 MHz) : 9.78 (s, 1H), 8.76 (t, J = 6.3 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H),

7.68 – 7.51 (m, 5H), 7.12 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 3.81 (q, J = 5.9 Hz, 1H),
3.69 (d, J = 5.9 Hz, 2H), 3.53 (s, 2H), 3.40 (s, 3H), 3.24 –3.15 (m, 1H).
C NMR (DMSO-d6, 75 MHz) : 168.1, 165.7, 153.6, 136.1, 132.8, 129.8, 129.3, 128.6, 121.2,

13

115.1, 65.1, 47.0, 45.8, 21.1.
Anal. Calcd. for C18H21N3O6S: C, 53.06; H, 5.20; N, 10.31. Found: C, 52.99; H, 5.40; N, 10.07.

2-(2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)benzamido)acetic
acid (47)
SCP-1 (1.00g, 3.00 mmol) was dissolved in absolute MeOH (30 mL). Glycine hydrochloride (1.00
g, 9.00 mmol) and NaHCO3 (0.504 g, 6.00 mmol) were added to the reaction mixture. The solution
was stirred at reflux for 24 h. The reaction mixture was cooled down to room temperature and
then diluted with deionized water (50 mL). The aqueous solution was extracted with ethyl acetate
(3 x 20 mL). The organic layers were combined and washed with 2N HCl (20 mL) and brine (20
mL). The organic layer was dried over anhydrous Na2SO4, filtered and the solvent was removed
under vacuum to give amide 47 as a white solid (0.600 g, 49% yield).
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1

H NMR (DMSO-d6, 300 MHZ) : 9.73 (s, 1H), 9.18 (s, 1H), 9.07 (t, J = 5.9 Hz, 1H), 7.93 –

7.81 (m, 1H), 7.74 – 7.66 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 (t, J = 5.9 Hz, 1H), 7.15 (d, J = 8.8
Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 3.98 (d, J = 5.8 Hz, 2H), 3.69 (d, J = 6.0 Hz, 2H).
C NMR (DMSO-d6, 75 MHz) : 171.6, 168.7, 165.9, 154.0, 137.4, 135.7, 133.2, 130.5, 129.9,

13

129.1, 121.5, 115.5, 46.2, 41.5.
Anal. Calcd. for C17H17N3O7S•H2O: C, 48.00; H, 4.50; N, 9.88. Found: C, 47.95; H, 4.60; N,
9.78.

Methyl 3-(2-(N-(2-((4-hydroxyphenyl)amino)-2-oxoethyl)sulfamoyl)benzamido)
propanoate (48)
SCP-1 (1.00g, 3.00 mmol) was dissolved in anhydrous DMF (30 mL). -Alanine methyl ester
hydrochloride (1.26 g, 9.00 mmol) and NaHCO3 (0.504 g, 6.00 mmol) were added to the reaction
mixture. The solution was stirred at 90 ℃ for 24 h. The reaction mixture was cooled down to room
temperature and then diluted with deionized water (50 mL). The aqueous solution was extracted
with ethyl acetate (3 x 20 mL). The organic layers were combined and washed with 2N HCl (20
mL) and brine (20 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the
solvent was removed under vacuum to give amide 48 as a white solid (0.653 g, 50% yield).

1

H NMR (DMSO-d6, 300 MHz) : 9.73 (s, 1H), 9.18 (s, 1H), 8.89 – 8.78 (m, 1H), 7.86 (d, J = 7.5

Hz, 1H), 7.63 (dq, J = 14.1, 6.9 Hz, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 8.8
Hz, 2H), 6.66 – 6.58 (m, 2H), 3.66 (s, 2H), 3.60 (s, 3H), 3.47 (q, J = 6.7 Hz, 2H), 2.61 (t, J = 6.9
Hz, 2H).
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C NMR (DMSO-d6, 75 MHz) : 171.8, 168.5, 165.4, 153.6, 136.9, 135.6, 132.8, 130.0, 129.2,

13

128.6, 121.1, 115.1, 51.5, 45.9, 35.4, 33.1.

Anal. Calcd. for C19H21N3O7S: C, 52.41; H, 4.86; N, 9.65. Found: C, 52.33; H, 4.90; N, 9.47.
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CHAPTER 2
Scalable synthesis and functionalization of a series of novel 3,3-diarylazetidines
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ABSTRACT

The 3,3-diarylazetidine ring has recently emerged as an important molecular scaffold in
medicinal chemistry. The constrained 3,3-diarylazetidine ring system provides a well-defined
positioning of the arene substituents, increased rigidity, fewer rotatable bonds relative to
corresponding acyclic system and can be isosteric with N-diarylmethylamines and geminal diaryl
functional groups. With the emerging interest in 3,3-diarylazetidines as novel motifs in drug
discovery programs, an easy, efficient, scalable synthetic method that could accommodate the
introduction of both electron-rich and electron-deficient aryl groups for preparation of diversely
substituted 3,3-diarylazetidines would be valuable to medicinal chemists. In this second project, a
versatile synthesis of 3,3-diaryl azetidines from N-Boc-3-aryl-3-azetidinols using Friedel-Crafts
arylation conditions with AlCl3 is described. A series of substituted diaryl azetidines were readily
prepared and isolated as the oxalate salts in high yield and high purity. The 3,3-diaryl azetidine
oxalates were then easily converted into N-alkyl and N-acyl analogues in high overall yields
(>85%).
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INTRODUCTION
2.1 Diarylmethanes
The importance of diarylalkanes as pharmaceutically active compounds has been well
documented. Various diarylmethane based molecules like podophyllotoxin (49), peperomin B
(50), tolterodine (51) and lasofoxifene (52)

exhibit antibacterial, antiprotozoal, anti-

inflammatory, antimuscarinic and anticonvulsant activity [56] [57] [58] [59].

Fig. 29. Some well-known biologically active diarylmethanes
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2.1.1 Synthesis of diarylmethanes

Diarylmethanes have mostly been synthesized via Friedel–Craft’s alkylation of the
corresponding benzyl alcohols with another arene, metal catalyzed cross coupling of aryl halides
with benzyl nucleophiles, metal catalyzed cross coupling of benzyl halides with aryl nucleophiles
and C–C bond formation between tosyl hydrazones and aryl boronic acids.

2.1.1.1 Friedel–Crafts reaction

In 1997, S. Fukuzawa et al. reported trifluoromethane sulfonic acid (TFSA) catalyzed
reductive Friedel–Craft’s alkylation of benzaldehyde acetals for the preparation of diarylmethanes
(Scheme 21) [60]. When low boiling arenes were used, the arene served as the solvent as well as
the reagent while for high boiling arenes 1,2-dichloroethane or nitromethane was used as a solvent.
Though both electron rich as well as electron poor aldehyde acetals responded to this reaction, the
reaction rate was faster with the electron rich aldehyde acetals with the ratio of ortho:meta:para
ratio being same as that observed for general Lewis acid catalyzed Friedel–Craft’s alkylation
reaction.

Scheme 21. Synthesis of diarylmethane using Friedel-craft’s alkylation
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Sun et al. in 2006 reported indium (III) chloride catalyzed electrophilic substitution of
trioxanes with arenes for the preparation of diarylmethanes [61]. The authors found that the
reaction was high yielding only with electron rich arenes while electronically poor ones gave low
yield. Later, the authors reported indium trichloride acetyl acetone to be an efficient Lewis catalyst
for the Friedel–Craft’s arylation of benzyl alcohols for the efficient preparation of diarylmethanes
(Scheme 22) [62].

Scheme 22. Synthesis of diarylmethanes using indium (III) chloride as catalyst

In 2009, Myrboh et al. reported AlCl3 catalyzed Friedel–Craft’s alkylation of benzylazines
with polynuclear hydrocarbons to form diarylmethanes in aprotic solvents [63]. The
corresponding azines were accessed from the respective carbonyl compounds through
condensation with aqueous solution of hydrazines.

Mendoza et al. in 2011 reported Bronsted acid catalyzed arylation of benzyl acetates and anisyl
acetates with arenes for the preparation of diarylmethanes (Scheme 23) [64]. Trifluoromethane
sulfonic acid and triflimide respectively were used as the Bronsted acid catalyst.
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Scheme 23. Bronsted and Lewis acid catalyzed arylation

2.1.1.2 Metal-free C-C bond formation

In 2009, Barluenga et al. reported metal free C-C bond formation for the synthesis of
diarylmethanes from tosyl hydrazones [65]. Boronic acids were used as the aryl source. The
authors proposed heating the tosyl hydrazone salts in presence of a base generates the diazo
intermediate. This intermediate reacts with aryl boronic acids to form the benzyl boronic acid. The
formation of benzyl boronic acid can be explained either through the intermediate formation of a
boronate or through the formation of a carbene (through the loss of nitrogen molecule). Reaction
of the carbene with the boronic acid forms the benzyl boronic acid. Protodeboronation of the
benzyl boronic acid led to the formation of the product (Scheme 24).

Scheme 24. Synthesis of diarylmethane using metal free C-C bond formation
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In 2012, Khodaei et al. reported triphenyl phosphine ditriflate (TPPD) mediated Friedel–
Craft’s alkylation of benzyl alcohols with arenes for the facile preparation of diarylmethanes
(Scheme 25) [66].

Scheme 25. Synthesis of diarylmethanes using triphenyl phosphine ditriflate

2.1.1.3 Copper and Palladium catalyzed cross coupling reactions

In 1996, Ku et al. reported copper catalyzed cross coupling of aryl Grignard reagents with
benzyl halides for the preparation of diarylmethanes [67] (Scheme 26). This was a high yielding,
easily scalable reaction for the preparation of diarylmethanes for multigram industrial scale.

Scheme 26. Copper catalyzed synthesis of diarylmethanes using Grignard reagent

Leibeskind et al. reported in 1997 and 1999, metal catalyzed cross coupling reactions of
heterobenzylic sulfonium salts with organostannanes, organoboronic acids as well as organozinc
reagents [68] [69] (Scheme 27). For the cross coupling with organostannanes and organoboronic
acids, palladium was used while for organozinc halides, nickel was used. For improving the
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efficiency of the organostannanes, Ph2P(O)O-Bu4N+ was used as Bu3Sn scavenger. The use of
highly nucleophilic phosphine ligands in order to stabilize the metal catalyst and the electrophilic
sulfonium salts leads to the competing side reactions which were overcome by using essentially
non-nucleophilic triaryl phosphites as ligands.

Scheme 27. Palladium catalyzed synthesis of diarylmethanes using organostannates

2.1.1.4 Suzuki-Miyaura coupling

Georghiou et al. in 1999 reported the Suzuki–Miyaura coupling of benzyl halides with aryl
and naphthyl boronic acids to form the respective diarylmethanes [70] (Scheme 28). The authors
observed using benzyl iodides caused a minor increase in the reaction yield compared to benzyl
bromides. Using benzyl bromides required a higher catalyst loading and the reaction took longer
to reach completion.

Scheme 28. Synthesis of diarylmethanes using Suzuki-Miyaura coupling
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In 2006, Molander et al. reported Suzuki coupling of benzyl halides with potassium
aryltrifluoroborates for the preparation of diarylmethanes [71]. The pre-catalyst used was
PdCl2(dppf).CH2Cl2 (Scheme 29).

Scheme 29. Synthesis of diarylmethanes using potassium aryltrifluoroborates

2.1.1.5 Stille coupling

Monteiro et al. reported Stille coupling of benzylic halides with aryl tributyl tin for the
preparation of diarylmethanes with palladium acetate as the palladium source, diphenyl
phosphinyl ferrocene (dppf) as the ligand and potassium fluoride as a base in dioxane as solvent
[72]. However, when the reaction was carried out in the absence of a base, triphenyl phosphine
was found to be a better ligand (Scheme 30).

Scheme 30. Synthesis of diarylmethanes using Stille coupling
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2.1.1.6 Kumada coupling

Sarkar and coworkers in 2010 developed a novel air stable bidentate ligand having an indole
moiety and N–P donor atom for the Nickel catalyzed Kumada coupling of aryl and benzyl
chlorides with aryl magnesium halides [73]. The Kumada coupling reactions of the benzyl
chlorides with the aryl magnesium halides were highly reactive yielding the corresponding
diarylmethanes in high yields (up to 90% yield) (Scheme 31).

Scheme 31. Synthesis of diarylmethanes using Kumada coupling

2.1.1.7 Hiyama coupling

Sarkar et al. in 2010 reported palladium nanoparticles as catalyst for the Hiyama coupling of
benzylic halides with aryl trialkoxy silanes [74]. The authors further demonstrated the importance
of this methodology by synthesizing the natural product 2,4-bis(4-hydroxybenzyl) phenol in only
3 steps starting from the readily available anisole (Scheme 32).
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Scheme 32. Synthesis of 2,4-bis(4-hydroxybenzyl) phenol using Hiyama coupling

2.1.1.8 Negishi coupling

In 2012, Lipshutz et al. reported a remarkably simple method to develop unsymmetrical
diarylmethanes that relies on an in situ organozinc-mediated, palladium-catalyzed cross-coupling
[75]. Thus, by mixing a benzyl and aryl halide together in the presence of Zn metal and
a Pd catalyst, diarylmethanes are formed at room temperature without assistance by a surfactant
(Scheme 33).

Scheme 33. Synthesis of diarylmethanes using Negishi coupling
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2.1.1.9 Lewis acid mediated sp3 C–O bond activation

Shi et al. in 2008 reported FeCl3 mediated sp3 C–O activation of benzyl ethers for the Friedel–
Craft’s alkylation of benzyl ethers with arenes [76] (Scheme 34).

Scheme 34. Lewis acid mediated synthesis of diarylmethanes

In 2012, Kraus et al. reported Lewis acid catalyzed rearrangement of benzylic ethers for the
facile preparation of diarylmethanes [77] (Scheme 35).

Scheme 35. Synthesis of diarylmethanes via benzylic ether rearrangement
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2.1.2 Diarylmethanes in drug discovery

Diarylmethanes are very important scaffolds in organic and medicinal chemistry. Some have
been used as dyes [78] [79], protecting groups for nucleosides, carbohydrates [80] [81] anticancer
drugs [82] epoxy resins, and antioxidants [83]. Piritrexim (53), a lipophilic inhibitor of the key
metabolic enzyme dihydrofolate reductase (DHFR) has been studied intensively as an anticancer
drug (Fig. 28). A noble structural feature of 53 is a methylene (CH2) bridge between the two halves
of the molecule. This bridge is also present in trimethoprim (54), another lipophilic DHFR
inhibitor widely used for therapy in AIDS patients, usually in combination with a sulfa drug to
enhance efficacy. Another member of this class that has been used clinically against these
infections is trimetrexate (55), which contains a longer CH-NH bridge [84] (Fig. 30).

Fig. 30. Structures of 53, 54 and 55 showing the diarylmethane scaffold
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In 2006, Panda et al. reported the synthesis of a series of aminoalkyl derivatives of substituted
and unsubstituted diarylmethanes (Fig. 31). These compounds were evaluated for antitubercular
activity. Indole and phenanthrene substituted derivatives showed promising activity against M.
tuberculosis H37Rv.

Fig. 31. Structures of substituted and unsubstituted diarylmethanes 56-59

Gout is the most common inflammatory arthritis caused by the deposition of monosodium
urate (MSU) in articular and periarticular tissues and characterized by recurrent joint swelling,
redness, warmth and severe pain [85]. If left untreated or poorly managed, tophaceous gout will
ultimately lead to permanent joint destruction, bone erosion and kidney impairment, dramatically
affecting patients’ quality of life and even threatening their lives [86]. Recently, Cai and coworkers
developed uric acid transporter 1 (URAT1, SLC22A12) inhibitors, for the treatment of gout, that
contained a diarylmethane backbone. Structure-activity relationship (SAR) studies were carried
out on the general backbone. The authors synthesized 33 compounds out of which 60 was found
to be the most potent (Fig. 32).
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Fig. 32. Structure of URAT1 inhibitor 60

2.2 Heterocycles in drug discovery

Heterocycles are key scaffold components in medicinal chemistry. They are fundamental
building blocks of most drugs on market today (Fig. 33). The importance of heterocycles is well
understood by modern medicinal chemists, since they play a significant role in molecular
properties such as the electronic distribution, three dimensionality, and scaffold rigidity. They are
often key factors in whole molecule properties such as lipophilicity or polarity and can determine
molecular reactivity, metabolic stability, and toxicity [87]. Most frequently, nitrogen heterocycles
or various positional combinations of nitrogen atoms, sulphur, and oxygen in five or sixmembered rings can be found in many drugs. According to statistics, more than 85% of all
biologically-active chemical entities contain a heterocycle [88].
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Fig. 33. Top 10 heterocyclic scaffolds in FDA approved drugs

2.2.1 Four-membered nitrogen heterocycles: Azetidines

With the exception of a single aziridine-containing drug (mitomycin), the most commonly
found for-membered nitrogen heterocycles are all β-lactams, of which 95% are fused to another
ring with the nitrogen atom shared (Fig. 34) [88]. They are least diverse in terms of diseases they
are used to treat. Case in point, all but the cholesterol lowering agent ezetimibe [89] of the βlactam drugs [90] are antibiotics or used in combination with antibiotics.

Fig. 34. Top four most common four-membered nitrogen heterocycles
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2.2.1.1 Syntheses of azetidines

Cyclization of a preformed chain by nucleophilic displacement of a leaving group by a
nitrogen nucleophile is, by far, the most common method to produce azetidines. Amines are the
most common nitrogen nucleophiles [91]. In 2006, Ju et al. reported the synthesis of N-substituted
azetidine by cyclization of aniline with 1,3-dichloropropane. The reaction was carried out in water
by the assistance of microwave (Scheme 36) [92].

Scheme 36. Synthesis of N-substituted azetidine

Traditional protocols in the presence of alcoholic intermediates involve the transformation of
the alcohol in sulfonic ester, mainly mesylate [93] [94] [95] tosylate [96] [97] [98] and triflates
[99] followed by base mediated cyclization. Hillier and co-worker reported the synthesis of 1,3substituted azetidines from 2-substituted-1,3-propanediols in a one-pot reaction (Scheme 37).

Scheme 37. Synthesis of 1,3 substituted azetidine
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De Kimpe’s group provided the synthesis of uncommon 3,3-dichloroazetidines (Scheme 38)
[100] and 3-fluoroazetidines (Scheme 39) [101] starting from imines.

Scheme 38. Synthesis of 3,3-dichloroazetidines

Scheme 39. Synthesis of 3-fluoroazetidines

2.3 Azetidines as a pharmaceutical scaffold
Azetidine is considered a privileged scaffold in drug discovery. It is a good compromise
between a satisfactory stability and a strong molecular rigidity, allowing an efficient tuning of
pharmacological properties displayed by molecules bearing this moiety [102]. Azetidines, despite
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their indisputable importance as bioactive compounds and pharmaceutical tools, have received
little attention by the chemical community compared to the higher homologous counterparts.
There are very few azetidine containing drugs are currently on the market. Dihydropyridine
azelnipidine (Calblock, 61) is Sankyo’s calcium channel blocker [103]. Exelixis’ cobimetinib
(Cotellic, 62), as a targeted cancer therapy, is a mitogen-activated protein kinase-1/2 (MEK1/2)
inhibitor (Fig. 35) [104].

Fig. 35. Structures of azetidine-based drugs 61 and 62

Another azetidine-containing drug ximelagatran (Exanta, 63) as a direct thrombin inhibitor
was discovered by AstraZeneca. Initially sold as an anticoagulant, it was pulled off the market in
2006 due to hepatoxicity (Fig. 36) [105].
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Fig. 36. Structure of azetidine-based drug 63

Azetidine carbamate 64 is an efficient, covalent inhibitor of monoacylglycerol lipase (MAGL)
discovered by Pfizer [106]. The hexafluoroisopropanol (HFIP) group here serves as the leaving
group when attacked by the key serine residue (Ser122) at the enzyme’s active site. Fatty acid
amide hydrolase (FAAH) inhibitors are potential treatment for pain. Vernalis discovered a mixture
of chiral azetidine-ureas VER-24052 (65) as a FAAH inhibitor (Fig. 37) [107].

Fig. 37. Structures of azetidine-based drugs 64 and 65
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In 2013, Roche reported an azetidine-containing bis-amide 66 as a selective JAK3 (Janus
kinase) inhibitor (IC50 = 0.26 nM) with a 10-fold selectivity over JAK1 (IC50 = 3.2 nM). In
addition, the combination of its selectivity over the kinome, good solubility and reasonable
exposure was translated to in vivo potency and selectivity in an acute PK/PD mouse model (Fig.
38) [108].

Fig. 38. Structure of azetidine-based drug 66

2.3.1 Synthesis of bioactive azetidines
Sankyo’s synthesis of azelnipidine (Calblock, 61) began with 1-benzhydryl- 3hydroxyazetidine,

readily

assembled

from

condensation

of

benzhydrylamine

with

epichlorohydrin. Subsequent 1,3- dicyclohexylcarbodiimide (DCC)-mediated esterification with
cyanoacetic acid produced ester, which was converted to an amidine in two additional steps. A
Hantzsch dihydropyridine synthesis between the amidine and an enone then delivered azelnipidine
61 (Scheme 40).
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Scheme 40. Synthesis of AzeInipidine 61

Exelixis’ synthesis of cobimetinib (Cotellic, 62) commenced with addition of a piperidineGrignard reagent to N-Cbz-3-azetidinone. The resulting 3-hydroxy azetidine underwent
Palladium-catalyzed hydrogenation, removing the Cbz protection, to afford the exposed azetidine.
Ester formation from the coupling between the free azetidine and an acid chloride in the presence
of diisopropylethylamine (DIPEA) produced cobimetinib (62) after deprotection of the Boc group.
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Scheme 41. Synthesis of Cotellic 62

2.4 Geminal 3,3-diaryl azetidines

The combination of saturated heterocycles with aromatic substituents provide particularly
attractive screening compounds as fragments or lead-like compounds due to the different potential
binding interactions available. However there remain challenges in readily accessing a broad array
of substituted heterocycles under mild conditions, as is appropriate in divergent and iterative
medicinal chemistry investigations [109]. The sp3-sp2 coupling of small rings or saturated
heterocycles with aromatic components presents a valuable transformation that can facilitate the
construction of important compound types in drug discovery. 3,3-Diarylazetidines are relatively
little studied but can be found in biologically active compounds in the patent literature (Fig. 39)
[110] [111].
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Fig. 39. Bioactive geminal diaryl azetidine structures

2.5 Synthesis of 3,3-diarylazetidines: Recent developments and scope

In 2019, Bull and coworkers reported the synthesis of 3,3-diarylazetidines by Fridel-Craft’s
alkylation of electron rich aromatics with azetidinols, using a calcium triflimide catalyst [112]. A
calcium catalyst generates azetidine carbocations from 3-arylazetidin-3-ols under mild conditions.
The reaction was compatible with functionalized substrates and a wide range of electron-rich
aromatic and heteroaromatic nucleophiles. The azetidinols were prepared using Grignard’s
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reagents (Scheme 42). The resulting 3-aryl-3-azetidinols were then reacted with various aromatic
nucleophiles to give the corresponding 3,3-diarylazetidines.

Scheme 42. Synthesis of 3-aryl-3-azetidinols

Initially, the authors examined N-Cbz azetidinols bearing a 4-methoxyphenyl group using
catalytic amounts of various Lewis acids and phenols such as o-cresol as nucleophiles (Scheme
43). Optimization studies for Fridel-Craft’s arylation of azetidinol 67 with o-cresol is shown in
Table 5.

Scheme 43. Synthesis of 3,3-diarylazetidine 68a
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Table 7. Fridel-Craft’s aryltion of 67 with o-cresol.
Entry
1

Cat (mol%)

Equiv of o-cresol

Li(NTf2)/Bu4NPF6

5

Solvent

Yield of 68a (%)

CH2Cl2

45

(11/5.5)
2
3
4
5

6

7

FeCl3 (5)

5

Ca(NTf2)2/Bu4NPF6

5

(5/5)
Ca(NTf2)2 (5)

5

Ca(NTf2)2/Bu4NPF6

3

(5/5)
Ca(NTf2)2/Bu4NPF6

3

(5/5)
Ca(NTf2)2/Bu4NPF6

3

(5/5)

CH2Cl2
CH2Cl2

CH2Cl2
CH2Cl2

PhMe

Heptane

75
92
0
94

96
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The Bu4NPF6 additive was crucial, with no reaction in its absence (Table 5-entry 4).
Decreasing the equivalents of the phenol from 5 to 3 maintained high yield (94%). Solvents like
toluene and heptane were suitable but dichloromethane was used because of improved substrate
solubility. These optimized conditions were then used to investigate the scope of the reaction. A
wide range of aromatic and heteroaromatic nucleophiles were used (Scheme 44).

87

Scheme 44. Synthesis of 3,3-diarylazetidines 68b-o

Table 8. Scope of heteroaromatics and phenol derivatives as nucleophiles

Compound no.

(Het)Ar nucleophile

68b

68c

68d

68e
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Product

Table contd.

68f

68g

68h

68i

68j

68k

68l

89

Table contd.

68m

68n

68p

The Cbz group was removed by using H2, Pd/C catalyst to give the free-base azetidine 69
(Scheme 45), important for further functionalization.

Scheme 45. Removal of Cbz group using H2, Pd/C
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2.5 Design strategy for synthesis of 3,3-diarylazetidines and subsequent
derivatization

Previous studies in our group have reported the synthesis of 3,3-diarylazetidines from N-Boc3-azetidinols [113]. The N-Boc-3-azetidinols were prepared from the readily available N-Boc-3azetidinone. This was achieved by reacting the azetidinone with aryllithium reagents.
Subsequently, the azetidinols underwent Friedel-Craft’s arylation using aluminum chloride
(AlCl3) as the Lewis acid. It was observed that the AlCl3 not only assists in the nucleophilic attack
of the aryl group but also deprotects the Boc group to give the free-base azetidine.

The goal of this project was to functionalize 3,3-diarylazetidines previously synthesized in the
group. Scheme 46 shows the she retrosynthetic approach for the synthesis of the functionalized
3,3-diarylazetidines. The 3,3-diarylazetidines will have to be prepared first. These diarylazetidines
will be functionalized by adding acyl and alkyl groups to the azetidine nitrogen.

Scheme 46. Retrosynthetic scheme for synthesis of N-functionalized 3,3-diarylazetidines
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RESULTS AND DISCUSSION

2.6 Synthesis of N-boc-3-aryl-3-azetidinols
Previously used synthetic methodology was used to synthesize the diarylazetidines. The series
of diarylazetidizes was synthesized in two steps. The first step involved the reaction of an
aryllithium compound with N-Boc-3-azetidinone (70). The arryllithium was prepared in situ using
a metal-halogen exchange between n-butyllithium (n-BuLi) and an aryl halide. Synthesis of NBoc-3-phenyl-3-azetidinone was attempted first. Bromobenzene was treated with n-BuLi in
Tetrahydrofuran (THF) at -78 ℃ to give phenyllithium after which 70 was added to the reaction
mixture and stirred at room temperature overnight to give N-Boc-3-phenyl-3-azetidinol (71a)
(Scheme 47).

Scheme 47. Synthesis of N-Boc-3-phenyl-3-azetidinol 71a

The mechanism for this reaction is shown in Scheme 48. The reaction takes place via a
nucleophilic addition of the phenyllithium on the carbonyl of the azetidinone.
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Scheme 48. Mechanism of nucleophilic addition of phenyllithium

71a was isolated by column chromatography. The first few attempts resulted in very low yields
(42%). The major product of the reaction was found to be homocoupled product 72 (presumably
biphenyl). Initially, 72 was mistaken as the desired product on the TLC plate (Rf = 0.5) and isolated
using column chromatography. However, 1H NMR showed peaks only in the aromatic region (⁓78 ppm). This homocoupled product could have formed via Wurtz coupling. This happens when
the lithiated product (phenyllithium) reacts with the aryl halide (bromobenzene) (Scheme 49).
This required us to reevaluate the TLC plate. There was a faint UV active spot with an R f value
of 0.3 which was isolated using column chromatography. 1H NMR confirmed its identity as 71a.

Scheme 49. Possible side reaction and formation of homocoupled product 72

To increase the yield of 71a and reduce the formation of 72, the amount of bromobenzene
added was reduced from 3 equivalents to 2 equivalents. This reduced the formation of the
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homocoupled product 72 but didn’t increase the yield of the azetidinol 71a drastically (62% yield).
Next, the concentration of phenyllithium in THF was investigated. It was concluded that using 1.3
equivalents and 0.25 M solution of the aryllithium gave a small amount of 72 and 71a was obtained
in high yield (96%). Table 7 shows the optimization studies for this reaction.

Table 9. Optimization studies for the synthesis of 71a

Entry

Equiv. of n-BuLi

Molarity of n-BuLi in THF (M)

Yield of 63a (%)

1

3

1.1

42

2

3

0.44

62

3

2

0.12

63

4

2

0.30

72

5

1.3

0.25
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Using the optimized conditions azetidinols 71a-c were prepared. Using electron withdrawing
groups like chlorine and fluorene resulted in lower yields of the azetidinols (Scheme 50).

Scheme 50. Synthesis of N-Boc-3-aryl-3-azetidinols 71a-c
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2.7 Synthesis of 3,3-diarylazetidines

The 3,3-diarylazetidines were prepared from the azetidinols 71a-c by Friedel-Crafts arylation
reaction using AlCl3 as the Lewis catalyst. This reaction can proceed via two mechanisms. The
AlCl3 could first remove the Boc group to give the free base azetidinol. It then enhances the
electrophilicity of the azetidinol by creating a complex with it. The O-H group is removed by
AlCl3 creating a bicyclic compound 73. The nucleophilic benzene attacks the electrophilic
carbocation to give the desired diaryl product 74a (Scheme 51 and 52).

Scheme 51. Boc removal using AlCl3
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Scheme 52. Friedel-Crafts arylation mechanism after Boc removal

Alternatively, the N-Boc-3-azetidinol could get arylated first via Friedel-Crafts arylation
after which the Boc group would be removed (Scheme 53 and 54).

Scheme 53. Friedel-Crafts arylation before Boc removal
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Scheme 54. Boc removal after Friedel-Crafts aylation

At the end of the reaction, The TLC plate showed a UV active spot corresponding to the NBoc-3-arylazetdinol as well as a spot on the baseline which could either correspond to the free
base 3-arylazetidinol or some other impurities. It was concluded that it is likely that the Boc group
was removed after the Friedel-Crafts arylation which would explain the N-Boc-3-arylazetidinol
on the TLC plate at the end of the reaction.

As summarized in Table 8, the azetidinols 71a-c and a variety of substituted benzenes (20
equiv.) were treated with AlCl3 without solvent at 0 °C for 2h to furnish the Friedel-Crafts
arylation products 74a-h (Scheme 55). The Boc-protecting group was removed during this step,
which allowed the azetidine to be easily isolated as the oxalic acid salt. This avoided the need for
chromatography and any additional purification steps. As the oxalate salts the 3,3-diarylazetidines
were crystalline solids that could be stored on the bench indefinitely.
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Scheme 55. Synthesis of 3,3-diarylazetidine oxalic acid salts

Table 10. Optimized yields of 3,3-diarylazetidine oxalic acid salts
Entry

71

X

Y

Yield of 74 (%)

a

71a

H

H

86

b

71a

H

CH3

83

c

71a

H

F

60

d

71a

H

Cl

86

e

71a

H

OCH3

72

f

71b

F

H

63

g

71c

Cl

H

70

h

71c

Cl

Cl

81

As seen in Table 10, both electron withdrawing and donating groups were tolerated and the
3,3-diarylazetidines were synthesized in moderate to good yields (60-86%). However, it was
observed that halogenated benzenes with electron withdrawing groups like fluorine gave lower
yields. This is seen in entry c when adding fluorobenzene lowers the yield to 60%. Activating
groups like toluene and 4-methoxybenzene (entries b and e) gave higher yields of 83% and 72%
respectively.
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2.8 Synthesis of N-functionalized 3,3-diarylazetidines

To demonstrate versatility of the 3,3-arylazetidine salts 74 toward further functionalization at
nitrogen, the preparation of a series of N-substituted analogues was explored. Initially, Nalkylation of 3,3-diarylazetidine oxalic acid salt 74a was carried out with benzyl bromide. As
illustrated in Table 11, a variety of bases (Et3N; NaHCO3, Na2CO3, t-BuOK, NaH, n-BuLi) and
solvents (EtOH, THF and DMF) were used.
Table 11. Optimization of N-alkylation of 74a
Entry

Base

Solvent

Yield of 75a (%)

1

Et3N

EtOH

46

2

Et3N

DMF

52

3

Na2CO3

DMF

56

4

t-BuOK

THF

32

5

NaH

EtOH

63

6

NaH

DMF

82

7

NaHCO3

DMF

90
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While many combinations of base and solvent gave modest yields of the N-alkylation
product, it was determined that using NaHCO3 (3 equivalents) in DMF at 110 ℃ furnished 75a in
90% yield. It was also determined that using DMF as the solvent in general gave higher yields as
the reaction could be heated to a higher temperature when compared to THF and EtOH. The
optimized conditions were then applied to N-alkylation with 3-bromoethylpropionate to give 75b
in 94% yield. The reaction conditions were also tolerated with aromatic compounds like 2bromopyridine. However, the N-arylated product 75c was obtained in only 54% yield (Scheme
56).

Scheme 56. N-alkylation of 74a

To further investigate the scope of this reaction, the 3,3-diarylazetidines were acylated at the
nitrogen using benzoyl chloride. Both symmetrical and unsymmetrical 3,3-diarylazetidines were
acylated and the N-acylated products were obtained in high yields (Scheme 57).
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Table 12. N-alkylated products of 74a
Entry

R-Br/ Ar-Br

Product 75

Yield of 75 (%)

a

91

b

94

c

54

Scheme 57. N-acylation of 74a and 74d
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CONCLUSION
In summary, we have developed a simple method for the preparation of 3,3-diarylazetidines
using AlCl3-mediated Friedel-Crafts arylation of N-Boc-3-aryl-3-azetidinols. The conditions
allowed for incorporation of both electron-rich and electron-deficient aryl groups to furnish the
3,3-diarylazetidines in good yield as stable oxalic acid salts. The salts exhibit exceptional shelf
life and can be efficiently converted into N-alkylated, N-arylated and N-acylated derivatives of
the 3,3-diarylazetidines. With easy access to the 3,3-diarylazetidines, this moiety will undoubtedly
be prominent isostere in future drug discovery programs.
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EXPERIMENTAL
General information

All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, VWR and CNH
Technologies and were used as received without further purification. Chromatography refers to
flash silica gel column chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent
Technology was used as the stationary phase). 1H NMR and 13C NMR spectra were recorded at
room temperature in DMSO-d6 on a Bruker 300 MHz instrument.
referenced to the DMSO solvent signal (2.48 ppm).

1

H chemical shifts were

13

C chemical shifts were referenced to the

DMSO solvent signal (40.00 ppm). Atlantic Microlab Inc., Norcross, GA performed all CHN
microanalyses.

General procedure A: Preparation of N-Boc-3-aryl-3-azetidinol (71a-c)

Bromobenzene or halogenated bromobenzene (40 mmol) was dissolved in anhydrous THF (144
mL) and cooled to -78 ℃. To this flask, n-BuLi (2.5 M, 40 mmol, 32 mL) was added dropwise.
The mixture was stirred at -78 ℃ for 10 minutes. N-boc-3-azetidinone (1, 3.4 g, 20 mmol) was
dissolved in anhydrous THF (4 mL) and then slowly added via syringe to the reaction mixture.
The mixture was allowed to warm to room temperature and stirred overnight. The reaction was
quenched with water, extracted with diethyl ether (3 x 100 mL) and the combined organic layers
were washed with brine (100 mL). The organic portion was dried over anhydrous sodium sulfate,
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filtered and the solvent was removed under vacuum. The crude oil was purified by column
chromatography (30% EtOAc:hexanes) to afford the 3-arylazetidinol 63a-c as a pale-yellow solid.

N-Boc-3-phenyl-3-azetidinol (71a)
According to General Procedure A, the reaction was performed with bromobenzene (6.2 g, 40
mmol). The azetidinol 63a was obtained as a pale-yellow solid (4.8 g, 96% yield). mp 85.3-87.8
℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.48 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.5 Hz, 2H), 7.27 (m, 1H),

6.31 (s, 1H), 4.02 (s, 4H), 1.40 (s, 9H).
C NMR (DMSO-d6, 75 MHz) : 156.3, 145.1, 128.6, 127.5, 125.0, 79.2, 70.1, 65.1, 28.5.

13

N-Boc-3-(4-fluorophenyl)-3-azetidinol (71b)

According to General Procedure A, the reaction was performed with 4-fluorobromobenzene (7.0
g, 40 mmol). The azetidinol 63b was obtained as a pale-yellow solid (3.8 g, 72% yield). mp 90.892.8 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.53-7.49 (m, 2H), 7.17-7.12 (m, 2H), 6.39 (s, 1H), 4.02 (s,

4H), 1.39 (s, 9H).
C NMR (DMSO-d6, 75 MHz) : 163.3, 160.1, 156.3, 141.3, 127.1, 127.0, 115.4, 115.1, 79.2,

13

69.8, 65.3, 28.4.
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N-Boc-3-(4-Chlorophenyl)-3-azetidinol (71c)

According to General Procedure A, the reaction was performed with 4-chlorobromobenzene (7.6
g, 40 mmol). The azetidinol 63c was obtained as a pale-yellow solid (4.8 g, 86% yield). mp 139.0140.6 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.50 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 6.43 (s, 1H),

4.00 (s, 4H), 1.40 (s, 9H).
C NMR (DMSO-d6, 75 MHz) : 156.3, 144.2, 132.2, 128.6, 127.0, 79.4, 69.7, 65.2, 28.5.

13

General Procedure B: Preparation of 3,3-diarylazetidine oxalate salts (74a-h)
Aluminum chloride (4.0 g, 30 mmol) was suspended in benzene or halogenated benzene (20
mmol) and cooled to 0 ℃ in an ice bath under an atmosphere of nitrogen. N-Boc-3-aryl-3azetidinol (2, 10 mmol) was dissolved in benzene or substituted benzene and added to the reaction
mixture via syringe. The reaction mixture was then stirred at 0 ℃ for 2 h under nitrogen. The
reaction was quenched with ice and stirred for 30 minutes. Saturated sodium bicarbonate solution
(20 mL) was added to the mixture followed by ammonium hydroxide to achieve a pH of 11. The
mixture was the extracted with diethyl ether (3 x 20 mL) and washed with brine (20 mL). The
organic layer was dried over anhydrous sodium sulfate, filtered and the solvent removed under
vacuum. The residue was then dissolved in a minimum amount of diethyl ether and an ether
solution of oxalic acid (10 mmol) was added dropwise to the residue solution. The oxalate salt
precipitated as a white solid which was collected by vacuum filtration.
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3,3-Diphenylazetidine hydrogen oxalate (74a)

General procedure B. The product was obtained from 71a and benzene as a white solid (2.57 g,
86% yield). mp 230.5-232.3 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 9.30 (s, 1H), 7.43 (d, J = 7.5 Hz, 4H), 7.35 (t, J = 7.6 Hz, 4H),

7.23 (t, J = 7.3 Hz, 2H), 4.62 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 162.8, 146.6, 129.0, 127.0, 126.6, 61.3, 60.4, 48.3.

13

Anal. Calcd. for C15H15N•(CO2H)2: C, 68.22; H, 5.72; N, 4.68. Found: C, 68.01; H, 5.88; N, 4.55.

3-(4-Methylphenyl)-3-phenyl-azetidine hydrogen oxalate (74b)

General procedure B. The product was obtained from 71a and toluene as a white solid (2.23 g,
71% yield). mp 185.6-187.6 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.40, (d, J = 7.8 Hz, 2H), 7.63-7.27 (m, 4H), 7.25-7.15 (m,

3H), 4.58, (s, 4H), 2.23 (s, 3H).
C NMR (DMSO-d6, 75 MHz) : 165.3, 146.2, 143.1, 136.7, 129.3, 127.4, 126.4, 115.6, 57.3,

13

48.9, 21.1.
Anal. Calcd. for C16H17N•(CO2H)2: C, 69.00; H, 6.11; N, 4.47. Found: C, 68.93; H, 6.30; N, 4.40.
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3-(4-Fluorophenyl)-3-phenylazetidine hydrogen oxalate (74c)

General procedure B. The product was obtained from 71a and fluorobenzene as a white solid
(1.90 g, 60% yield). mp 164.2-166.4 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.51-7.41 (m, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.25-7.15 (m, 3H),

4.61 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 164.4, 162.8, 160.4, 145.9, 142.2, 129.4, 128.8, 128.7, 127.5,

13

126.5, 126.2 116.2, 116.0, 57.3, 48.7, 31.7.
Anal. Calcd. for C15H14NF•(CO2H)2: C, 64.35; H, 5.09; N, 4.41. Found: C, 64.13; H, 5.15; N,
4.25.

3-(4-Chlorophenyl)-3-phenylazetidine hydrogen oxalate (74d).

General procedure B. The product was obtained from 71a and chlorobenzene as a white solid
(2.86 g, 86% yield). mp 214.6-217.6 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.47 (d, J = 8.6 Hz, 2H), 7.43-7.40 (m, 4H), 7.38 – 7.33 (m,

2H), 7.27 – 7.21 (m, 1H), 4.60 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 164.8, 145.2, 144.7, 132.0, 129.2, 129.1, 128.3, 127.4, 126.2,

13

57.0, 48.6.
Anal. Calcd. for C15H14NCl•(CO2H)2: C, 61.18; H, 4.48; N, 4.20. Found: C, 60.95; H, 4.78; N,
3.94.
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3-(4-Methoxyphenyl)-3-phenylazetidine hydrogen oxalate (74e).

General procedure B. The product was obtained from 71a and anisole as a white solid (2.36 g,
72% yield). mp 160.0-162.8 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 9.49 (s, 1H), 7.49-7.32 (m, 6H), 7.23 (m 1H), 6.89 (d, J = 8.6

Hz, 2H), 4.57 (s, 4H), 3.70 (s, 3H).
C NMR (DMSO-d6, 75 MHz) : 158.4, 146.1, 137.7, 129.1, 127.6, 127.1, 126.2, 114.2, 57.1,

13

55.6, 48.6.
Anal. Calcd. for C16H17NO•(CO2H)2•H2O: C, 62.24; H, 6.09; N, 4.03. Found: C, 62.03; H, 6.37;
N, 3.75.

3-Phenyl-3-(4-fluorophenyl)azetidine hydrogen oxalate (74f)

General procedure B. The product was obtained from 71b and benzene (1.99 g, 63% yield). mp
164.2-166.4 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.51-7.41 (m, 4H), 7.35 (t, J = 7.5 Hz, 2H), 7.25-7.15 (m, 3H),

4.61 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 164.4, 162.8, 160.4, 145.9, 142.2, 129.4, 128.8, 128.7, 127.5,

13

126.5, 126.2 116.2, 116.0, 57.3, 48.7, 31.7.
Anal. Calcd. for C15H14NF•(CO2H)2: C, 64.35; H, 5.09; N, 4.41. Found: C, 64.13; H, 5.15; N,
4.25.
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3-Phenyl-3-(4-chlorophenyl)azetidine hydrogen oxalate (74g)

General procedure B. The product was obtained from 71c and chlorobenzene as a white solid
(2.33 g, 70% yield). mp 214.6-217.6 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.47 (d, J = 8.6 Hz, 2H), 7.43-7.40 (m, 4H), 7.38 – 7.33 (m,

2H), 7.27 – 7.21 (m, 1H), 4.60 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 164.8, 145.2, 144.7, 132.0, 129.2, 129.1, 128.3, 127.4, 126.2,

13

57.0, 48.6.
Anal. Calcd. for C15H14NCl•(CO2H)2: C, 61.18; H, 4.48; N, 4.20. Found: C, 60.95; H, 4.78; N,
3.94.

3,3-Di(4-chlorophenyl)azetidine hydrogen oxalate (74h)

General procedure B. The product was obtained from 71c and chlorobenzene as a white solid
(2.87 g, 81% yield). mp 219.6-221.1 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 9.63 (s, 1H), 7.47 (d, J = 8.1 Hz, 4H), 7.41 (d, J = 7.9 Hz, 4H),

4.54 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 144.5, 135.5, 132.32, 129.4, 128.6, 56.9, 48.3.

13

Anal. Calcd. for C16H16NCl•(CO2H)2: C, 55.45; H, 4.11; N, 3.80. Found: C, 55.40; H, 4.12; N,
3.71.
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General procedure C: Preparation of N-substituted 3,3-diarylazetidines

3,3-Diarylazetidine oxalate salt (1 equiv.) was dissolved in anhydrous DMF (20 mL) followed by
the addition of the alkyl, aryl or acyl bromide (3 equiv) and NaHCO3 (4 equiv). The mixture was
heated at 110 ℃ for 16 h. The reaction was poured into water (100 mL) and extracted with diethyl
ether (3 x 20 mL). The combined organic layers were washed with water (5 x 10 mL), brine (20
mL), dried over anhydrous Na2SO4 and filtered. The solvent was removed under vacuum. The
residue was then purified.

N-Benzyl-3,3-diphenylazetidine (75a)

General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), benzyl bromide
(0.600 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol) and was purified by column
chromatography (50% EtOAc:hexanes). The product was obtained as a pale-yellow oil. (0.450 g,
90% yield).
1

H NMR (DMSO-d6, 300 MHz) : 7.38-7.20 (m, 15 H), 5.47 (s, 2H), 3.48 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 139.6, 128.8, 128.7, 128.3, 128.3, 127.4, 115.1, 57.4.

13

Anal. Calcd for C22H21N: C, 88.25; H, 7.07; N, 4.68. Found: C, 88.19; H, 7.00; N, 4.53.

Ethyl-3-(3,3-diphenylazetidinyl)-propionate hydrogen oxalate (75b)

General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), ethyl 3bromopropionate (0.630 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol). The residue was
dissolved in a minimal amount of diethyl ether. Oxalic acid dissolved in a minimal amount of
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diethyl ether was then added to it. The oxalate salt precipitated out as an off-white solid and was
collected by vacuum filtration. (0.614 g, 92% yield). mp 185.0 ℃ (decomp.)

1

H NMR (DMSO-d6, 300 MHz) : 7.39 (d, J = 7.4 Hz, 4H), 7.32 (t, J = 6.6 Hz, 4H), 7.20 (t, J =

6.6 Hz, 2H), 4.46 (s, 4H), 4.06 (q, J = 6.6 Hz, 2H), 3.17 (t, J = 7.4 Hz, 3H), 2.52(t, J = 7.2 Hz,
2H), 1.16 (t, J = 7.1 Hz, 3H).
C NMR (DMSO-d6, 75 MHz) : 170.6, 163.0, 145.7, 128.6, 126.6, 126.0, 64.8, 60.4, 51.7, 46.6,

13

30.5, 14.1.
Anal. Calcd for C20H23NO2•C2H2O4•H2O: C, 63.30; H, 6.52; N, 3.36. Found: C, 63.10; H, 6.50;
N, 3.21.

N-(2-Pyridinyl)-3,3-diphenylazetidine (75c)

General procedure C. The product was prepared using 74a (0.200 g, 0.668 mmol), 2bromopyridine (0.200 mL, 2.00 mmol) and NaHCO3 (0.300 g, 2.67 mmol). The product was
isolated and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a
colorless oil (0.103 g, 54% yield).
1

H NMR (DMSO-d6, 300 MHz) : 8.07 (d, J = 6Hz, 1H), 7.52 (t , J = 6 Hz, 1H), 7.39-7.29 (m,

8H), 7.19 (t, J = 6 Hz, 2H), 6.65 (t, J = 6 Hz, 1H), 6.47 (d, J = 6 Hz, 1H), 4.45 (s, 4H).
C NMR (DMSO-d6, 75 MHz) : 160.6, 147.7, 146.9, 137.1, 128.5, 126.2, 113.3, 106.2, 63.7,

13

46.8.
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N-Benzoyl-3,3-diphenylazetidine (76a)
General procedure C. The product was prepared using 74a (0.500 g, 1.67 mmol), benzoyl
chloride (0.600 mL, 5.01 mmol) and NaHCO3 (0.561 g, 6.68 mmol). The product was isolated
and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a white solid.
(0.502g, 96% yield). mp 179.4-181.0 ℃.
1

H NMR (DMSO-d6, 300 MHz) : 7.66 (d, J = 7.3 Hz, 2H), 7.56 – 7.43 (m, 3H), 7.39 (d, J = 8.1

Hz, 4H), 7.32 (t, J = 7.5 Hz, 4H), 7.20 (t, J = 6.7 Hz, 2H), 4.93 (s, 2H), 4.71 (s, 2H).
C NMR (DMSO-d6, 75 MHz) : 169.2, 146.5, 131.2, 128.6, 128.5, 127.9, 126.5, 126.3, 65.9,

13

61.67, 46.7.
Anal. Calcd for C22H19NO: C, 84.31; H, 6.11; N, 4.47. Found: C, 84.08; H, 5.96; N, 4.40.

N-Benzoyl-3-(4-chlorophenyl)-3-phenylazetidine (76b)
General procedure C. The product was prepared using 74d (0.360 g, 1.08 mmol), benzoyl
chloride (0.376 mL, 3.24 mmol) and NaHCO3 (0.363 g, 4.32 mmol). The product was isolated
and purified using column chromatography (50% Ethyl acetate: Hexanes) to obtain a colorless oil
(0.323 g, 86% yield).
1

H NMR (DMSO-d6, 300 MHz) : 7.69 – 7.61 (m, 2H), 7.50 (d, J = 6.9 Hz, 1H), 7.45 (d, J = 7.2

Hz, 2H), 7.37 (d, J = 14.7 Hz, 7H), 7.31 (d, J = 7.9 Hz, 1H), 7.21 (q, J = 7.1, 5.9 Hz, 1H), 4.90
(s, 2H), 4.68 (s, 2H).
C NMR (DMSO-d6, 75 MHz) : 169.5, 146.4, 145.8, 133.2, 131.6, 129.1, 128.9, 128.7, 128.3,

13

127.1, 126.7, 66.1, 61.9, 46.7.
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Anal. Calcd for C22H18ClNO: C, 75.97; H, 5.22; N, 4.03. Found: C, 75.81; H, 5.01; N, 3.95
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CHAPTER 3
General Synthesis of Alkyl Pyruvate Esters
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ABSTRACT

A general synthesis of pyruvate esters was developed. Using this method, a series of alkyl
pyruvate esters were synthesized in moderate to high yields (56-93%). This synthesis can be used
to synthesize both mono-pyruvate and di-pyruvate esters. This was achieved in four steps starting
from the readily available triethyl-2-phosphonopropionate which was converted to the alkene
ethyl 2,3-dimethyl-2-butenoate using Horner-Wadsworth-Emmons reaction. The ethyl ester was
hydrolyzed to the corresponding carboxylic acid after which a series of esters were prepared using
Steglich esterification. The esters were then converted to their corresponding pyruvate esters via
ozonolysis.
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INTRODUCTION
3.1 Keto acids
Keto acids contain two oxygen-containing functional groups: the carboxylic acid (COOH)
and ketone group (C=O) [114]. There are three classes of keto acids: alpha-keto acid, beta-keto
acid and gamma-keto acid (Fig. 40). Out of these three, particularly important in biology are the
α-keto acids (keto group adjacent to the carboxylic acid), since they are involved in the Krebs
cycle and in glycolysis [115].

Fig. 40. Alpha, beta and gamma keto esters

-Keto acids, especially the -keto acid analogues of the naturally occurring amino acids, are
of major importance in intermediary metabolism. Thus, pyruvic acid is a metabolite involved in a
number of enzyme-catalyzed intracellular phenomena, and oxaloacetic acid (77), -ketoglutaric
acid (78), and oxalosuccinic acid (79) are intermediates in the tricarboxylic acid cycle (Krebs’s
cycle) (Fig. 40) [116] [117] [118].
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Fig. 41. Structures of -keto acids

3.1.1 Properties of keto acids
The straight-chain -keto acids are either liquids or low-melting solids. The branched-chain
and phenyl-substituted -keto acids vary from liquids to high-melting solids [119] [120]. Some aketo acids are unstable as the free acid and exhibit a tendency to decarboxylate and polymerize.
The majority are relatively stable as salts, of which the sodium and barium salts have most often
been prepared. In general, -keto acids are relatively stable in neutral solution and can be stored
frozen at -20 ℃ with little decomposition, but there are notable exceptions. It is well-known that
pyruvic acid (80) readily polymerizes on storage in aqueous solution to DL--hydroxy--methyl-ketoglutaric acid (81) and higher molecular weight compounds [121].

Fig. 42. Polymerization of Pyruvic acid
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Schellenberger and coworkers noted that the molecular weight of pure trimethyl pyruvic acid
(82) when measured cryoscopically in dioxane, up to 0.01 mol fraction was 10% greater than
expected [122]. Since association by hydrogen bonding is unlikely, it was concluded that some
dimerization occurred (Scheme 58). Subsequently, crystalline dimer was obtained from cold
samples of trimethyl pyruvic acid. Glucksmann first isolated the dimer in 1989 [123]. It was
concluded from dipole measurements and from infrared spectroscopic data that the dimer was an
"activated ester" (83).

Scheme 58. Dimerization of trimethyl pyruvic acid

It is well-known that many -keto acids are metabolized via enzyme-catalyzed oxidative
decarboxylation (i.e. via pyruvate, -ketoglutarate, and branched-chain -keto acid
dehydrogenases) [124]. It is also well-known that -keto acids are rapidly and quantitatively
decarboxylated by such mild oxidizing reagents as ceric sulfate [125], hydrogen peroxide
[126], peroxyphthalic acid [127], potassium permanganate [128], and lead tetraacetate [129].
In 1979, Seigel and coworkers reported decarboxylation of -keto acids by hydrogen peroxide
(H2O2) is base catalyzed and is accelerated in the presence of Fe2+ (but not other cations) [130].
In aqueous solutions of H2O2, 84 undergoes relatively slow decarboxylation to form 85 in
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quantitative yields. The addition of catalytic amounts of ferrous (Fe2+) salts to the reaction
mixture cause a dramatic rate enhancement, without reducing the yield of 85 (Scheme 59).

Scheme 59. Oxidative decarboxylation of -keto acid 84

In 1947, Waters reported that -keto acids can be reduced by hydrogen to the corresponding

-hydroxy acid [119]. It has been known for more than 30 years that lactate dehydrogenase is
nonspecific and that it catalyzes the reduction of a large number of -keto acids to the
corresponding -hydroxy acids (87), some of these -keto acids are reduced at rates similar to
that found with pyruvate (Scheme 60) [131].

Scheme 60. Reduction of -keto acids

In addition to decarboxylation and reduction, -keto acids are also susceptible to free-radical
induced fragmentation. In 1968, Evans and Leermakers reported photolysis reactions of -
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ketodecanoic acid [132]. -ketodecanoic acid (88) on photolysis, was found to split into 1-heptene
(89) and pyruvic acid (80) (Scheme 61).

Scheme 61. Photolysis of -keto acid 88

3.1.2 Synthesis of -keto acids
The first -keto acid to be prepared was pyruvic acid (80). This compound was prepared by
Berzelius in 1835 [133]. Many of the more biologically important a-keto acids were prepared over
75 years ago, e.g., oxaloacetic (oxalacetic) (77) and a-ketoglutaric (78). Waters lists the methods
of synthesis of 36 -keto acids. Many of the -keto acids have been prepared by unique methods
[119]. Some of the recent developments for the synthesis of -keto acids have been described
below.
In 1994, Wasserman

and Ho reported the synthesis

of

-keto acids using

(cyanomethylene)phosphoranes [134]. In this method, (cyanomethylene)phosphoranes (90) was
coupled with carboxylic acids or acid chlorides to give cyano keto phosphoranes (91). 91 then
undergoes oxidation and subsequent nucleophilic attack to give an -keto ester (92) which can be
hydrolyzed to the acid (93) (Scheme 62).
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Scheme 62. Synthesis of -keto acid using (cyanomethylene)phosphoranes

This method however, produced stoichiometric amount of waste from phosphorus reagents.
Therefore, a more atom-economical approach was necessary.
Crich and coworkers developed a selenium-catalyzed oxidation of ketones to prepare arylsubstituted glyoxylic acids using iodoxybenzene (PhIO2) as the oxidizing agent and fluorous
selenic acid (10 mol %) as the catalyst [135]. By using a biphasic fluorous system, the fluorous
phase containing the catalyst could be recovered and reused in new reactions. The method was
successfully applied in the synthesis of five different aryl-substituted glyoxylic acids in 89−92%
yield after 3 h at room temperature (Scheme 63).

Scheme 63. Synthesis of -keto acids fluorous selenic acid as catalyst
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Table 13. Some selected -keto acids synthesized by Crich and coworkers [135]

Entry

-keto acid

Ketone

Yield (%)

1

89

2

92

3

90

4

92

In 2016, Shibuya et al. reported the synthesis of -keto esters from -hydroxy acids using 2azaadamantane N-oxyl (AZADO), a nitroxyl radical catalyst [136]. This was a promising
approach and highly atom-economical which does not require deprotection and hydrolysis
(Scheme 64). A broad range of -hydroxy acids were efficiently oxidized to provide the
corresponding -keto acids in high yield (Table 14).

Scheme 64. Synthesis of -keto acids using AZADO as a catalyst
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Table 14. Some -keto acids synthesized by Furukawa et al. [136]

Entry

-hydroxy acid

-keto acid

Yield (%)

1

89

2

86

3

95

4

98

5

99

3.1.3 -keto acids as acylating agents
In 1991, Fontana and coworkers [137] reported for the first time the use of -keto acids as
acylating agents in the selective acylation of heteroaromatic bases 94−96. A silver-catalyzed
oxidative decarboxylation of -keto acids by (NH4)2S2O8 in a biphasic system (H2O/CH2Cl2) or
in water was used to prepare mono and diacyl derivatives 97−99 (Scheme 65).
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Scheme 65. Silver catalyzed acylation of heteroaromatic bases using -keto acids

In 2008, Gooen and coworkers reported synthesis of unsymmetrical ketones using -keto
acids by direct acylation of aromatic rings [138]. Twenty-six differently substituted
unsymmetrical ketones 102 were prepared in 5−99% yields after 16−36 h of reaction at 170 °C,
by the cross-coupling reaction of -keto acid potassium salts 100 and aryl bromides 101. The
reaction was catalyzed by Cu/Pd, in the presence of P-(o-Tol)3 and 1,10-phenanthroline as ligands
and using a mixture of NMP/quinoline (3:1) as the solvent (Scheme 66).

Scheme 66. Pd/Cu-catalyzed decarboxylative cross-coupling
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Table 15. Selected examples of direct acylation using -keto acids [138]

Entry

100

101

102

Yield of 102 (%)

a

83

b

82

c

57

d

45

e

90

Chen and coworkers [139] have developed an interesting way to prepare ynones 103,
ynamides 104, and ynoates 105, respectively, by the reaction of alkynes with -keto acids,
carbamoyl keto acids, and alkoxycarbonyl keto acids. The authors have combined the use of
photoredox catalysis with hypervalent iodine(III) reagents, i.e., Benziodoxole acetate (BI-OAc)
and alkynyl benziodoxole (BI-alkyne, 106), under 4 W blue LED irradiation (Scheme 67).
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Scheme 67. Hypervalent Iodine(III) and Ru(II)-Photocatalyzation of BI-alkyne

The usefulness of this method was demonstrated in the synthesis of ynamide 104a (Fig. 43),
which is an effective inhibitor for the metabotropic glutamate receptor 5 (mGlu5 receptor) with a
therapeutic potential for both peripheral and CNS disorders [140].

Fig. 43 Inhibitor for mGlu5 receptor
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3.2 Pyruvic acid

Pyruvic acid also known as 2-oxopropanoic acid (80) is the simplest alpha-keto acid (Fig. 44).
It plays a central role in energy metabolism in living organisms. It is widely used in drug,
agrochemical, chemical and food industries. Some applications of pyruvic acid include
significantly increasing fat and weight loss [141], improving exercise endurance capacity [142],
effectively reducing cholesterol [143], serving as a potent antioxidant [144], and reducing anoxic
injury and free radical generation [145]. Pyruvate, the conjugate base, CH3COCOO−, is a key
intermediate in several metabolic pathways throughout the cell.

Fig. 44. Pyruvic acid

3.2.1 Chemical syntheses of pyruvic acid

In 1932, Howland and Fraser developed a method for the synthesis of pyruvic acid on an
industrial scale [146]. In this process, pyruvic acid is distilled from a mixture of tartaric acid and
potassium hydrogen sulfates at 220°C. The crude acid obtained is then distilled under vacuum.
This process is simple but not cost-effective. The total cost is estimated to be about US $8,000–
9,000/ton.
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3.2.2 Biotechnological production of pyruvic acid

Compared to the chemical method, production of pyruvic acid by using biotechnological
methods is an alternative approach to reduce the production cost. There are three methods for
biotechnological production of pyruvate: the direct fermentation method, the resting cell method,
and the enzymatic method. Of these, direct fermentative production of pyruvate from a carbon
source (such as glucose) has merits in terms of both cost-effectiveness and the high purity of the
product. However, as pyruvate is located at a vital junction of cell metabolism, it is usually
difficult to obtain strains that can accumulate large amounts of pyruvate extracellularly.
In 1989, researchers in Toray industries, Japan, identifiede some yeast strains belonging to the
genus Tirulopsis, that produced more than 50 g/l pyruvate [147]. This result indicated that the
fermentative production of pyruvate can be commercialized. Pyruvate production using the
fermentative method, with a scale of about 400 tons per year, was industrialized by Toray
Industries in 1992 and the fermentation has now been scaled-up to 50 m3 fermentors [148].

3.3 Pyruvate esters

Pyruvate is a three-carbon (triose) ketoacid (107, Fig. 45) that is produced in biological
systems in the end stages of glycolysis, a product of sugar metabolism. It is also a breakdown
product of certain amino acids (alanine, glycine, cysteine, Serine). Pyruvate can be reduced to
lactate in the cytoplasm, a fermentative event in mammalian cells, or oxidatively decarboxylated
to acetyl CoA in the mitochondrion [149]. It has been suggested that pyruvate and certain pyruvate
derivatives may have utility in treating certain disorders and promoting health. For example,
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pyruvate is sold as a dietary supplement for use in promoting weight loss and enhancing energy.
It has also been suggested as a therapeutic intervention for clinical management of myocardial
insufficiency [150] and to prevent the adverse effects of myocardial ischemia [151].

Fig. 45 General formula for pyruvate

U.S. Pat. No. 6,086,789 describes certain pyruvate derivatives as useful for dermatologic
indications as well as for treating diabetic ketosis, myocardial ischemia, injured organs and
hypercholesterolemia. Specifically, it ascribes these activities to various esters of pyruvate,
including polyol-pyruvate esters, pyruvate thioesters, glycerol pyruvate esters, and
dihydroxyacetone-pyruvate ester (Fig. 46). Related U.S. Pat. No. 5,968,727 describes the use of
pyruvate thioesters, such as cysteine, methionine and homocysteine, and glycerol pyruvate esters
and dihydroxyacetone-pyruvate esters, in organ preservation solutions and for treating ischemia.
Similarly, certain pyruvate and pyruvyl amino acid conjugates have been suggested for use in
diabetes [152] [153].
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Fig. 46. Some biologically active pyruvate esters

U.S. Pat. No. 5,283,260, describes the treatment of diabetes with a physiologically acceptable
form of pyruvate. The patent discloses a pyruvate compound in the form of a covalently linked
pyruvyl-amino acid. However, administration of large amounts of pyruvate-amino acid may result
in nitrogen overload which could harm patients with liver and/or kidney pathology.
Notwithstanding the acceptance of pyruvate as an effective component of a reperfusion solution
or other varied applications, pyruvic acid is a strong and unstable acid which cannot be infused as
such. Furthermore, it has been recognized that traditional pharmacological pyruvate compounds,
such as salts of pyruvic acid, are not particularly physiologically suitable. For example, these com
pounds lead to the accumulation of large concentrations of ions (calcium or sodium) in the patient's
body fluids. Similarly, amino acid compounds containing pyruvate can lead to excessive nitrogen
loads [154].
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3.3.1 Preparation of ethyl pyruvate: Recent developments

Pyruvate (107), is an effective scavenger of reactive oxygen species (ROS) and has been
shown to be salutary in numerous models of redox-mediated tissue or organ injury. However, it is
unstable in solution and, hence, not attractive for development as a therapeutic agent. Pyruvate
esters like ethyl pyruvate are thought to be more stable and has been reported to mitigate the
damage caused by various stressors, such as, hemorrhagic shock, stroke, sepsis, and acute
pancreatitis [155] [156] [157] [158]. Preparation of pyruvate esters directly from pyruvic acid has
proven to be difficult. Pyruvic acid easily undergoes decarboxylation to give acetic acid (108) and
carbon dioxide (Scheme 68). Therefore, an alternate approach must be taken for preparation of
these esters.

Scheme 68. Decarboxylation of pyruvic acid

Currently, the commercial production of pyruvate esters is realized by the dehydrative
decarboxylation of tartaric acid. Excess KHSO4 as a dehydrating agent is required in this process,
leading to low atom efficiency and environmental pollution [159]. Thus, the development of a
green, efficient, alternative route for the production of pyruvate is necessary. In 2018, Zhou et al.
reported a highly efficient oxidation of ethyl lactate (109) to ethyl pyruvate (110) in the presence
of TS-1 catalyst (a Titanium-substituted zeolite) and aqueous 30% hydrogen peroxide (H2O2)
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[160]. The reaction was carried out under mild conditions without any solvent (Scheme 69). At
50 ℃, 109 can be completely oxidized to 110 with ≥95% yield. However, the prolongation of
reaction time and higher temperature led to the hydrolysis and eventual decarboxylation of 110.

Scheme 69. Oxidation of ethyl lactate to ethyl pyruvate

In the same year, Shiju et al. reported the direct oxidative dehydrogenation of lactates with
molecular oxygen is a “greener” alternative for producing pyruvate esters [161]. The authors
reported a one-pot synthesis of mesoporous vanadia−titania (Meso-VTN), acting as highly
efficient and recyclable catalysts for the conversion of ethyl lactate to ethyl pyruvate (Scheme
70). Mesoporous vanadia−titania nanocrystals (meso-VTN) were synthesized via the coassembly
of vanadium and titanium precursors in the presence of an amphiphilic triblock copolymer as a
templating agent. These new materials feature a large surface area and a high density of isolated
vanadium species.
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Scheme 70. Oxidative dehydrogenation of ethyl lactate to ethyl pyruvate

3.3.2 Biological applications of ethyl pyruvate

Ethyl pyruvate was originally regarded as simply a way to administer pyruvate anion, whilst
avoiding some of the problems associated with the instability of pyruvate in aqueous solutions.
Increasingly, however, it is becoming apparent that certain pyruvate esters, including ethyl
pyruvate, have pharmacological effects, such as suppression of inflammation, that are quite
distinct from those exerted by pyruvate anion.
Sims et al. found that treatment with ethyl pyruvate restores much of the structural and
functional damage to the intestinal mucosa that normally occurs when rats are subjected to
mesenteric ischemia/reperfusion [162]. Treatment with ethyl pyruvate seemed to be more
effective than treatment with an equimolar dose of sodium pyruvate. Similar findings indicating
that ethyl pyruvate is more effective than pyruvate, were reported by Varma et al.., who compared
the two compounds an in vitro study of redox-mediated cellular injury [163].
Sepsis, a lethal syndrome that develops in response to infection, occurs in 750,000 patients per
year in the United States and is fatal in 20–40% of cases [164] [165]. It is mediated by an early
(e.g., tumor necrosis factor) and late [e.g., high mobility group B-1 (HMGB1)] proinflammatory
cytokine response to infection. Fink and coworkers identified ethyl pyruvate, a stable lipophilic,
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as an experimental therapeutic that effectively protects animals from ischemia/reperfusioninduced tissue injury [166] [162]. Ethyl pyruvate administration significantly improved survival
in standard models of lethal hemorrhagic shock [167]. The authors reported that ethyl pyruvate
rescued animals from lethal sepsis caused by peritonitis, even when dosing began 24 h after cecal
puncture. It inhibited the release of tumor necrosis factor and HMGB1 from endotoxin stimulated
RAW 264.7 murine cell lines and attenuated activation of both the p38 mitogen-activated protein
kinase (MAPK) and NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells)
signaling pathways. Ethyl pyruvate treatment of septic mice decreased circulating levels of
HMGB1, indicating that delayed administration of ethyl pyruvate protects against lethal sepsis.
In 2010, Muller and coworkers reported that ethyl pyruvate elicits a potent immune-based
antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic
enzyme for many human tumors [168]. Consistent with its reported ability to interfere with NFκB function, ethyl pyruvate blocks IDO induction both in vitro and in vivo. The findings that IDO
is effectively blocked by ethyl pyruvate treatment deepens emerging links between IDO and
inflammatory processes. Furthermore, these findings rationalize oncologic applications for this
agent by providing a compelling basis to reposition ethyl pyruvate as a low-cost
immunochemotherapy for clinical evaluation in cancer patients.
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3.4 Project rationale and design strategy

As previously described, pyruvate esters have been increasingly of interest to the
pharmaceutical industry. It can be used to treat various medical conditions and has proved to more
effective than pyruvic acid itself. Simple esters like methyl pyruvate and ethyl pyruvate have been
synthesized and studied in the past. However, the more complex esters of pyruvic acid have been
difficult to develop. Therefore, it was of interest to develop a general synthesis of a series of
pyruvate esters.
Our group had previously developed a synthesis for glyceryl tripyruvate (111). The first step
involved the synthesis of ethyl-4-substituted--methylcinnamate (112) using Horner-WadsworthEmmons

reaction

[169]

starting

from

4-substituted-benzaldehyde

(113)

and

(carbethoxyethylidene)triphenylphosphorane (114). The ethyl cinnamate 112 was then converted
to the corresponding carboxylic acid (115) which was subsequently converted to 4-substituted-methylcinnamoyl chloride (116) in quantitative yield using thionyl chloride. 116 was then
converted to glyceryl tris(4-substituted--methylcinnamate) (117) in 61% yield by reacting 116
with glycerol in pyridine. The triester 117 was converted to the tripyruvate (118) using ozonolysis
chemistry in 89% yield. The tripyruvate 118 was isolated from the byproducts by liquid/liquid
extraction. The tripyruvate (118) water solution was then freeze-dried to yield 118 in pure form
as clear oil. The synthetic scheme is illustrated in Scheme 71.
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Scheme 71. Synthesis of glyceryl tripyruvate
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Using similar synthetic procedures, a synthetic route for pyruvate esters was developed. The
retrosynthetic route is illustrated in Scheme 72. Using Horner-Wadsworth-Emmons reaction,
synthesis

of

ethyl

2,3-dimethylbut-2-enoate

could

be

achieved

from

ethyl-2-

(diethoxyphospryl)propanoate and acetone. The ethyl ester can be hydrolyzed to the
corresponding acid which can be converted to a series of esters using a coupling reagent like N(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDCI). The esters can then undergo ozonolysis
to give the corresponding pyruvates.

Scheme 72. Retrosynthetic route for a series of pyruvate esters
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RESULTS AND DISCUSSION

3.5 Synthesis of ethyl 2,3-dimethyl-2-butenoate

Ethyl 2,3-dimethyl-2-butenoate was prepared using Horner-Wadsworth-Emmons reaction.
This method is used to synthesize olefins from phosphorus ylides (phosphonates) and
aldehydes/ketones [170]. Ethyl 2,3-dimethyl-2-butenoate (118) was synthesized from triethyl-2phosphonopropionate (119) and acetone in the presence of a base. A general reaction scheme is
illustrated in Scheme 73.

Scheme 73. General scheme for synthesis of ethyl 2,3-dimethyl-2-butenoate

Bases like sodium hydride (NaH) and sodium ethoxide (NaOEt) were found to be suitable
bases for this reaction. First, sodium metal was used to prepare NaOEt in situ with ethanol as the
solvent. The reaction was run at room temperature under an inert atmosphere to give 118 as a
colorless oil. The reaction conditions were optimized by varying the number of equivalents of
sodium metal. However, the highest yield was only 32%. The reaction was repeated with
purchased anhydrous NaOEt in various amounts which gave 118 in 21-32% yield.
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Next, NaH was used as the base in THF. Varying the amount of acetone also affected the yield
of the reaction. It was determined that using 3 equivalents of NaH and 1.5 equivalents of acetone
were the best conditions for the reaction and gave 118 in 75% yield.

Scheme 74. Optimized reaction scheme for synthesis of 118

Scheme 75. Mechanism for synthesis of 118
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Table 16. Optimization of reaction conditions for synthesis of 118
Entry

Base

Equivalents

Solvent

Acetone (equiv.)

Yield of 118 (%)

1

NaOEt

1

THF

1

21

2

NaOEt

1.5

EtOH

1

23

3

NaOEt

2

EtOH

1

23

4

NaOEt

3

EtOH

1

30

5

NaOEt

5

EtOH

1

32

6

NaOEt

5

EtOH

3

30

7

NaH

1

THF

1

56

8

NaH

1.5

THF

1

55

9

NaH

3

THF

1

60

10

NaH

3

THF

1.5

75
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3.6 Synthesis of 2,3-dimethyl-2-butenoic acid

The next step in the synthesis of pyruvate esters was to convert 118 to its corresponding
carboxylic acid (120). This was achieved by base hydrolysis of 118. First, 3 equivalents of
lithium hydroxide (LiOH) was used as the base (Scheme 76). The reaction was stirred at room
temperature but there was no visible product formation by TLC. The reaction was then heated to
50 ℃ which led to the formation of 120 in 52% yield.

Scheme 76. Synthesis of 120 using LiOH

The reaction was repeated with 3 equivalents of sodium hydroxide (NaOH) as the base
and EtOH as the solvent. NaOH was dissolved in minimum amount of water and was then added
to the reaction mixture. The reaction was stirred overnight to give 120 in 57% yield. These
conditions were optimized (Table 17) by heating the reaction mixture to reflux temperature. This
led to the formation of the acid 120 as a light-yellow solid in 99% yield.
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Table 17. Reaction conditions for synthesis of 120

Entry

Base

Solvent

Temperature (℃)

Yield of 120 (%)

1

LiOH

THF:H2O (1:1)

25

0

2

LiOH

THF:H2O (1:1)

50

52

3

NaOH

EtOH/H2O

25

57

4

NaOH

EtOH/H2O

Reflux

99

3.7 Synthesis of esters of 2,3-dimethyl-2-butenoic acid

With the acid in hand, a series of esters were prepared using Steglich esterification [171]. The
acid 120 was treated with benzyl alcohols (121a), 4-bromobenzyl alcohol (121b), ethylene glycol
(121c) and neopentyl glycol (121d) (Fig. 47) in the presence of a carbodiimide coupling reagent
(EDCI) and a suitable organic base N, N-dimethyl aminopyridine (DMAP) or N,N-diisopropyl
ethylamine (DIPEA). The reaction conditions were optimized with benzyl alcohol (121a)
(Scheme 77, Table 18). It was noted that using 3 equivalents of the alcohol and 5 equivalents of
DIPEA were required in order to prepare 122a in 86% yield.
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Fig. 47. Alcohols used to prepare the esters of 120

Scheme 77. Synthesis of benzyl ester 125

Table 18. Reaction condition optimization for synthesis of 122a

Entry

Equivalents of 121a

Base

Equivalents of base

Yield of 122a (%)

1

1

DMAP

1

46

2

1.5

DMAP

2

45

3

3

DMAP

3

50

4

3

DIPEA

3

75

5

3

DIPEA

5

86
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The optimized conditions were then used to prepare esters 122a-f in 75-89% yield (Scheme
78). It was observed that dialcohols like ethylene glycol and neopentyl alcohol produced the
monoesters 122c and 122d. The monoesters were then used to repeat the esterification with the
acid 120 to produce the diesters 122e and 122f (Fig. 48).

Scheme 78. Synthesis of esters 122a-f

Fig. 48. Structures of synthesized esters 122a-f
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Synthesis of diesters 122e and 122f is illustrated in scheme 79 and 80 below.

Scheme 79. Synthesis of diester 122e

Scheme 80. Synthesis of diester 122f
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Table 19. Optimized yields of esters 122a-f
Entry

ROH

Yield of 122 (%)

a

121a

86

b

121b

89

c

121c

75

d

121d

78

e

122c

76

f

122d

78

3.8 Synthesis pf pyruvate esters

Pyruvate esters were prepared by ozonolysis of the synthesized esters 122a-d. Ozolnolysis is
a method to oxidatively cleave alkenes or alkynes with ozone (O3). The carbon-carbon double
bond is replaced by a double bond with oxygen. The intermediate formed is an ozonide molecule
which is further reduced to carbonyl products.
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Scheme 81. Ozonide formation during ozonolysis

The ozonide intermediate is reduced with either triphenyl phosphine (PPh3) or dimethyl sulfide
(DMS) to give the carbonyl compounds. Using this method, the esters 122a-b and 122e-f were
treated with ozone at -78 ℃ in dichloromethane and then subsequently reduced with PPh3 to give
the corresponding pyruvate esters 123a-d (Fig. 49) in moderate to high yields (56-93%) (Scheme
82). The pyruvate esters were separated from the byproduct triphenyl phosphine oxide by column
chromatography and obtained as colorless oils.

Scheme 82. Synthesis of pyruvate esters 123a-d via ozonolysis
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Fig. 49. Structures of synthesized pyruvate esters 123a-d
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CONCLUSION

In summary, a general synthesis for the preparation of pyruvate esters was developed. A series
of alkyl pyruvate esters were synthesized in moderate to high yield in four steps. HornerWadsworth-Emmons reaction was used to synthesize the alkene precursor which was converted
to the corresponding ester and subsequently converted to pyruvate esters via ozonolysis. The
reaction conditions can be applied to prepare both mono and diesters. Mono esters were isolated
in higher yields compared to diesters. The pyruvate esters were found to be stable and did not
undergo decomposition.
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EXPERIMENTAL

General information

All reactions were carried out in oven-dried glassware under a N2 atmosphere unless otherwise
noted. All chemicals were purchased from Alfa Aesar, Sigma Aldrich, and VWR and were used
as received without further purification. Chromatography refers to flash silica gel column
chromatography (0.060–0.200mm (60 Å) silica gel from Sorbent Technology was used as the
stationary phase). 1H NMR and 13C NMR spectra were recorded at room temperature in DMSOd6 on a Bruker 300 MHz instrument. 1H chemical shifts were referenced to the DMSO solvent
signal (2.48 ppm). 13C chemical shifts were referenced to the DMSO solvent signal (40.00 ppm).

Synthesis of ethyl 2,3-dimethyl-2-butenoate (118)

Sodium hydride (6.05 g, 0.252 mol) was added to anhydrous THF (50 mL). The mixture was
stirred at

room temperature for 30 minutes under inert

atmosphere. Triethyl-2-

phosphonopropionate (20.0 mL, 0.0840 mol) was added to the solution and stirred for an
additional 30 minutes. Anhydrous acetone (9.26 mL, 0.126 mol) was then added to the reaction
mixture and the reaction was stirred for 24 hours at room temperature. The reaction was diluted
with water (50 mL) extracted with diethyl ether (3 x 50 mL). The organic layers were combined
and washed with brine (100 mL) and dried over anhydrous sodium sulfate. The sodium sulfate
was filtered and the solvent was removed under vacuum to give 118 as a colorless oil (9.00 g, 75%
yield).
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1

HNMR (DMSO-d6, 300 MHz) : 4.08 (q, J = 7.0 Hz, 2H), 1.92 (s, 3H), 1.79 – 1.72 (m, 6H), 1.19

(t, J = 7.3 Hz, 3H).
C NMR (DMSO-d6, 75 MHz) : 168.5, 142.2, 137.6, 122.0, 59.5, 22.4, 22.0, 15.4, 14.1.

13

Synthesis of 2,3-dimethyl-2-butenoic acid (120)

Ethyl 2,3-dimethyl-2-butenoate (10.0 mL, 0.0703 mol) was dissolved in ethanol (30.0 mL). NaOH
(8.44 g, 0.211 mol) was dissolved separately in water (20.0 mL) was added to the reaction mixture.
The mixture was heated at reflux for 24 h. The reaction mixture was concentrated under vacuum
and diluted with water (50 mL). The solution was made acidic to pH 2 by adding 3M HCl. The
aqueous solution then was extracted with ethyl acetate (3 x 15 mL). The organic layers were
combined and washed with brine (30 mL) and dried over anhydrous sodium sulfate. The sodium
sulfate was filtered and the solvent was removed under vacuum to give a light-yellow oil. The oil
was cooled to give light yellow crystals (8.00 g, 99% yield). mp 52.3-54.0 ℃

1

H NMR (DMSO-d6, 300 MHz) : 12.07 (s, 1H), 1.92 (s, 3H), 1.74 (d, J = 3.6 Hz, 7H).
C NMR (DMSO-d6, 75 MHz) : 170.4, 141.3, 122.8, 22.5, 22.1, 15.6.

13

Synthesis of 2,3-dimethyl-2-butenoate esters (122a-f)

General procedure A
2,3-dimethyl-2-butenoic acid (1 equivalent), alcohol (3 equivalents), and EDC•HCl (3
equivalents) were dissolved in anhydrous DMF (20.0 mL). DIPEA (5 equivalents) was added to
the reaction mixture and stirred under inert atmosphere for 24 h. The reaction was diluted with
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water (100 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined
and washed with water (5 x 20 mL), brine (50 mL) and the dried over anhydrous sodium sulfate.
The sodium sulfate was filtered and the solvent was removed under vacuum. The residue was
purified by column chromatography (30% EtOAc:Hex) to give the esters 122a-d as colorless oils.

Benzyl 2,3-dimethyl-2-butenoate (122a)

General procedure A. Ester 122a was prepared using 120 (1.00 g, 8.76 mmol), alcohol 121a
(2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and was
obtained as a colorless oil (1.60 g, 89% yield).
1

H NMR (DMSO-d6, 300MHz) : 7.35-7.30 (m, 5H), 5.12 (s, 2H), 1.93 (s, 3H), 1.80 (s, 3H), 1.75

(s, 3H).
C NMR (DMSO-d6, 75 MHz) : 168.3, 143.5, 136.5, 128.4, 127.9, 121.7, 112.5, 65.3, 46.0,
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22.6, 15.4.

4-bromobenzyl 2,3-dimethyl-2-butenoate (122b)

General procedure A. Ester 122b was prepared using 120 (1.00 g, 8.76 mmol), alcohol 121a
(2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and was
obtained as a colorless oil (2.21 g, 89% yield).
1

H NMR (DMSO-d6, 300 MHz) : 7.55 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 5.09 (s, 2H),

1.93 (s, 3H), 1.78 (d, J = 11.0 Hz, 6H).
CNMR (DMSO-d6, 75 MHz) : 168.3, 143.5, 136.5, 128.4, 127.9, 121.7, 112.5, 65.3, 22.6, 15.4.
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2-hydroxyethyl 2,3-dimethylbut-2-enoate (122c)

General procedure A. Mono ester 122e was prepared using 120 (1.00 g, 8.76 mmol), alcohol
121a (2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and
was obtained as a colorless oil (1.04 g, 75% yield)
1

H NMR (DMSO-d6, 300 MHz) : 5.37 (s, 1H), 4.27 (t, J = 7.3 Hz, 2H), 3.8 (t, J = 7.3 Hz, 2H),

2.37 (s, 3H), 2.21 (s, 3H), 1.92 (s, 3H).

3-hydroxy-2,2-dimethylpropyl 2,3-dimethylbut-2-enoate (122d)

General procedure A. Mono ester 122d was prepared using 120 (1.00 g, 8.76 mmol), alcohol
121a (2.72 mL, 26.3 mmol), EDC•HCl (4.08 26.3 mmol) and DIPEA (7.63 mL, 4.37 mmol) and
was obtained as a colorless oil (1.75 g, 78% yield).
1

H NMR (DMSO-d6, 300 MHz) : 4.60 (t, J = 5.4 Hz, 1H), 3.80 (s, 2H), 3.17 (d, J = 5.4 Hz, 2H),

1.95 (d, J = 6.6 Hz, 3H), 1.83 – 1.72 (m, 6H), 0.83 (s, 6H).

Ethane-1,2-diyl bis(2,3-dimethylbut-2-enoate) (122e)
General procedure A. Diester 122e was prepared from 120 (0.120 g, 1.05 mmol), 122 c (0.500
g, 3.16 mmol), EDC•HCl (0.490 g, 3.16 mmol) and DIPEA (1.00 mL, 5.25 mmol) and was
obtained as a colorless oil (0.208g, 76% yield).
1

H NMR (DMSO-d6, 300 MHz) : 4.28 (s, 4H), 1.92 (s, 6H), 1.75 (s, 12H).
C NMR (DMSO-d6, 75 MHz) : 168.7, 144.0, 122.0, 112.9, 62.1, 23.0, 15.4.
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2,2-dimethylpropane-1,3-diyl bis(2,3-dimethylbut-2-enoate) (122f)
General procedure A. Diester 122f was prepared from 120 (0.200 g, 1.67 mmol), 122d (1.00 g,
5.00 mmol), EDC•HCl (0.777 g, 5.00 mmol) and DIPEA (1.45 mL, 8.35 mmol) and was obtained
as a colorless oil (0.390 g, 78% yield)
1

H NMR (DMSO-d6, 300 MHz) : 3.86 (s, 4H), 1.93 (s, 6H), 1.78-1.76 (m, 12H), 0.94 (s, 6H).

Synthesis of pyruvate esters (123a-d)

General procedure B
The esters 122a-b and 122e-f were dissolved in anhydrous DCM (20.0 mL) and the reaction was
cooled to -78 ℃. Ozone was bubbled through the solution until blue color persisted. Oxygen was
then bubbled through until the blue color disappeared and solution turned colorless. Triphenyl
phosphine (2 equivalents) was added to the reaction mixture and stirred at room temperature
overnight. Water (20 mL) was added to the reaction mixture and the organic and aqueous layers
were separated. The aqueous layer was extracted with DCM (3 x 15 mL). The organic layers were
combined and washed with brine (20 mL) the organic layer was then dried over anhydrous sodium
sulfate, filtered and the solvent was removed under vacuum. The residue was purified by column
chromatography (50% EtOAc/Hex) to give the pyruvate esters 123a-d as colorless oils.

Benzyl 2-oxopropanoate (123a)

General procedure B. The pyruvate ester 123a was obtained from 122a (0.500 g, 2.45 mmol) as
a colorless oil (0.406 g, 93% yield).
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1

H NMR (DMSO-d6, 300 MHz) : 7.41-7.35 (m, 5H), 5.22 (s, 2H), 2.38 (s, 3H).
C NMR (DMSO -d6, 75 MHz) : 191.6, 168.3, 143.5, 136.5, 128.4, 127.9, 65.3, 15.4.
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4-Bromobenzyl 2-oxopropanoate (123b)

General procedure B. The pyruvate ester 123b was obtained from 122b (0.500 g, 1.76 mmol) as
a colorless oil (0.400 g, 88% yield).
1

H NMR (DMSO-d6, 300 MHz) : 7.57 (d, J = 9Hz, 2H), 7.38 (d, J = 9Hz, 2H), 5.21 (s, 2H), 2.39

(s, 3H).
C NMR (DMSO-d6, 75 MHz) : 191.6, 168.3, 136.5, 128.4, 127.9, 121.7, 112.6, 65.3, 22.6.

13

Ethane-1,2-diyl bis(2-oxopropanoate) (123c)

General procedure B. The pyruvate ester 123c was obtained from 122e (0.100 g, 0.400 mmol)
as a colorless oil (0.0453 g, 56% yield).
1H

NMR (DMSO-d6, 300 MHz) : 4.44 (s, 4H), 2.36 (s, 6H).

C NMR (DMSO-d6, 75 MHz) : 191.6, 160.3, 63.6, 27.0.

13

2,2-Dimethylpropane-1,3-diyl bis(2-oxopropanoate) (123d)

General procedure B. The pyruvate ester 123d was obtained from 122f (0.100 g, 0.337 mmol)
as a colorless oil (0.0543 g, 66% yield).
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1

H NMR (DMSO-d6, 300 MHz) : 4.02 (s, 4H), 2.37 (s, 6H), 1.00 (s, 6H).
C NMR (DMSO-d6, 75 MHz) : 191.7, 160.3, 70.4, 27.2, 21.6.
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APPENDIX

Crystal data for compound 23b

Empirical formula

C18H15Cl2O6S

Formula weight

422.83 g mol-1

Temperature

90 K

Cu K radiation, 

1.54184 Å

Crystal system

Orthorhombic, P212121

Unit cell dimensions

a = 4.793 (2) Å
b = 10.7214(5) Å
c = 35.1362 (15) Å

Volume

1807.19 (14) Å3

Z

4

F (000)

872

Density, Dx

1.554 Mg m-3

Absorption coefficient, 

3.32 mm-1

Glancing angle, 

−

Crystal size

0.38 x 0.04 x 0.02 mm

Physical appearance

Needle, colorless

Reflections

7594
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)

Cl1
S1
O1
O2
O3
O4
O5
O6
N1
N2
H2N
C1
C2
C3
C4
H4
C5
H5
C6
H6
C7
H7
C8
H8A
H8B
C9
C10
C11
H11
C12
H12
C13
C14
H14
C15
H15
C16
C17
H17A
H17B
C18
H18A
H18B

X
0.1699 (2)
0.41916 (18)
0.2404 (7)
0.5969 (6)
0.2181 (6)
0.4988 (5)
0.4861 (5)
0.1861 (6)
0.2633 (6)
0.0749 (6)
-0.092 (5)
0.3330 (8)
0.5372 (7)
0.5967 (7)
0.7692 (7)
0.8083
0.8834 (8)
1.0025
0.8250 (9)
0.9042
0.6522 (8)
0.6141
0.0922 (8)
-0.0812
0.0397
0.2446 (7)
0.1705 (7)
0.0632 (8)
-0.0777
0.1598 (8)
0.0855
0.3664 (7)
0.4713 (7)
0.6092
0.3729 (8)
0.4428
0.3845 (8)
0.5638 (8)
0.7490
0.5914
0.4432 (9)
0.5921
0.3672

y
0.18375 (15)
0.93409 (8)
0.5987 (3)
0.9658 (3)
1.0249 (3)
0.6870 (3)
0.4160 (2)
0.2545 (3)
0.7966 (3)
0.6470 (3)
0.663 (4)
0.6971 (4)
0.7492 (4)
0.8740 (3)
0.9412 (4)
1.0269
0.8772 (4)
0.9200
0.7530 (4)
0.7113
0.6875 (4)
0.6016
0.7755 (4)
0.7321
0.8569
0.6973 (4)
0.5830 (3)
0.6143 (3)
0.6763
0.5558 (4)
0.5767
0.4667 (3)
0.4314 (4)
0.3681
0.4897 (3)
0.4663
0.3036 (3)
0.2532 (4)
0.2314
0.3194
0.1403 (4)
0.0958
0.0830

z
0.66169 (3)
0.33766 (2)
0.32286 (9)
0.36869 (7)
0.32606 (7)
0.40902 (8)
0.56660 (7)
0.56434 (7)
0.34577 (8)
0.43556 (8)
0.4328 (12)
0.32104 (10)
0.29226 (10)
0.29797 (10)
0.27388 (10)
0.2782
0.24288 (10)
0.2257
0.23700 (10)
0.2157
0.26170 (11)
0.2575
0.37926 (10)
0.3716
0.3905
0.40930 (10)
0.46866 (9)
0.50398 (10)
0.5058
0.53683 (10)
0.5611
0.53331 (9)
0.49841 (10)
0.4967
0.46556 (10)
0.4413
0.57833 (9)
0.60987 (10)
0.5994
0.6291
0.62901 (12)
0.6430
0.6095

Uiso*/Ueq
0.0475 (4)
0.0171 (2)
0.0348 (8)
0.0223 (6)
0.0219 (6)
0.0220 (6)
0.0162 (5)
0.0220 (6)
0.0181 (7)
0.0143 (6)
0.017*
0.0221 (9)
0.0178 (7)
0.0156 (7)
0.0178 (7)
0.021*
0.0219 (8)
0.026*
0.0236 (8)
0.028*
0.0228 (8)
0.027*
0.0212 (8)
0.025*
0.025*
0.0154 (7)
0.0135 (7)
0.0174 (7)
0.021*
0.0172 (7)
0.021*
0.0147 (7)
0.0181 (7)
0.022*
0.0167 (7)
0.020*
0.0147 (7)
0.0191 (8)
0.023*
0.023*
0.0280 (9)
0.034*
0.034*

Atomic displacement parameters (Å2)

Cl1
S1

U11

U22

U33

U12

U13

U23

0.0232 (5)
0.0176 (4)

0.0896 (10)
0.0203 (4)

0.0297 (5)
0.0133 (4)

-0.0022 (6)
0.0019 (4)

-0.0033 (4)
-0.0004 (3)

0.0278 (6)
0.0023 (4)
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O1
O2
O3
O4
O5
O6
N1
N2
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18

0.0450 (19)
0.0233 (13)
0.0238 (14)
0.0107 (13)
0.0197 (12)
0.0260 (14)
0.0192 (14)
0.0101 (13)
0.0134 (17)
0.0179 (17)
0.0165 (16)
0.0204 (17)
0.0210 (18)
0.0246 (19)
0.025 (2)
0.0148 (17)
0.0157 (17)
0.0117 (15)
0.0182 (17)
0.0200 (16)
0.0164 (16)
0.0197 (17)
0.0208 (18)
0.0197 (18)
0.0190 (17)
0.029 (2)

0.0235 (17)
0.0289 (15)
0.0206 (14)
0.0298 (15)
0.0161 (13)
0.0201 (14)
0.0203 (16)
0.0184 (15)
0.040 (3)
0.0188 (18)
0.0179 (18)
0.0153 (17)
0.030 (2)
0.030 (2)
0.0182 (19)
0.029 (2)
0.0174 (18)
0.0147 (17)
0.0171 (17)
0.0196 (18)
0.0158 (18)
0.0178 (18)
0.0180 (18)
0.0114 (16)
0.0205 (19)
0.027 (2)

0.0360 (17)
0.0147 (12)
0.0215 (13)
0.0256 (13)
0.0129 (11)
0.0199 (13)
0.0147 (15)
0.0145 (14)
0.0127 (16)
0.0169 (16)
0.0125 (15)
0.0179 (17)
0.0148 (17)
0.0161 (17)
0.0255 (19)
0.0199 (17)
0.0132 (16)
0.0142 (16)
0.0169 (17)
0.0119 (15)
0.0120 (16)
0.0167 (16)
0.0115 (16)
0.0131 (15)
0.0180 (17)
0.028 (2)

-0.0023 (15)
0.0032 (12)
0.0067 (11)
0.0024 (11)
-0.0005 (10)
-0.0068 (12)
-0.0016 (12)
0.0020 (12)
-0.0007 (17)
0.0000 (15)
0.0027 (15)
0.0001 (15)
0.0024 (17)
0.0054 (18)
-0.0003 (17)
0.0041 (16)
-0.0003 (14)
-0.0004 (13)
0.0036 (15)
0.0010 (15)
-0.0041 (13)
0.0067 (15)
0.0028 (15)
0.0027 (15)
0.0023 (17)
-0.0016 (19)

0.0029 (15)
-0.0029 (11)
-0.0025 (11)
0.0002 (10)
-0.0035 (9)
-0.0079 (11)
0.0010 (12)
-0.0020 (12)
-0.0042 (14)
-0.0043 (14)
-0.0020 (14)
-0.0026 (14)
0.0005 (15)
0.0011 (15)
-0.0049 (16)
0.0033 (15)
-0.0009 (13)
-0.0008 (13)
0.0009 (15)
0.0029 (13)
-0.0043 (13)
-0.0011 (14)
0.0020 (14)
0.0018 (14)
-0.0041 (14)
-0.0092 (18)

0.0060 (13)
-0.0020 (10)
0.0007 (10)
0.0100 (12)
0.0038 (10)
0.0039 (11)
0.0055 (12)
0.0027 (12)
0.0001 (16)
0.0039 (15)
0.0028 (13)
0.0006 (15)
0.0031 (15)
-0.0071 (16)
-0.0052 (16)
0.0109 (16)
0.0050 (14)
0.0020 (13)
0.0029 (14)
-0.0004 (14)
0.0039 (13)
0.0005 (15)
-0.0004 (13)
-0.0014 (13)
0.0034 (15)
0.0103 (17)

Geometric parameters (Å, )
Cl1-C18
S1-O2
S1-O3
S1-N1
S1-C3
O1-C1
O4-C9
O5-C16
O5-C13
O6-C16
N1-C1
N1-C8
N2-C9
N2-C10
N2-H2N
C1-C2
C2-C7
C2-C3
C3-C4
C4-C5
C4-H4
C5-C6
C5-H5

1.804 (5)
1.425 (3)
1.430 (3)
1.677 (3)
1.756 (4)
1.146 (5)
1.225 (4)
1.363 (4)
1.412 (4)
1.194 (5)
1.416 (5)
1.452 (4)
1.344 (5)
1.426 (4)
0.82 (2)
1.514 (5)
1.376 (5)
1.384 (5)
1.386 (5)
1.399 (5)
0.9500
1.377 (6)
0.9500

C6-C7
C6-H6
C7-H7
C8-C9
C8-H8A
C8-H8B
C10-C11
C10-C15
C11-C12
C11-H11
C12-C13
C12-H12
C13-C14
C14-C15
C14-H14
C15-H15
C16-C17
C17-C18
C17-H17A
C17-H17B
C18-H18A
C18-H18B
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1.390 (6)
0.9500
0.9500
1.534 (5)
0.9900
0.9900
1.384 (5)
1.398 (5)
1.393 (5)
0.9500
1.383 (5)
0.9500
1.378 (5)
1.395 (5)
0.9500
0.9500
1.503 (5)
1.501 (6)
0.9900
0.9900
0.9900
0.9900

O2-S1-O3
O2-S1-N1
O3-S1-N1
O2-S1-C3
O3-S1-C3
N1-S1-C3
C16-O5-C13
C1-N1-C8
C1-N1-S1
C8-N1-S1
C9-N2-C10
C9-N2-H2N
C10-N2-H2N
O1-C1-N1
O1-C1-C2
N1-C1-C2
C7-C2-C3
C7-C2-C1
C3-C2-C1
C2-C3-C4
C2-C3-S1
C4-C3-S1
C3-C4-C5
C3-C4-H4
C5-C4-H4
C6-C5-C4
C6-C5-H5
C4-C5-H5
C5-C6-C7
C5-C6-H6
C7-C6-H6
C2-C7-C6
C2-C7-H7
C6-C7-H7
N1-C8-C9
N1-C8-H8A
C9-C8-H8A

117.34 (17)
110.26 (16)
110.25 (17)
113.88 (17)
110.51 (16)
91.65 (16)
116.5 (3)
120.9 (3)
116.9 (3)
121.8 (3)
123.9 (3)
115 (3)
120 (3)
124.6 (4)
128.8 (4)
106.5 (3)
119.7 (4)
127.1 (4)
113.2 (3)
122.5 (3)
111.7 (3)
125.7 (3)
117.0 (4)
121.5
121.5
120.8 (4)
119.6
119.6
121.1 (4)
119.5
119.5
118.9 (4)
120.5
120.5
111.9 (3)
109.2
109.2

C9-C8-H8B
H8A-C8-H8B
O4-C9-N2
O4-C9-C8
N2-C9-C8
C11-C10-C15
C11-C10-N2
C15-C10-N2
C10-C11-C12
C10-C11-H11
C12-C11-H11
C13-C12-C11
C13-C12-H12
C11-C12-H12
C14-C13-C12
C14-C13-O5
C12-C13-O5
C13-C14-C15
C13-C14-H14
C15-C14-H14
C14-C15-C10
C14-C15-H15
C10-C15-H15
O6-C16-O5
O6-C16-C17
O5-C16-C17
C18-C17-C16
C18-C17-H17A
C16-C17-H17A
C18-C17-H17B
C16-C17-H17B
H17A-C17-H17B
C17-C18-Cl1
C17-C18-H18A
Cl1-C18-H18A
C17-C18-H18B
Cl1-C18-H18B

109.2
107.9
124.9 (3)
121.2 (3)
113.8 (3)
120.1 (3)
119.7 (3)
120.2 (3)
120.7 (3)
119.7
119.7
118.4 (3)
120.8
120.8
122.1 (3)
118.9 (3)
118.9 (3)
119.3 (3)
120.3
120.3
119.4 (3)
120.3
120.3
123.4 (3)
127.0 (3)
109.6 (3)
113.5 (3)
108.9
108.9
108.9
108.9
107.7
110.9 (3)
109.5
109.5
109.5
109.5

N1-C8-H8B

109.2

H18A-C18-H18B

108.0

O2-S1-N1-C1
O3-S1-N1-C1
C3-S1-N1-C1
O2-S1-N1-C8
O3-S1-N1-C8
C3-S1-N1-C8
C8-N1-C1-O1
S1-N1-C1-O1
C8-N1-C1-C2
S1-N1-C1-C2
O1-C1-C2-C7
N1-C1-C2-C7

-114.8 (3)
114.0 (3)
1.4 (3)
57.6 (3)
-73.5 (3)
173.9 (3)
8.5 (6)
-179.0 (3)
-173.7 (3)
-1.2 (4)
0.7 (7)
-176.9 (4)

C3-C2-C7-C6
C1-C2-C7-C6
C5-C6-C7-C2
C1-N1-C8-C9
S1-N1-C8-C9
C10-N2-C9-O4
C10-N2-C9-C8
N1-C8-C9-O4
N1-C8-C9-N2
C9-N2-C10-C11
C9-N2-C10-C15
C15-C10-C11-C12

-0.4 (5)
176.5 (3)
0.5 (6)
68.3 (4)
-103.8 (3)
5.5 (6)
-172.4 (3)
19.2 (6)
-162.7 (3)
130.4 (4)
-49.2 (5)
1.6 (6)
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O1-C1-C2-C3
N1-C1-C2-C3
C7-C2-C3-C4
C1-C2-C3-C4
C7-C2-C3-S1
C1-C2-C3-S1
O2-S1-C3-C2
O3-S1-C3-C2
N1-S1-C3-C2
O2-S1-C3-C4
O3-S1-C3-C4
N1-S1-C3-C4
C2-C3-C4-C5
S1-C3-C4-C5
C3-C4-C5-C6

177.8 (4)
0.1 (4)
0.2 (5)
-177.2 (3)
178.2 (3)
0.8 (4)
111.8 (3)
-113.6 (3)
-1.3 (3)
-70.3 (4)
64.3 (4)
176.7 (3)
0.1 (5)
-177.6 (3)
-0.1 (5)

N2-C10-C11-C12
C10-C11-C12-C13
C11-C12-C13-C14
C11-C12-C13-O5
C16-O5-C13-C14
C16-O5-C13-C12
C12-C13-C14-C15
O5-C13-C14-C15
C13-C14-C15-C10
C11-C10-C15-C14
N2-C10-C15-C14
C13-O5-C16-O6
C13-O5-C16-C17
O6-C16-C17-C18
O5-C16-C17-C18

-178.0 (3)
0.5 (6)
-2.3 (6)
173.6 (3)
-85.8 (4)
98.2 (4)
2.0 (6)
-173.9 (3)
0.2 (6)
-1.9 (6)
177.6 (3)
-7.8 (5)
170.7 (3)
-11.0 (6)
170.6 (3)

C4-C5-C6-C7

-0.2 (6)

C16-C17-C18-Cl1

-77.7 (4)

Hydrogen-bond geometry (Å, )
D-H...A

D-H

N2-H2N...O4i

0.82 (2)

H...A
2.15 (3)

Symmetry code: (i) X-1, y, z.
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D...A

D-H...A

2.948 (4)

163 (4)

Crystal structure data for compound 29

Empirical formula

C22H26ClNO11

Formula weight

515.89 g mol-1

Crystal system

Triclinic, P1

Unit cell dimensions

a = 5.6938 (2) Å
b = 9.5493 (3) Å
c = 23.0194 (10) Å
 = 80.255 (3)
 = 84.336 (3)
 = 74.482 (3)

Volume

1186.04 (8) Å3

Z

2

F(000)

540

Density, Dx

1.445 Mg m3

Reflections

4969

Cu K radiation, 

1.54184 Å

Absorption coefficient, 

1.98 mm-1

Glancing angle, 

−

Temperature

100 K

Crystal appearance

Lath, colorless

Crystal dimensions

0.31 x 0.12 x 0.01 mm
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
Cl1
O1
O2
O3
O4
O5
O6
O7
O8
O9
O10
O11
N1
H1N
C1
H1
C2
H2
C3
H3
C4
H4
C5
H5
C6
H6A
H6B
C7
C8
H8A
H8B
H8C
C9
C10
H10A
H10B
H10C
C11
C12
H12A
H12B
H12C
C13
C14
H14A
H14B
H14C
C15
C16

x

y

z

Uiso*/Ueq

-0.7062 (2)
0.4826 (6)
0.6996 (6)
0.7625 (6)
0.2796 (6)
0.2860 (6)
-0.1918 (7)
1.0924 (7)
0.5915 (7)
0.5555 (8)
-0.0614 (7)
-0.3347 (7)
-0.1986 (8)
-0.190 (11)
0.3965 (9)
0.2763
0.6153 (9)
0.7466
0.5412 (9)
0.4418
0.3936 (9)
0.5002
0.1851 (9)
0.0763
0.0363 (10)
0.0029
0.1268
0.9415 (10)
0.9947 (11)
1.0625
0.8434
1.1129
0.7644 (10)
1.0094 (11)
1.0060
1.0525
1.1311
0.3745 (10)
0.2280 (11)
0.3028
0.0607
0.2252
-0.2142 (10)
-0.4503 (11)
-0.5842
-0.4471
-0.4750
0.3047 (9)
0.1213 (10)

1.00327 (13)
0.6306 (4)
0.3340 (4)
0.2967 (4)
0.4222 (4)
0.6612 (4)
0.7809 (4)
0.3215 (4)
0.1134 (4)
0.4408 (5)
0.9829 (4)
0.8003 (4)
0.9709 (4)
1.059 (5)
0.5551 (5)
0.5031
0.4463 (5)
0.4963
0.3774 (5)
0.3079
0.4927 (5)
0.5495
0.5953 (5)
0.5366
0.7155 (6)
0.6747
0.7910
0.2832 (5)
0.1763 (6)
0.2201
0.1528
0.0861
0.1653 (6)
0.0966 (6)
0.0045
0.1640
0.0761
0.4047 (5)
0.3298 (6)
0.2236
0.3487
0.3683
0.9146 (6)
0.9640 (6)
0.9550
0.9026
1.0669
0.7108 (5)
0.6551 (5)

0.50527 (6)
0.77619 (15)
0.81977 (15)
0.94607 (16)
1.00594 (15)
0.86546 (15)
0.92324 (16)
0.83128 (19)
0.98913 (18)
1.06609 (18)
0.88502 (18)
0.57867 (16)
0.61503 (19)
0.612 (2)
0.8286 (2)
0.8198
0.8574 (2)
0.8600
0.9182 (2)
0.9142
0.9549 (2)
0.9669
0.9195 (2)
0.9100
0.9522 (2)
0.9938
0.9517
0.8091 (2)
0.7659 (3)
0.7285
0.7590
0.7819
0.9804 (2)
1.0043 (3)
1.0305
1.0266
0.9716
1.0592 (2)
1.1066 (2)
1.1126
1.0945
1.1436
0.8899 (2)
0.8605 (3)
0.8899
0.8303
0.8419
0.7371 (2)
0.7224 (2)

0.0312 (3)
0.0263 (8)
0.0244 (7)
0.0255 (7)
0.0255 (7)
0.0261 (8)
0.0310 (8)
0.0372 (9)
0.0365 (9)
0.0418 (10)
0.0355 (9)
0.0314 (8)
0.0238 (9)
0.029*
0.0232 (10)
0.028*
0.0233 (10)
0.028*
0.0232 (10)
0.028*
0.0234 (10)
0.028*
0.0256 (11)
0.031*
0.0334 (13)
0.040*
0.040*
0.0285 (11)
0.0342 (12)
0.051*
0.051*
0.051*
0.0273 (11)
0.0378 (13)
0.057*
0.057*
0.057*
0.0282 (11)
0.0350 (13)
0.053*
0.053*
0.053*
0.0313 (12)
0.0393 (14)
0.059*
0.059*
0.059*
0.0240 (10)
0.0285 (11)
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H16
C17
H17
C18
C19
H19
C20
H20
C21
C22
H22A
H22B
Cl2
O12
O13
O14
O15
O16
O17
O18
O19
O20
O21
O22
N2
H2N
C23
H23
C24
H24
C25
H25
C26
H26
C27
H27
C28
H28A
H28B
C29
C30
H30A
H30B
H30C
C31
C32
H32A
H32B
H32C
C33
C34
H34A

0.1104
-0.0459 (10)
-0.1717
-0.0291 (9)
0.1549 (10)
0.1674
0.3199 (9)
0.4435
-0.3351 (10)
-0.4925 (10)
-0.3866
-0.5809
-0.5533 (2)
0.7046 (6)
0.7343 (6)
0.8760 (6)
0.5657 (6)
0.6617 (7)
0.3916 (7)
1.1230 (7)
0.5747 (7)
0.9071 (7)
0.6816 (8)
-0.0867 (7)
-0.0767 (8)
-0.135 (10)
0.6287 (9)
0.4528
0.7832 (10)
0.9603
0.7040 (9)
0.5370
0.7032 (10)
0.8734
0.5622 (10)
0.3869
0.5779 (11)
0.5516
0.7414
0.9255 (10)
0.8543 (11)
0.8860
0.6801
0.9500
0.7857 (10)
0.9889 (11)
0.9264
1.1176
1.0559
0.6862 (10)
0.5109 (10)
0.4874

0.5595
0.7371 (5)
0.6983
0.8783 (5)
0.9332 (6)
1.0285
0.8513 (5)
0.8908
0.9285 (5)
1.0582 (5)
1.1038
1.1330
0.31244 (14)
0.5089 (4)
0.7914 (4)
0.8247 (4)
0.6921 (4)
0.4608 (4)
0.3178 (4)
0.8094 (4)
1.0042 (4)
0.6781 (5)
0.1321 (4)
0.2630 (4)
0.5040 (5)
0.587 (5)
0.5742 (5)
0.6294
0.6774 (5)
0.6243
0.7436 (5)
0.8117
0.6248 (6)
0.5714
0.5181 (6)
0.5718
0.3896 (6)
0.4238
0.3201
0.8414 (6)
0.9361 (6)
0.8750
0.9863
1.0094
0.9558 (5)
1.0265 (6)
1.1162
0.9582
1.0515
0.7126 (6)
0.7885 (6)
0.8951
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0.7403
0.6821 (2)
0.6724
0.6554 (2)
0.6707 (2)
0.6528
0.7114 (2)
0.7219
0.5801 (2)
0.5416 (2)
0.5117
0.5663
0.66050 (6)
0.40215 (15)
0.35463 (15)
0.22857 (15)
0.16795 (15)
0.31063 (15)
0.25014 (17)
0.34078 (18)
0.18398 (18)
0.10762 (17)
0.29495 (18)
0.58902 (16)
0.56905 (19)
0.579 (3)
0.3455 (2)
0.3478
0.3180 (2)
0.3172
0.2559 (2)
0.2579
0.2199 (2)
0.2085
0.2542 (2)
0.2599
0.2232 (2)
0.1807
0.2271
0.3653 (2)
0.4127 (3)
0.4513
0.4113
0.4065
0.1942 (2)
0.1720 (3)
0.1442
0.1518
0.2053
0.1150 (2)
0.0689 (2)
0.0654

0.034*
0.0252 (10)
0.030*
0.0218 (10)
0.0272 (11)
0.033*
0.0261 (11)
0.031*
0.0245 (10)
0.0289 (11)
0.035*
0.035*
0.0367 (3)
0.0272 (8)
0.0258 (8)
0.0258 (8)
0.0276 (8)
0.0285 (8)
0.0342 (9)
0.0356 (9)
0.0381 (9)
0.0382 (9)
0.0400 (10)
0.0315 (9)
0.0261 (9)
0.031*
0.0242 (10)
0.029*
0.0247 (10)
0.030*
0.0237 (10)
0.028*
0.0251 (11)
0.030*
0.0289 (11)
0.035*
0.0355 (13)
0.043*
0.043*
0.0283 (11)
0.0366 (13)
0.055*
0.055*
0.055*
0.0274 (11)
0.0368 (13)
0.055*
0.055*
0.055*
0.0270 (11)
0.0326 (12)
0.049*

H34B
H34C
C35
C36
H36A
H36B
H36C
C37
C38
H38
C39
H39
C40
C41
H41
C42
H42
C43
C44
H44A
H44B

0.3541
0.5753
0.4721 (11)
0.2583 (11)
0.3184
0.1591
0.1587
0.5096 (9)
0.3782 (10)
0.4220
0.1826 (9)
0.0902
0.1229 (9)
0.2536 (10)
0.2101
0.4495 (10)
0.5399
-0.1665 (9)
-0.3681 (10)
-0.4713
-0.2961

0.7642
0.7564
0.1927 (6)
0.1405 (7)
0.0488
0.1233
0.2155
0.5037 (5)
0.4004 (5)
0.3304
0.3980 (5)
0.3282
0.4987 (5)
0.6036 (6)
0.6735
0.6065 (6)
0.6777
0.3916 (5)
0.4395 (6)
0.5375
0.4483

0.0799
0.0310
0.2877 (3)
0.3189 (3)
0.3458
0.2897
0.3416
0.4437 (2)
0.4462 (2)
0.4197
0.4870 (2)
0.4879
0.5267 (2)
0.5240 (2)
0.5505
0.4822 (2)
0.4803
0.5971 (2)
0.6425 (3)
0.6270
0.6787

0.049*
0.049*
0.0352 (13)
0.0394 (14)
0.059*
0.059*
0.059*
0.0240 (10)
0.0261 (11)
0.031*
0.0271 (11)
0.033*
0.0239 (10)
0.0291 (11)
0.035*
0.0275 (11)
0.033*
0.0252 (11)
0.0308 (12)
0.037*
0.037*

Atomic displacement parameters (Å2)

Cl1
O1
O2
O3
O4
O5
O6
O7
O8
O9
O10
O11
N1
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14

U11

U22

U33

U12

U13

U23

0.0314 (7)
0.0244 (19)
0.0250 (18)
0.0206 (18)
0.0256 (18)
0.028 (2)
0.026 (2)
0.024 (2)
0.030 (2)
0.048 (3)
0.033 (2)
0.043 (2)
0.025 (2)
0.020 (2)
0.026 (3)
0.017 (2)
0.022 (3)
0.023 (3)
0.030 (3)
0.032 (3)
0.035 (3)
0.031 (3)
0.037 (3)
0.037 (3)
0.038 (3)
0.032 (3)
0.029 (3)

0.0264 (6)
0.0255 (18)
0.0207 (17)
0.0226 (17)
0.0283 (18)
0.0201 (17)
0.0266 (19)
0.030 (2)
0.031 (2)
0.051 (3)
0.034 (2)
0.0182 (18)
0.016 (2)
0.019 (2)
0.015 (2)
0.023 (3)
0.023 (2)
0.025 (3)
0.032 (3)
0.019 (2)
0.031 (3)
0.024 (3)
0.034 (3)
0.021 (2)
0.034 (3)
0.027 (3)
0.032 (3)

0.0369 (7)
0.0278 (19)
0.0271 (18)
0.0320 (19)
0.0231 (18)
0.0264 (19)
0.036 (2)
0.059 (3)
0.046 (2)
0.035 (2)
0.042 (2)
0.035 (2)
0.031 (2)
0.029 (3)
0.030 (3)
0.028 (3)
0.024 (3)
0.026 (3)
0.033 (3)
0.030 (3)
0.035 (3)
0.026 (3)
0.039 (3)
0.028 (3)
0.032 (3)
0.032 (3)
0.057 (4)

-0.0049 (5)
-0.0068 (15)
-0.0029 (14)
-0.0024 (14)
-0.0073 (15)
-0.0002 (15)
-0.0023 (16)
-0.0093 (17)
-0.0104 (17)
-0.029 (2)
-0.0132 (18)
-0.0059 (16)
-0.0063 (18)
-0.0005 (19)
-0.004 (2)
-0.001 (2)
-0.004 (2)
-0.002 (2)
0.003 (2)
-0.006 (2)
-0.006 (2)
-0.004 (2)
0.001 (3)
-0.007 (2)
-0.011 (3)
-0.001 (2)
-0.009 (3)

-0.0084 (5)
-0.0015 (14)
0.0000 (14)
-0.0057 (14)
-0.0020 (14)
-0.0004 (14)
0.0013 (16)
0.0035 (18)
-0.0003 (17)
-0.0115 (19)
-0.0041 (17)
-0.0099 (17)
-0.0074 (18)
-0.0006 (19)
-0.002 (2)
-0.0051 (19)
-0.0004 (19)
0.000 (2)
-0.005 (2)
-0.001 (2)
0.005 (2)
-0.005 (2)
-0.016 (3)
-0.007 (2)
0.000 (2)
-0.001 (2)
-0.013 (3)

-0.0080 (5)
-0.0004 (14)
-0.0080 (14)
-0.0029 (14)
-0.0041 (14)
-0.0031 (14)
-0.0025 (15)
-0.0127 (18)
0.0034 (17)
0.0006 (19)
-0.0035 (17)
-0.0059 (14)
-0.0009 (17)
-0.0077 (19)
-0.0078 (19)
-0.005 (2)
-0.0037 (19)
-0.004 (2)
-0.006 (2)
0.004 (2)
-0.007 (2)
-0.004 (2)
-0.002 (2)
-0.004 (2)
0.001 (2)
-0.008 (2)
0.001 (3)
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C15
C16
C17
C18
C19
C20
C21
C22
Cl2
O12
O13
O14
O15
O16
O17
O18
O19
O20
O21
O22
N2
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
C40
C41
C42
C43
C44

0.026 (3)
0.033 (3)
0.029 (3)
0.022 (3)
0.030 (3)
0.026 (3)
0.031 (3)
0.035 (3)
0.0351 (7)
0.0262 (19)
0.0211 (18)
0.0259 (19)
0.0284 (19)
0.038 (2)
0.040 (2)
0.026 (2)
0.038 (2)
0.030 (2)
0.041 (3)
0.036 (2)
0.029 (2)
0.027 (3)
0.030 (3)
0.019 (3)
0.029 (3)
0.033 (3)
0.048 (4)
0.027 (3)
0.044 (4)
0.032 (3)
0.042 (3)
0.027 (3)
0.031 (3)
0.041 (4)
0.036 (3)
0.024 (3)
0.033 (3)
0.029 (3)
0.026 (3)
0.035 (3)
0.033 (3)
0.030 (3)
0.033 (3)

0.020 (2)
0.018 (2)
0.022 (3)
0.018 (2)
0.023 (3)
0.022 (3)
0.019 (2)
0.019 (2)
0.0325 (7)
0.0301 (19)
0.0265 (18)
0.0236 (18)
0.0315 (19)
0.0242 (18)
0.033 (2)
0.029 (2)
0.029 (2)
0.047 (2)
0.036 (2)
0.0209 (19)
0.016 (2)
0.022 (2)
0.022 (2)
0.025 (3)
0.029 (3)
0.032 (3)
0.036 (3)
0.028 (3)
0.039 (3)
0.023 (3)
0.029 (3)
0.027 (3)
0.036 (3)
0.033 (3)
0.037 (3)
0.019 (2)
0.020 (2)
0.021 (2)
0.014 (2)
0.024 (3)
0.024 (3)
0.018 (2)
0.022 (3)

0.023 (3)
0.034 (3)
0.026 (3)
0.024 (2)
0.031 (3)
0.033 (3)
0.022 (2)
0.032 (3)
0.0451 (8)
0.0247 (19)
0.033 (2)
0.0302 (19)
0.0255 (19)
0.0272 (19)
0.034 (2)
0.054 (3)
0.046 (2)
0.032 (2)
0.045 (2)
0.036 (2)
0.034 (2)
0.025 (3)
0.025 (3)
0.028 (3)
0.020 (2)
0.025 (3)
0.031 (3)
0.032 (3)
0.034 (3)
0.028 (3)
0.042 (3)
0.027 (3)
0.031 (3)
0.033 (3)
0.050 (4)
0.024 (3)
0.024 (3)
0.033 (3)
0.028 (3)
0.029 (3)
0.027 (3)
0.028 (3)
0.037 (3)

-0.001 (2)
-0.006 (2)
-0.008 (2)
-0.001 (2)
-0.008 (2)
-0.010 (2)
-0.004 (2)
0.000 (2)
-0.0143 (6)
-0.0078 (15)
-0.0087 (15)
-0.0122 (15)
-0.0115 (16)
-0.0135 (16)
-0.0158 (18)
-0.0076 (16)
-0.0095 (18)
-0.0057 (19)
-0.0137 (19)
-0.0077 (16)
-0.0068 (18)
-0.007 (2)
-0.011 (2)
-0.008 (2)
-0.014 (2)
-0.018 (2)
-0.026 (3)
-0.011 (2)
-0.020 (3)
-0.008 (2)
-0.016 (3)
-0.007 (2)
-0.009 (2)
-0.009 (3)
-0.020 (3)
-0.002 (2)
-0.005 (2)
-0.008 (2)
-0.0010 (19)
-0.006 (2)
-0.012 (2)
-0.008 (2)
-0.008 (2)

-0.003 (2)
-0.005 (2)
-0.003 (2)
-0.0015 (19)
-0.003 (2)
-0.001 (2)
-0.001 (2)
-0.012 (2)
0.0095 (6)
-0.0007 (14)
-0.0023 (14)
-0.0003 (15)
-0.0007 (15)
-0.0027 (15)
-0.0082 (17)
-0.0023 (18)
-0.0080 (18)
0.0036 (16)
-0.0050 (19)
0.0056 (16)
0.0015 (18)
-0.001 (2)
0.000 (2)
0.001 (2)
0.000 (2)
0.002 (2)
0.002 (2)
-0.007 (2)
-0.004 (3)
-0.002 (2)
0.008 (3)
0.004 (2)
-0.002 (2)
-0.008 (3)
-0.005 (3)
-0.001 (2)
-0.001 (2)
-0.002 (2)
-0.001 (2)
-0.003 (2)
-0.001 (2)
-0.004 (2)
0.003 (2)

-0.0014 (19)
-0.004 (2)
-0.003 (2)
-0.0054 (18)
-0.006 (2)
-0.005 (2)
-0.0038 (18)
-0.008 (2)
-0.0101 (6)
-0.0015 (14)
-0.0099 (15)
-0.0018 (14)
-0.0054 (15)
-0.0048 (14)
-0.0023 (16)
-0.0102 (18)
0.0017 (17)
-0.0028 (17)
-0.0042 (18)
-0.0044 (15)
-0.0061 (17)
-0.0050 (19)
-0.005 (2)
-0.004 (2)
-0.003 (2)
-0.003 (2)
-0.005 (2)
-0.001 (2)
-0.009 (2)
-0.005 (2)
-0.007 (2)
-0.008 (2)
-0.006 (2)
-0.005 (2)
-0.001 (3)
0.0025 (19)
-0.0041 (19)
-0.006 (2)
-0.0008 (18)
-0.006 (2)
-0.001 (2)
-0.0040 (19)
-0.004 (2)

Geometric parameters (Å, )
Cl1-C22
O1-C15
O1-C1
O2-C7
O2-C2
O3-C9

1.774 (5)
1.396 (6)
1.409 (6)
1.345 (6)
1.448 (5)
1.360 (6)

Cl2-C44
O12-C37
O12-C23
O13-C29
O13-C24
O14-C31
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1.783 (5)
1.397 (6)
1.401 (6)
1.359 (6)
1.443 (6)
1.360 (6)

O3-C3
O4-C11
O4-C4
O5-C1
O5-C5
O6-C13
O6-C6
O7-C7
O8-C9
O9-C11
O10-C13
O11-C21
N1-C21
N1-C18
N1-H1N
C1-C2
C1-H1
C2-C3
C2-H2
C3-C4
C3-H3
C4-C5
C4-H4
C5-C6
C5-H5
C6-H6A
C6-H6B
C7-C8
C8-H8A
C8-H8B
C8-H8C
C9-C10
C10-H10A
C10-H10B
C10-H10C
C11-C12
C12-H12A
C12-H12B
C12-H12C
C13-C14
C14-H14A
C14-H14B
C14-H14C
C15-C16
C15-C20
C16-C17
C16-H16
C17-C18
C17-H17
C18-C19
C19-C20
C19-H19

1.437 (6)
1.355 (6)
1.437 (6)
1.412 (5)
1.434 (6)
1.352 (7)
1.453 (6)
1.205 (7)
1.201 (7)
1.203 (7)
1.206 (7)
1.230 (6)
1.348 (6)
1.419 (6)
0.85 (4)
1.518 (7)
1.0000
1.510 (7)
1.0000
1.523 (6)
1.0000
1.526 (6)
1.0000
1.501 (7)
1.0000
0.9900
0.9900
1.500 (7)
0.9800
0.9800
0.9800
1.489 (7)
0.9800
0.9800
0.9800
1.506 (7)
0.9800
0.9800
0.9800
1.490 (8)
0.9800
0.9800
0.9800
1.384 (7)
1.391 (7)
1.381 (7)
0.9500
1.406 (7)
0.9500
1.388 (7)
1.379 (7)
0.9500

O14-C25
O15-C33
O15-C26
O16-C23
O16-C27
O17-C35
O17-C28
O18-C29
O19-C31
O20-C33
O21-C35
O22-C43
N2-C43
N2-C40
N2-H2N
C23-C24
C23-H23
C24-C25
C24-H24
C25-C26
C25-H25
C26-C27
C26-H26
C27-C28
C27-H27
C28-H28A
C28-H28B
C29-C30
C30-H30A
C30-H30B
C30-H30C
C31-C32
C32-H32A
C32-H32B
C32-H32C
C33-C34
C34-H34A
C34-H34B
C34-H34C
C35-C36
C36-H36A
C36-H36B
C36-H36C
C37-C38
C37-C42
C38-C39
C38-H38
C39-C40
C39-H39
C40-C41
C41-C42
C41-H41
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1.439 (6)
1.349 (6)
1.451 (6)
1.420 (6)
1.430 (6)
1.347 (7)
1.446 (6)
1.195 (7)
1.197 (7)
1.214 (6)
1.193 (7)
1.230 (6)
1.348 (6)
1.419 (6)
0.84 (4)
1.511 (6)
1.0000
1.520 (7)
1.0000
1.517 (7)
1.0000
1.530 (7)
1.0000
1.500 (7)
1.0000
0.9900
0.9900
1.493 (7)
0.9800
0.9800
0.9800
1.496 (7)
0.9800
0.9800
0.9800
1.484 (7)
0.9800
0.9800
0.9800
1.508 (8)
0.9800
0.9800
0.9800
1.379 (7)
1.389 (7)
1.387 (7)
0.9500
1.394 (7)
0.9500
1.389 (7)
1.402 (7)
0.9500

C20-H20
C21-C22
C22-H22A

0.9500
1.519 (7)
0.9900

C42-H42
C43-C44
C44-H44A

0.9500
1.505 (7)
0.9900

C22-H22B

0.9900

C44-H44B

0.9900

C15-O1-C1
C7-O2-C2
C9-O3-C3
C11-O4-C4
C1-O5-C5
C13-O6-C6
C21-N1-C18
C21-N1-H1N
C18-N1-H1N
O1-C1-O5
O1-C1-C2
O5-C1-C2
O1-C1-H1
O5-C1-H1
C2-C1-H1
O2-C2-C3
O2-C2-C1
C3-C2-C1
O2-C2-H2
C3-C2-H2
C1-C2-H2
O3-C3-C2
O3-C3-C4
C2-C3-C4
O3-C3-H3
C2-C3-H3
C4-C3-H3
O4-C4-C3
O4-C4-C5
C3-C4-C5
O4-C4-H4
C3-C4-H4
C5-C4-H4
O5-C5-C6
O5-C5-C4
C6-C5-C4
O5-C5-H5
C6-C5-H5
C4-C5-H5
O6-C6-C5
O6-C6-H6A
C5-C6-H6A
O6-C6-H6B
C5-C6-H6B
H6A-C6-H6B
O7-C7-O2
O7-C7-C8

115.7 (4)
118.3 (4)
118.0 (4)
118.9 (4)
111.2 (4)
116.8 (4)
127.0 (4)
123 (4)
110 (4)
107.0 (4)
107.8 (4)
110.0 (4)
110.7
110.7
110.7
109.5 (4)
105.9 (4)
110.5 (4)
110.3
110.3
110.3
106.8 (4)
110.3 (4)
111.9 (4)
109.3
109.3
109.3
109.5 (4)
105.7 (4)
109.4 (4)
110.7
110.7
110.7
108.5 (4)
108.7 (4)
112.5 (4)
109.0
109.0
109.0
108.3 (4)
110.0
110.0
110.0
110.0
108.4
123.5 (5)
125.4 (5)

C37-O12-C23
C29-O13-C24
C31-O14-C25
C33-O15-C26
C23-O16-C27
C35-O17-C28
C43-N2-C40
C43-N2-H2N
C40-N2-H2N
O12-C23-O16
O12-C23-C24
O16-C23-C24
O12-C23-H23
O16-C23-H23
C24-C23-H23
O13-C24-C23
O13-C24-C25
C23-C24-C25
O13-C24-H24
C23-C24-H24
C25-C24-H24
O14-C25-C26
O14-C25-C24
C26-C25-C24
O14-C25-H25
C26-C25-H25
C24-C25-H25
O15-C26-C25
O15-C26-C27
C25-C26-C27
O15-C26-H26
C25-C26-H26
C27-C26-H26
O16-C27-C28
O16-C27-C26
C28-C27-C26
O16-C27-H27
C28-C27-H27
C26-C27-H27
O17-C28-C27
O17-C28-H28A
C27-C28-H28A
O17-C28-H28B
C27-C28-H28B
H28A-C28-H28B
O18-C29-O13
O18-C29-C30

112.8 (4)
117.5 (4)
117.3 (4)
119.4 (4)
110.9 (4)
115.3 (5)
128.0 (4)
118 (4)
114 (4)
108.0 (4)
109.8 (4)
109.0 (4)
110.0
110.0
110.0
105.7 (4)
109.9 (4)
109.2 (4)
110.7
110.7
110.7
109.5 (4)
107.2 (4)
111.2 (4)
109.6
109.6
109.6
108.7 (4)
104.7 (4)
110.4 (4)
110.9
110.9
110.9
107.4 (4)
109.5 (4)
112.4 (4)
109.2
109.2
109.2
107.9 (4)
110.1
110.1
110.1
110.1
108.4
123.7 (5)
125.9 (5)
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O2-C7-C8
C7-C8-H8A
C7-C8-H8B
H8A-C8-H8B
C7-C8-H8C
H8A-C8-H8C
H8B-C8-H8C
O8-C9-O3
O8-C9-C10
O3-C9-C10
C9-C10-H10A
C9-C10-H10B
H10A-C10-H10B
C9-C10-H10C
H10A-C10-H10C
H10B-C10-H10C
O9-C11-O4
O9-C11-C12
O4-C11-C12
C11-C12-H12A
C11-C12-H12B
H12A-C12-H12B
C11-C12-H12C
H12A-C12-H12C
H12B-C12-H12C
O10-C13-O6
O10-C13-C14
O6-C13-C14
C13-C14-H14A
C13-C14-H14B
H14A-C14-H14B
C13-C14-H14C
H14A-C14-H14C
H14B-C14-H14C
C16-C15-C20
C16-C15-O1
C20-C15-O1
C17-C16-C15
C17-C16-H16
C15-C16-H16
C16-C17-C18
C16-C17-H17
C18-C17-H17
C19-C18-C17
C19-C18-N1
C17-C18-N1
C20-C19-C18
C20-C19-H19
C18-C19-H19
C19-C20-C15
C19-C20-H20
C15-C20-H20

111.0 (5)
109.5
109.5
109.5
109.5
109.5
109.5
123.9 (5)
125.8 (5)
110.3 (4)
109.5
109.5
109.5
109.5
109.5
109.5
123.5 (5)
125.9 (5)
110.5 (4)
109.5
109.5
109.5
109.5
109.5
109.5
123.8 (5)
125.3 (5)
110.8 (5)
109.5
109.5
109.5
109.5
109.5
109.5
119.9 (5)
122.8 (4)
117.3 (4)
120.6 (5)
119.7
119.7
119.7 (5)
120.1
120.1
119.1 (5)
117.9 (4)
122.9 (4)
120.9 (5)
119.5
119.5
119.8 (5)
120.1
120.1

O13-C29-C30
C29-C30-H30A
C29-C30-H30B
H30A-C30-H30B
C29-C30-H30C
H30A-C30-H30C
H30B-C30-H30C
O19-C31-O14
O19-C31-C32
O14-C31-C32
C31-C32-H32A
C31-C32-H32B
H32A-C32-H32B
C31-C32-H32C
H32A-C32-H32C
H32B-C32-H32C
O20-C33-O15
O20-C33-C34
O15-C33-C34
C33-C34-H34A
C33-C34-H34B
H34A-C34-H34B
C33-C34-H34C
H34A-C34-H34C
H34B-C34-H34C
O21-C35-O17
O21-C35-C36
O17-C35-C36
C35-C36-H36A
C35-C36-H36B
H36A-C36-H36B
C35-C36-H36C
H36A-C36-H36C
H36B-C36-H36C
C38-C37-C42
C38-C37-O12
C42-C37-O12
C37-C38-C39
C37-C38-H38
C39-C38-H38
C38-C39-C40
C38-C39-H39
C40-C39-H39
C41-C40-C39
C41-C40-N2
C39-C40-N2
C40-C41-C42
C40-C41-H41
C42-C41-H41
C37-C42-C41
C37-C42-H42
C41-C42-H42
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110.4 (5)
109.5
109.5
109.5
109.5
109.5
109.5
123.9 (5)
126.5 (5)
109.6 (5)
109.5
109.5
109.5
109.5
109.5
109.5
123.8 (5)
126.0 (5)
110.2 (4)
109.5
109.5
109.5
109.5
109.5
109.5
124.9 (6)
125.1 (5)
110.0 (5)
109.5
109.5
109.5
109.5
109.5
109.5
120.6 (5)
121.2 (4)
118.2 (4)
120.6 (5)
119.7
119.7
119.4 (5)
120.3
120.3
120.1 (5)
117.2 (4)
122.5 (4)
120.1 (5)
119.9
119.9
119.1 (5)
120.5
120.5

O11-C21-N1
O11-C21-C22
N1-C21-C22
C21-C22-Cl1
C21-C22-H22A
Cl1-C22-H22A
C21-C22-H22B
Cl1-C22-H22B

124.9 (5)
122.8 (4)
112.3 (4)
111.5 (4)
109.3
109.3
109.3
109.3

O22-C43-N2
O22-C43-C44
N2-C43-C44
C43-C44-Cl2
C43-C44-H44A
Cl2-C44-H44A
C43-C44-H44B
Cl2-C44-H44B

124.5 (5)
123.1 (5)
112.3 (4)
111.7 (4)
109.3
109.3
109.3
109.3

H22A-C22-H22B

108.0

H44A-C44-H44B

107.9

C15-O1-C1-O5
C15-O1-C1-C2
C5-O5-C1-O1
C5-O5-C1-C2
C7-O2-C2-C3
C7-O2-C2-C1
O1-C1-C2-O2
O5-C1-C2-O2
O1-C1-C2-C3
O5-C1-C2-C3
C9-O3-C3-C2
C9-O3-C3-C4
O2-C2-C3-O3
C1-C2-C3-O3
O2-C2-C3-C4
C1-C2-C3-C4
C11-O4-C4-C3
C11-O4-C4-C5
O3-C3-C4-O4
C2-C3-C4-O4
O3-C3-C4-C5
C2-C3-C4-C5
C1-O5-C5-C6
C1-O5-C5-C4
O4-C4-C5-O5
C3-C4-C5-O5
O4-C4-C5-C6
C3-C4-C5-C6
C13-O6-C6-C5
O5-C5-C6-O6
C4-C5-C6-O6
C2-O2-C7-O7
C2-O2-C7-C8
C3-O3-C9-O8
C3-O3-C9-C10
C4-O4-C11-O9
C4-O4-C11-C12
C6-O6-C13-O10
C6-O6-C13-C14
C1-O1-C15-C16
C1-O1-C15-C20

-75.7 (5)
166.1 (4)
178.1 (4)
-65.1 (5)
-102.3 (5)
138.5 (4)
-69.8 (5)
174.0 (4)
171.7 (4)
55.5 (5)
-141.7 (4)
96.6 (5)
73.5 (4)
-170.2 (4)
-165.8 (4)
-49.5 (5)
104.1 (5)
-138.0 (4)
-74.9 (5)
166.4 (4)
169.6 (4)
50.9 (5)
-170.9 (4)
66.4 (5)
-175.6 (4)
-57.7 (5)
64.1 (5)
-178.0 (5)
-105.1 (5)
75.3 (5)
-164.4 (4)
3.3 (7)
-175.8 (4)
-0.6 (7)
178.7 (4)
-2.6 (7)
179.6 (4)
-2.9 (7)
176.9 (4)
-45.2 (6)
136.2 (5)

C37-O12-C23-O16
C37-O12-C23-C24
C27-O16-C23-O12
C27-O16-C23-C24
C29-O13-C24-C23
C29-O13-C24-C25
O12-C23-C24-O13
O16-C23-C24-O13
O12-C23-C24-C25
O16-C23-C24-C25
C31-O14-C25-C26
C31-O14-C25-C24
O13-C24-C25-O14
C23-C24-C25-O14
O13-C24-C25-C26
C23-C24-C25-C26
C33-O15-C26-C25
C33-O15-C26-C27
O14-C25-C26-O15
C24-C25-C26-O15
O14-C25-C26-C27
C24-C25-C26-C27
C23-O16-C27-C28
C23-O16-C27-C26
O15-C26-C27-O16
C25-C26-C27-O16
O15-C26-C27-C28
C25-C26-C27-C28
C35-O17-C28-C27
O16-C27-C28-O17
C26-C27-C28-O17
C24-O13-C29-O18
C24-O13-C29-C30
C25-O14-C31-O19
C25-O14-C31-C32
C26-O15-C33-O20
C26-O15-C33-C34
C28-O17-C35-O21
C28-O17-C35-C36
C23-O12-C37-C38
C23-O12-C37-C42

C20-C15-C16-C17

0.6 (8)

C42-C37-C38-C39

-104.4 (4)
136.9 (4)
173.4 (4)
-67.3 (5)
140.7 (4)
-101.6 (5)
-63.7 (5)
178.3 (4)
178.2 (4)
60.1 (5)
99.1 (5)
-140.2 (4)
72.2 (5)
-172.4 (4)
-168.2 (4)
-52.7 (5)
104.0 (5)
-138.0 (4)
-77.1 (5)
164.6 (4)
168.6 (4)
50.3 (6)
-173.4 (4)
64.3 (5)
-171.7 (4)
-54.8 (6)
69.1 (6)
-174.1 (5)
-102.8 (5)
74.3 (6)
-165.2 (4)
9.2 (7)
-169.0 (4)
-2.6 (7)
177.6 (4)
-0.2 (7)
-177.6 (4)
-7.9 (8)
172.2 (4)
77.4 (6)
-102.0 (5)
0.4 (8)
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O1-C15-C16-C17
C15-C16-C17-C18
C16-C17-C18-C19
C16-C17-C18-N1
C21-N1-C18-C19
C21-N1-C18-C17
C17-C18-C19-C20
N1-C18-C19-C20
C18-C19-C20-C15
C16-C15-C20-C19
O1-C15-C20-C19
C18-N1-C21-O11
C18-N1-C21-C22
O11-C21-C22-Cl1

-178.0 (4)
0.3 (8)
-0.6 (7)
-177.9 (5)
156.5 (5)
-26.2 (8)
0.0 (7)
177.4 (4)
1.0 (8)
-1.3 (8)
177.4 (4)
1.0 (9)
-178.8 (5)
10.0 (7)

O12-C37-C38-C39
C37-C38-C39-C40
C38-C39-C40-C41
C38-C39-C40-N2
C43-N2-C40-C41
C43-N2-C40-C39
C39-C40-C41-C42
N2-C40-C41-C42
C38-C37-C42-C41
O12-C37-C42-C41
C40-C41-C42-C37
C40-N2-C43-O22
C40-N2-C43-C44
O22-C43-C44-Cl2

-179.0 (5)
-1.6 (8)
2.0 (8)
179.1 (5)
-150.7 (5)
32.2 (8)
-1.4 (8)
-178.6 (5)
0.2 (8)
179.7 (4)
0.2 (8)
-1.0 (8)
175.6 (5)
-23.5 (7)

N1-C21-C22-Cl1

-170.3 (4)

N2-C43-C44-Cl2

159.8 (4)

Hydrogen-bond geometry (Å, )
D-H...A

D-H
i

N1-H1N...O22
N2-H2N...O11

H...A

0.85 (4)
0.84 (4)

2.15 (5)
2.05 (5)

Symmetry code: (i) X, y+1, z.
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D...A

D-H...A

2.973 (5)
2.854 (5)

165 (5)
161 (6)
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